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Background: In patients with Chronic Obstructive Pulmonary Disease (COPD) daily physical 
activity (PA) levels are significantly lower than in healthy age-matched individuals. PA 
counselling has been employed to address the complex behaviour of PA and was shown via a 
systematic review and meta-analysis to be effective in improving daily PA levels (steps/day) 
both as a standalone intervention and alongside pulmonary rehabilitation (PR). However, in 
patients reporting low baseline levels of PA (≤4000 steps/day), PA counselling alongside PR 
did not induce clinically important improvements in daily PA levels. A plausible reason 
involves the concept of a “low functional reserve”, indicating that these patients are less likely 
to become more physically active within their functional limits.  
Objectives: 1) to perform a systematic review and meta-analysis on PA counselling as a 
standalone intervention and alongside PR in COPD, 2) to determine the criterion validity and 
test-retest reliability of a commercially available pedometer used by COPD patients to self-
monitor and report daily PA levels, 3) to evaluate daily PA levels, muscle function, anxiety 
and depression in patients with COPD living in the North East of England in comparison to 
healthy age-matched individuals from the same region in a cross sectional study design, and 4) 
to investigate the feasibility, acceptability and efficacy of combining PR, designed to improve 
exercise capacity, with comprehensive PA behavioural modification interventions, designed to 
translate PR-induced improvements in exercise capacity into improved daily PA, in COPD 
patients with low baseline PA levels. .  
Methods: To accomplish the latter objective a prospective, single centre, two parallel-group, 
RCT, compared the efficacy of a PR programme combined with PA behavioural modification 
interventions (PR+PA: incorporating motivational interviewing, face-to-face twice weekly 




COPD (FEV1: 49±19 % predicted) exhibiting low baseline exercise capacity (6MWT: 
289±85m) and daily PA levels (3293±2000 steps/day). In both groups (PR+PA and PA alone) 
patients with profound anxiety and depression (≥8 HADS score) received sessions of Cognitive 
Behavioural Therapy (CBT) by a specialist respiratory nurse.  
Results: Compared to PR alone, PR+PA induced clinically important improvements in both 
PA levels (by 1016 steps/day; 95% CI 556 to 1474 steps/day, p = 0.001) and patients’ PA 
experiences (by 7 points; 95% CI 4 to 11 points, p= 0.001) that were assessed by the European 
Medicines Agency qualified Clinical PROactive Physical Activity in COPD instrument (C-
PPAC). Importantly, both groups reported clinically important improvements in the 6MWT (≥ 
30 m) and CAT questionnaire (≥ -2 points), however improvements in upper and lower muscle 
strength were significantly greater in the PR+PA compared to PR group.   
These findings were supported by evidence of adequate PR completion rates (80%) and high 
patient acceptability of the PA behavioural modification interventions, with 75% of patients 
indicating that they “liked taking part in the intervention a lot”, and 58% of patients claiming 
that the intervention “helped them a lot” regarding completing more PA outside of PR. 
Furthermore, patient adherence to the components of the behavioural modification 
interventions was high, including the weekly use of the pedometer (6.6±0.2 days) and 
interaction with the PA diary (93±17%) to self-monitor and report daily step counts.  
Conclusions: The findings suggest that in COPD patients with low baseline exercise capacity 
and daily PA levels, improvements in exercise capacity following completion of a standard PR 
programme may translate into clinically important improvements in daily PA levels only when 
tailored PA behavioural modification interventions are added to PR. In addition, PA 
behavioural modification interventions were proven to be feasible to incorporate into a standard 
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CHAPTER 1: INTRODUCTION 
W13002500 2  
 
1.1 Background 
Chronic Obstructive Pulmonary Disease (COPD) is a debilitating and progressive disease, 
primarily affecting the respiratory system (Global Initiative for Chronic Obstructive Lung 
Disease, 2021). In many patients, it may also have adverse extra-pulmonary effects, such as 
skeletal muscle dysfunction and weakness (Cooper, 2009). Combined, the pulmonary and 
skeletal muscle abnormalities exacerbate exercise-associated symptoms such as breathlessness 
and leg discomfort (O’Donnell & Gebke, 2014; Troosters et al., 2013). These symptoms make 
every day physical activity (PA) an unpleasant experience, which patients actively try to avoid 
(Pitta et al., 2005b; Troosters et al., 2010; Watz, Waschki, Meyer, & Magnussen, 2009). These 
recurring factors, alongside a depressive mood and associated fear factor, deteriorate patients 
physical state and increase the intensity of breathlessness. Thus, patients are forced into a 
vicious cycle of inactivity and worsening symptoms (Cooper, 2009; Shrikrishna et al., 2012; 
Troosters et al., 2013).  
PA levels are therefore remarkably lower in patients with COPD than healthy age-matched 
individuals, associated with poor outcomes, including an increased risk of hospitalisation and 
mortality in these patients (Garcia-Aymerich, Lange, Benet, Schnohr, & Antó, 2006; Garcia-
Aymerich et al., 2009; Garcia-Rio et al., 2012; Vaes et al., 2014; Waschki et al., 2011). 
Implementation of exercise training as part of Pulmonary Rehabilitation (PR) is an integral 
non-pharmacological component in COPD management that aims to reverse the systemic 
consequences of COPD (Bolton et al., 2013; Spruit et al., 2013). Currently PR programmes 
have shown substantial improvements in exercise capacity and health status; however, these 
findings have not consistently progressed into improvements in daily PA due to PA in COPD 
being a complex health behaviour (Cindy Ng, Mackney, Jenkins, & Hill, 2012; Spruit, Pitta, 
McAuley, ZuWallack, & Nici, 2015; Troosters et al., 2013; Watz et al., 2014).   
CHAPTER 1: INTRODUCTION 
W13002500 3  
PA behavioural modification interventions, including the identification of barriers, goal setting, 
self-efficacy, motivation, self-monitoring and feedback, aim to impact upon the vicious cycle 
of inactivity in COPD (de Blok et al., 2006). Patients receive such interventions in order to 
modify their behaviour towards enhanced PA through the application of a pedometer, which 
allows patient monitoring and feedback of their daily steps along with frequently adjusted goal 
setting (Mantoani, Rubio, McKinstry, MacNee, & Rabinovich, 2016). Previous research has 
shown that PA counselling, a behavioural modification intervention, as a standalone 
intervention and alongside PR provided inconsistent improvements in steps/day in COPD, 
primarily due to diverse trial designs (Burge, Cox, Abramson, & Holland, 2020; Lahham, 
McDonald, & Holland, 2016; Mantoani et al., 2016). As a result, more research is needed to 
interpret the reasons for these inconsistencies and provide novel approaches that can promote 
effective and reliable improvements in PA.  
Alongside the physical barriers influencing daily PA, the distressing nature of COPD has a 
significant impact on patients’ psychological wellbeing, with major focusing points including 
the sense of feeling unwell, the inability to perform everyday activities and the emotional 
consequences of the condition (Pumar et al., 2014; Yohannes & Alexopoulos, 2014). These 
thoughts can often promote anxiety and depression, which are prevalent in patients with COPD 
and are associated with reduced PA and poorer treatment outcomes (Ng et al., 2007; Pumar et 
al., 2014; Tabak, Brusse-Keizer, van der Valk, Hermens, & Vollenbroek-Hutten, 2014). 
Cognitive behavioural therapy (CBT) is a psychological approach that focuses on 
understanding how experiences are interpreted, providing an interaction between thoughts, 
mood, behaviour and physical sensation (Heslop-Marshall et al., 2018). CBT has been shown 
to be effective in reducing elevated levels of anxiety and depression (Heslop-Marshall et al., 
2018). However, it is yet to be investigated whether CBT incorporated into PR and PA 
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behavioural modification interventions can provide a combined approach to positively impact 
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2.1 What is COPD?  
COPD is a common, preventable and treatable disease that is characterised by persistent 
respiratory symptoms and airflow limitation that is due to airways and/or alveolar 
abnormalities usually caused by significant exposure to noxious particles or gases (Global 
Initiative for Chronic Obstructive Lung Disease, 2021).  
 
2.2 Aetiology  
COPD is primarily caused by long-term exposure to cigarette smoking, however exposure to 
biomass fuels, workplace dust and fumes exposure, history of respiratory-tract infections 
during childhood, chronic asthma and a history of pulmonary tuberculosis may influence or 
further cause COPD prevalence (Global Initiative for Chronic Obstructive Lung Disease, 2021; 
National Clinical Guideline, 2010).  
 
2.2.1 Cigarette smoking  
The most common cause of COPD is long-term exposure to tobacco smoking, with the majority 
of patients in primarily high-income countries reporting a history of tobacco exposure on 
diagnosis of COPD (Global Initiative for Chronic Obstructive Lung Disease, 2021). It is 
reasoned that tobacco smoking is responsible for nine in every ten cases, demonstrating an 
effective relationship between tobacco smoke exposure and a higher risk of developing COPD. 
Furthermore, COPD severity, based on a decline in Forced Expiratory Volume in 1 second 
(FEV1), is related to a greater smoking history (Global Initiative for Chronic Obstructive Lung 
Disease, 2021). In addition, the inhalation of cigarette smoke through passive means, where 
non-smokers are exposed to cigarette smoke (passive smoking), can significantly increase the 
risk of developing COPD (Yin et al., 2007).  
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2.2.2 Genetics 
It has been shown that smokers with a family history of severe COPD are at an increased risk 
of airflow limitation and COPD development (Global Initiative for Chronic Obstructive Lung 
Disease, 2021). Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder causing a 
reduction in the production of alpha 1-antitrypsin due to a mutation in the SERPINA1 gene on 
chromosome 14 (Chapman, Robinson, Stradling, West, & Wrightson, 2014; Thun et al., 2013). 
Those with AATD who are exposed to cigarette smoking or occupational exposures may have 
an increased likelihood of developing COPD (Global Initiative for Chronic Obstructive Lung 
Disease, 2021).  
 
2.2.3 Occupational exposure and air pollution 
The development of COPD from occupational exposures, including organic and inorganic 
dusts, fumes and chemical agents, are an under-appreciated risk factor for developing COPD 
(Eisner et al., 2010; Paulin et al., 2015). For example, a population-based study found several 
occupations including sculptors, gardeners and warehouse workers were at greater risk of 
developing COPD among never-smokers and never-asthmatics (De Matteis et al., 2019). 
Furthermore, a cross-sectional observational study highlighted that self-reported exposure to 
workplace dust and fumes was associated with increased airflow limitation, respiratory 
symptoms, emphysema and gas trapping, in both men and woman assessed by computed 
tomography scans (Marchetti et al., 2014).  
Exposure to urban air pollution is extremely harmful to individuals with pre-existing lung 
disease, however its role as a risk factor for COPD remains unclear. One thing that is clear is 
that it appears to have a relatively small role compared to the role of cigarette smoking in the 
development of COPD (Eisner et al., 2010).  
CHAPTER 2: LITERATURE REVIEW 
W13002500 8  
2.2.4 Age and gender  
COPD is well known to be more prevalent in the elderly population, however it is not clear 
whether age should be considered a risk factor for developing COPD or whether the long-term 
exposure to causative agents is to blame (Global Initiative for Chronic Obstructive Lung 
Disease, 2021). Previously, COPD prevalence and mortality rates were much greater among 
men than woman, although recent data from developing countries has begun reporting an 
almost equal prevalence of COPD in men and woman, which probably reflects the changing 
patterns of tobacco smoking in developing countries (Barnes, 2016; Landis et al., 2014).  
 
2.2.5 Asthma  
It remains unclear whether asthma plays a part in the development of chronic airflow limitation 
and COPD. An early report from a longitudinal cohort found that adults with asthma had a 12 
fold higher risk of acquiring COPD over time compared to adults without asthma, following 
adjustment for smoking (Silva, Sherrill, Guerra, & Barbee, 2004). Around the same time, 
another longitudinal study of people with asthma found the development of irreversible airflow 
limitation and reduced transfer coefficient in around 20% of subjects (Vonk et al., 2003). In 
2018, a meta-analysis documented that individuals reporting a history of asthma (childhood or 
adult onset asthma) were 7.2 times more likely to develop COPD (Asamoah-Boaheng et al., 
2018).    
 
2.3 Pathogenesis  
The long-term exposure and inhalation of cigarette smoke and other noxious particles, such as 
biomass fuels and workplace exposures to dust and fumes, causes pathological changes in the 
airways, lung parenchyma and pulmonary vasculature (Hogg & Timens, 2009). Pathological 
changes characteristic of COPD includes chronic inflammation and structural changes due to 
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repeated injury and repair of the lungs (Global Initiative for Chronic Obstructive Lung Disease, 
2021). Lung inflammation is a common response that appears to be modified in patients who 
go on to develop COPD. This modified response “chronic inflammation” may induce 
parenchymal tissue destruction (Emphysema), mucous hypersecretion (Chronic Bronchitis) 
and disruption of the normal repair and defense mechanisms within the small airways, causing 
small airways inflammation and fibrosis (Bronchiolitis) (Global Initiative for Chronic 
Obstructive Lung Disease, 2021; Tuder & Petrache, 2012). These pathological changes do not 
always occur together and the relative contributions of which vary from person to person 
(Global Initiative for Chronic Obstructive Lung Disease, 2021). 
The consequences of these pathological changes include a decline in lung elastic recoil, 
increased lung compliance, increased resistance to airflow in the small conducting airways, air 
trapping and progressive airflow obstruction. (Global Initiative for Chronic Obstructive Lung 
Disease, 2021).  
Commonly, disease severity is associated with greater inflammatory and structural changes in 
the airways and continues following smoking cessation (Global Initiative for Chronic 
Obstructive Lung Disease, 2021). Alongside inflammation, both an imbalance between 
proteases and antiproteases (Stockley, 1999) as well as an imbalance between oxidants and 
antioxidants (Domej, Oettl, & Renner, 2014) within the lungs can impact the pathogenesis of 
COPD.  
 
2.4 Prevalence and Incidence  
The World Health Organisation (WHO) reported approximately 251 million cases of COPD 
worldwide in 2016 (World Health Organisation, 2017), with a prevalence varying between 1% 
and 4% of the overall population (Global Initiative for Chronic Obstructive Lung Disease, 
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2021). In the UK, around 1.2 million people are diagnosed with COPD, with many more people 
living with undiagnosed COPD (British Lung Foundation, 2020).   
In many countries, the prevalence of COPD has continued to increase in the latter part of the 
last century (Hurd, 2000), although recent data has begun reporting a stabilisation of COPD 
prevalence in several developed countries (Ford et al., 2013; Soriano et al., 2010; Vasankari et 
al., 2010). However, with an increased prevalence of smokers in developing countries, and an 
aging population in high-income countries, the overall prevalence of COPD is expected to rise 
over the next 40 years (Soriano et al., 2010).  
In most developed countries, studies have demonstrated a greater prevalence in men than in 
woman, which is likely a result of historical smoking patterns (Gershon, Wang, Wilton, Raut, 
& To, 2010; Rosenberg, Kalhan, & Mannino, 2015). In addition, a greater prevalence of COPD 
was reported in older individuals, particularly over the age of 75 years old (Rosenberg et al., 
2015). This relates to the knowledge that COPD is associated with aging and longer exposure 
to noxious particles and gases, as detailed earlier (Mercado, Ito, & Barnes, 2015).  
 
2.5 Economic Burden  
COPD is associated with significant economic burden which has a substantial impact on 
worldwide health care systems, with COPD treatment costing around $2.1 trillion per annum 
(Global Initiative for Chronic Obstructive Lung Disease, 2021). The three most important 
factors that determine the level of economic and societal costs for COPD patients are disease 
severity, presence of comorbidities and exacerbations of disease (Mannino & Buist, 2007).  
Specifically, in the UK, the annual cost of COPD is around £1.9 billion, with around 140,000 
hospital admissions and one million bed days annually (British Lung Foundation, 2019). As a 
result, COPD is increasing the burden on the NHS, making research into COPD management 
essential.  
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2.6 Diagnosis and classification of COPD  
To fully diagnose and understand the extent and/or severity of COPD, spirometry after the 
intake of bronchodilators is required and confirmed with post-bronchodilator FEV1/Forced 
Vital Capacity (FVC) < 0.70 alongside the observation of relevant symptoms (dyspnea, sputum 
production or chronic cough) and a history of exposure to risk factors for the disease (i.e. 
tobacco smoking). The severity of COPD can be established using the Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) stages of COPD, outlined in Table 1 (Global 
Initiative for Chronic Obstructive Lung Disease, 2021).  
 
 
Table 1. GOLD guidelines for COPD severity 
COPD GOLD Stage  Severity of airflow obstruction  FEV1 (% predicted)  
I Mild airflow limitation FEV1≥ 80%  
II Moderate airflow limitation 50% ≤ FEV1 < 80%  
III Severe airflow limitation 30% ≤ FEV1 < 50% 
IV Very severe airflow limitation   FEV1< 30% or < 50% with respiratory failure  
Abbreviations: GOLD: Global Initiative for Chronic Obstructive Lung Disease, FEV1: Forced Expiratory 
Volume in one second.  
 
 
2.7 Impact on mortality  
Increasing evidence is available to suggest that COPD increases the risk of mortality across the 
general population and is one of the four main causes of death, with a recorded mortality of 3.2 
million in 2015, equating to 5% of all deaths globally in that year (World Health Organisation, 
2017). In this context, it is expected that COPD will become the third leading cause of death, 
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with projections of up to 4.5 million deaths annually by 2030 (Global Initiative for Chronic 
Obstructive Lung Disease, 2021; May & Li, 2015). This increase in mortality has mainly been 
caused by a greater prevalence of smoking, reduced mortality from other common causes of 
death and the aging population in high-income countries (Global Initiative for Chronic 
Obstructive Lung Disease, 2021). The WHO suggests that respiratory death rates in the UK 
are almost double than the European Union average. Specifically, the UK ranked 12th for the 
number of COPD deaths per million per year between 2001-2010, with 29,776 people dying 
from COPD in 2012. Of these, 15,245 were males and 14,531 were females (British Lung 
Foundation, 2020).  
 
2.8 COPD symptoms  
Breathlessness is the hallmark symptom of COPD, alongside chronic cough, sputum 
production, wheeze and chest tightness (Global Initiative for Chronic Obstructive Lung 
Disease, 2021). In addition, many patients experience additional systemic features such as 
exertional fatigue, weight loss and skeletal muscle dysfunction and wasting (Global Initiative 
for Chronic Obstructive Lung Disease, 2021). The burden of these symptoms has a substantial 
detrimental impact on quality of life, health status and daily physical activities, and contributes 
to elevated levels of anxiety and depression, increased exacerbation risk and a worse disease 
prognosis (Doyle et al., 2013; Katajisto et al., 2012; Miravitlles & Ribera, 2017; Tsiligianni, 
Kocks, Tzanakis, Siafakas, & van der Molen, 2011).  
 
2.9 COPD symptoms and physical inactivity 
Both clinical and functional determinants of COPD (including dyspnea, quality of life and 
exercise capacity) are consistently associated with physical inactivity (Gimeno-Santos et al., 
2014), with symptoms found to have a negative impact on patients’ levels of PA, irrespective 
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of the time of day (Miravitlles et al., 2014). Patients commonly perceive that symptoms cause 
a substantial limitation on their abilities to perform activities of daily living and can often 
impair sleep (Kessler et al., 2011).  
Interestingly, patients have reported that the worst time for symptoms were during the morning, 
with both cough and sputum production reported as the most troublesome symptoms (van Buul, 
Kasteleyn, Chavannes, & Taube, 2017). Morning COPD symptoms are considered to be a key 
barrier towards performing daily physical activities, with a systematic review reporting that 
37-91% of COPD patients experienced PA limitations associated with morning symptoms (van 
Buul et al., 2017). A range of daily activities including ‘going shopping’ and ‘taking part in 
hobbies and sport’ as well as morning chores (i.e., ‘getting up’, ‘showering and dressing’), 
were cited by patients as key functional areas that were impacted by morning symptoms of 
COPD (Kessler et al., 2011; van Buul et al., 2017). Furthermore, it was noted that many routine 
activities took on average 10 minutes longer to complete compared to before morning 
symptoms occurred (van Buul et al., 2017). Some patients reported having to request assistance 
to successfully complete several daily activities, due to increased levels of impaired daily 
functioning. Therefore, many perceived themselves as a burden to others, and instead of 
seeking support, chose to avoid those daily activities (Kessler et al., 2011; van Buul et al., 
2017).   
Patients with COPD tend to reduce PA levels early in the disease progression to avoid elevated 
symptoms of dyspnea (Troosters et al., 2010; Watz et al., 2009). A reduction in levels of PA 
has been associated with limb muscle deconditioning, primarily found in the quadricep muscles 
(Maltais et al., 2014). This is typically caused by muscle fiber atrophy and a shift in quadriceps 
fiber type distribution, from type I to type IIx fibers, a typical feature of advanced COPD 
(Caron, Debigaré, Dekhuijzen, & Maltais, 2009; Gosker, Zeegers, Wouters, & Schols, 2007; 
Kim, Mofarrahi, & Hussain, 2008; Whittom et al., 1998). Capillary density and the number of 
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capillaries per muscle fiber are often diminished in the limb muscles of patients with COPD. 
Furthermore, mitochondrial functionality is altered and oxidative capacity within COPD limb 
muscles is reduced, consistent with the type I to type IIx fiber type shift (Gosker et al., 2007; 
Whittom et al., 1998). Based on the elevated symptoms of dyspnea and muscle deconditioning 
as a result of the above pathophysiological changes, patients are forced into a vicious cycle of 
inactivity (Figure 1) (Troosters et al., 2013).  
The vicious cycle of inactivity is a widely accepted theory regarding the mechanisms of 
physical inactivity in patients with COPD, acknowledged by Troosters et al. (2013). Within 
this model, it is suggested that symptoms of both dyspnea and leg discomfort, that are 
associated with physical inactivity, are a result of both skeletal muscle wasting and airway 
remodelling that limit airflow and increase the requirements for minute ventilation. An 
increased severity of COPD brings a greater prevalence of symptoms, making conducting 
activities of daily living an unpleasant experience, creating fear of performing such activities. 
The associated fear factor naturally inclines those individuals to become more sedentary and 
depressed, subsequently causing an inactive lifestyle. This inactive lifestyle may further reduce 
cardiovascular function and promote skeletal muscle deconditioning, as well as deteriorating 
people’s physical state and increasing the frequency of breathlessness. 
As a result, patients are forced into a more sedentary lifestyle, creating a vicious cycle of 
inactivity and worsening symptoms (Troosters et al., 2013).   
This cycle of inactivity is likely aggravated by acute COPD exacerbations. In an early study 
by Donaldson, Wilkinson, Hurst, Perera, and Wedzicha (2005), they found that time spent 
outdoors prior to an exacerbation and 5 weeks following the exacerbation were significantly 
reduced. Following admission to hospital with an acute exacerbation, PA levels dropped and 
failed to recover after a one month follow up. In addition, at one month, levels of PA were 
much lower in patients post exacerbation than in stable outpatients with equally severe COPD 
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(Pitta et al., 2006b). Inevitably, muscle strength decreased in the first week of hospital 
admission following an exacerbation and was associated with the degree of immobility 
reported (Pitta et al., 2006b). Following the work of Donaldson et al. (2005), extensive research 
has been published regarding the influence of exacerbations on levels of PA in patients with 
COPD (Alahmari et al., 2016; Alahmari et al., 2014; Albarrati, Gale, Munnery, Cockcroft, & 
Shale, 2020; Crook et al., 2018; Demeyer et al., 2018; Ehsan et al., 2013; Pitta et al., 2006b). 
An acute reduction in PA at the onset of an exacerbation has been reported in exacerbations 
requiring both admission to hospital (Pitta et al., 2006b) and ambulatory treatment (Alahmari 
et al., 2014; Ehsan et al., 2013). Interestingly, sustained reductions in PA have been shown 1 
month after hospital discharge following exacerbations (Pitta et al., 2006b) whereas following 
a community-treated exacerbation, PA levels almost returned to stable levels (Ehsan et al., 
2013). A recently published research letter from (Demeyer et al., 2018) found that both 
moderate and severe exacerbations accelerated physical inactivity in COPD patients. 
Specifically, they detailed that the number of exacerbations experienced by patients was related 
to the decline in step count, with a mean change of 251, -144 and -797 steps/day observed in 
patients who presented no, one or two or more exacerbations, respectively (Demeyer et al., 
2018). Furthermore, patients experiencing at least one severe exacerbation or two or more 
moderate exacerbations presented a larger decline in PA than those with no exacerbations 
(Demeyer et al., 2018).  
Several hypotheses may explain the decrease in PA levels following exacerbations. Firstly, the 
decline may be a consequence of a loss in exercise capacity, although data from Demeyer et 
al. (2018) failed to demonstrate an association between changes in exercise capacity and 
exacerbations. Secondly, a more plausible hypothesis may be based on a worsening of 
symptoms during an exacerbation leading to increased inactivity, associated with the vicious 
cycle of symptoms and inactivity detailed earlier (Troosters et al., 2013). An explanatory 
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analysis from (Demeyer et al., 2018) reported an association between exacerbations and an 
increase in dyspnea, which supports the latter hypothesis as a plausible mechanism for 
decreased PA. Thirdly, deterioration of limb muscle function during acute exacerbation of 
COPD may significantly impair a patient’s ability to conduct activities of daily living (Abdulai 
et al., 2018). Specifically, assessing those with an exacerbation, quadriceps muscle force was 
reduced, and quadriceps cross-sectional area had been observed to decrease by up to 5% over 
5 days of hospitalisation as a result of an exacerbation, impacting upon this vicious cycle of 





Figure 1. The vicious cycle of inactivity model, from (Troosters et al., 2013)  
 
2.10 Physical activity in healthy individuals 
PA is defined by Caspersen, Powell, and Christenson (1985) as ‘any bodily movement 
produced by skeletal muscles that results in energy expenditure’ and can be categorised into  
occupational, sports, conditioning, household and other every day activities of daily living. PA 
is an important determinant of cardiorespiratory fitness (Blair et al., 1989) and regular PA of 
moderate and high intensity is associated with greater levels of cardiorespiratory fitness (Myers 
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et al., 2004). Importantly, several studies have consistently demonstrated that higher levels of 
PA and cardiorespiratory fitness are associated with lower all-cause and cardiovascular 
mortality in healthy individuals (Blair et al., 1989; McKinney et al., 2016; Myers et al., 2004) 
and can reduce disabilities (Berk, Hubert, & Fries, 2006; Shah, Buchman, Leurgans, Boyle, & 
Bennett, 2012; Warburton, Nicol, & Bredin, 2006) and the risk of falling in the older population 
(Chan et al., 2007; Graafmans, Lips, Wijlhuizen, Pluijm, & Bouter, 2003; Heesch, Byles, & 
Brown, 2008). Furthermore, regular PA is associated with improved health outcomes in 
relation to the prevention of several chronic diseases including cardiovascular disease, diabetes 
and several types of cancer (Warburton et al., 2006)  
To remain physically active and sustain a healthy level of cardiorespiratory fitness, healthy 
adults aged 18-64 years are recommended to complete at least 150-300 minutes of moderate-
intensity aerobic PA, or at least 75-150 minutes of vigorous-intensity aerobic PA (World 
Health Organization, 2020). Furthermore, all adults should include muscle-strengthening 
activities at moderate or greater intensity on 2 or more days, to facilitate greater health benefits 
(World Health Organization, 2020) Worryingly, even with these recommendations and the 
clear benefits of regular participation in PA, global estimates show that only one in four 
(27.5%) adults (World Health Organization, 2020) and more than three-quarters (81%) of 
adolescents (World Health Organization, 2020) do not meet the WHO recommendations.   
 
 
2.11 COPD and physical inactivity 
Based on the symptoms of COPD and the associated mechanisms that influence patients’ 
abilities to undertake PA, knowledge regarding physical inactivity in patients with COPD has 
been extensively covered. This research began to accelerate following the early work of 
Schonhofer, Ardes, Geibel, Kohler, and Jones (1997), who assessed the feasibility of simple 
activity monitors to detect daily PA levels. Schonhofer et al. (1997) demonstrated that it was 
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possible to obtain repeatable measurements of daily activities in patients with severe lung 
disease using a simple activity monitor. Based on this data, they documented that patients 
suffering from chronic lung disease’s such as COPD, experienced significant reductions in 
daily movement compared to the average level in age and sex matched healthy individuals 
(Schonhofer et al., 1997). 
Following these findings, research has continued to demonstrate that COPD patients conduct 
significantly lower quantities of PA on a daily basis than their healthy age-matched 
counterparts, with many also indicating reductions in movement intensity and time spent in 
moderate to vigorous PA (MVPA). (Hernandes et al., 2009; Pitta et al., 2005b; Singh & 
Morgan, 2001; Troosters et al., 2010; Vorrink, Kort, Troosters, & Lammers, 2011; Walker, 
Burnett, Flavahan, & Calverley, 2008; Waschki et al., 2012; Watz et al., 2009).   
A detailed examination of PA in patients with COPD was undertaken by (Pitta et al., 2005b), 
using a validated triaxial accelerometer (DynaPort Activity Monitor; McRoberts BV) in 50 
COPD patients (FEV1%pred 43) and 25 healthy age-matched controls. Authors reported 
significant reductions in movement intensity; (1.8 vs 2.4 m/s2), standing time (191 vs 295 min) 
and walking time (44 vs 81 min, all p<0.001) in COPD patients compared to healthy controls, 
respectively (Pitta et al., 2005b). Moreover, they discovered that 30% of COPD patients were 
unable to meet the WHO recommendations of PA (30 minutes of moderate intensity activity) 
(World Health Organization, 2020) and even in those patients who achieved the 
recommendations, the reported average movement intensity was 17% lower than healthy 
controls (Pitta et al., 2005b).  
Watz et al. (2009) added to this research by measuring PA in a substantial number of COPD 
patients, investigating both the degree of inactivity compared to a control group and the 
relationships between clinical characteristics and PA. They found that steps/day and minutes 
of at least moderate PA all decreased compared to a control group that consisted of individuals 
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with normal lung function reporting early symptoms of Chronic Bronchitis (Watz et al., 2009). 
Interestingly, significant limitations in PA were present in patients with COPD from GOLD 
stages II, with the most severe levels of physical inactivity found in very severe COPD patients 
(GOLD stage IV) (Watz et al., 2009).  
Similar findings were shown by Troosters et al. (2010), however this time research was 
conducted across multi-centres, with investigations regarding the extent of physical inactivity 
highlighted across three different regions of the world. Regardless of the region of origin, 
significant reductions in steps/day were found following the analysis of 70 COPD patients 
(FEV1%pred 54) and 30 healthy controls (5584 vs 9372 steps/day respectively). In agreement 
with Watz et al. (2009), authors demonstrated a gradual reduction in both steps/day and time 
spent in moderate intensity PA as the severity of COPD increased (Troosters et al., 2010). 
Moreover, it was clear that inactivity was present early in the course of the disease, with a 
similar pattern shown across all centres (Troosters et al., 2010).  
As well as highlighting the impact of physical inactivity in COPD patients compared to healthy 
controls, research has begun investigating the longitudinal impact of COPD on PA levels and 
the influence of geographical area on PA variation among COPD patients. Boutou et al. (2019) 
analysed PA data over a 12-month period, comparing the impact of geographical location and 
associated factors on levels of PA. Based on a cohort of 157 COPD patients living across five 
European cities (Athens, Edinburgh, Leuven, London, and Groningen), there were significant 
time effects with a decline in almost every measure of PA over 12 months. In addition, major 
discrepancies in baseline PA levels were found, with steps/day ranging from 3338 to 5166 
across the five European cities (Boutou et al., 2019). Plausible explanations for these findings 
included differences in climate (i.e., daylight hours, rainfall & temperature), socio-cultural and 
socio-economics within the area of living (Boutou et al., 2019). On analysis, variations in 
climate posed the greatest influence to PA levels, with hours of rainfall providing the largest 
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negative effect on average steps/day (Boutou et al., 2019). The findings of Boutou et al. (2019) 
provide useful insight into PA levels across a wide spectrum of COPD patients, highlighting 
that interventions to improve PA may need to be modified to suit changing levels of PA based 
on geographic location and associated factors. 
 
2.12 Physical inactivity, hospitalisation, and survival in COPD  
The overall impact of physical inactivity on COPD patients is significant in terms of its 
association with increased risk for hospitalisation and all-cause mortality. Several longitudinal 
studies have assessed the association between PA and COPD related hospital admissions or 
readmissions as a result of COPD exacerbations (Benzo et al., 2010; Chen & Narsavage, 2006; 
Garcia-Aymerich et al., 2003; Garcia-Aymerich et al., 2006; Garcia-Aymerich, Lange, Serra, 
Schnohr, & Antó, 2008; Garcia-Rio et al., 2012; Pitta et al., 2006b). All of the above studies 
reported a statistically significant association between low levels of PA and increased risk for 
hospitalisation (Benzo et al., 2010; Chen & Narsavage, 2006; Garcia-Aymerich et al., 2003; 
Garcia-Aymerich et al., 2006; Garcia-Aymerich et al., 2008; Garcia-Rio et al., 2012; Pitta et 
al., 2006b). Specifically Garcia-Aymerich et al. (2006), found patients reporting levels of PA 
greater than “low” had a lower risk of COPD related hospital admission during a 20 year follow 
up than those who reported very low levels of PA, after adjusting for cofounders. Similar 
findings were reported by Benzo et al. (2010) with self-reported time ≥2 hours of PA per day 
associated with reduced hospitalisation. However, PA was assessed via self-reported 
questionnaires, limiting the robustness of the data. Importantly, the majority of studies have 
shown that PA equivalent to walking or cycling for a duration of 2 hours per week was 
associated with a significant reduction in risk for hospital admission due to COPD (Benzo et 
al., 2010; Chen & Narsavage, 2006; Garcia-Aymerich et al., 2003; Garcia-Aymerich et al., 
2006; Garcia-Aymerich et al., 2008; Garcia-Rio et al., 2012; Pitta et al., 2006b). 
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Regarding the effect of physical inactivity on survival in COPD patients, three longitudinal 
studies have demonstrated an association between low PA levels and greater all-cause 
mortality, over a follow-up period of 3-12 years (Garcia-Aymerich et al., 2006; Garcia-
Aymerich et al., 2011; Garcia-Rio et al., 2012). The association was consistent across various 
patient characteristics, methods of PA measurement and settings. It’s therefore plausible that 
patients who remain physically active should have a better prognosis compared to those who 
have a significant decline in PA. Therefore, treatment strategies to improve levels of PA in 
patients with COPD are essential to impact upon and lower the overall risk for hospitalisation 
and mortality in these patients.  
 
2.13 Capturing physical activity in COPD   
Prior to investigating treatment strategies to improve PA, understanding the available tools to 
capture levels of PA and their feasibility, validity and accuracy in a research setting are 
important. Capturing PA in COPD can include several tools from self-reported questionnaires, 
the doubly labelled water method, direct observations, and various motion sensors including 
step counters and accelerometers (Watz et al., 2014).   
 
2.13.1 Self-reported questionnaires  
The use of self-reported questionnaires and diaries to quantify activities of daily living has been 
implemented for numerous years and are specifically tailored to present subjective data 
regarding PA levels (Pitta et al., 2006a; Watz et al., 2014). This approach remains the most 
popular form of quantifying PA and is commonly implemented in large clinical trials and 
epidemiological studies due to their low cost and simplicity (Pitta et al., 2006a; Watz et al., 
2014). Although most self-reported approaches are cost effective and convenient, they do have 
drawbacks, which cannot be overlooked. For instance, relying on memory and recall of the 
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individual (Washburn, Heath, & Jackson, 2000), as well as variables such as questionnaire 
design and characteristics of both individuals and interviewer/researcher, can often affect the 
reliability of the results (Pitta et al., 2006a; Pitta, Troosters, Spruit, Decramer, & Gosselink, 
2005a; Watz et al., 2014). Furthermore, many individuals often request guidance from a 
relative, friend or healthcare practitioner, introducing significant bias. Social desirability bias 
is often a concern for self-reported measures, with many individuals commonly over reporting 
levels of PA and underestimating the time spent in sedentary activities (Watz et al., 2014). 
 
2.13.2 Pedometers   
Pedometers are small, lightweight, portable devices, containing either a horizontal spring-
suspended lever arm or piezo-electric cantilevered beam which detects vertical acceleration of 
the hips during walking (Crouter, Schneider, & David R Bassett, 2005). Primarily these 
instruments measure step counts but can also provide data on walking speed and burnt calories. 
The data derived from a pedometer can be used to provide information on distance walked, and 
an estimate of energy expenditure. Pedometers are low cost and easily worn, with easy to 
follow step counts on a digital screen, providing a simple but effective assessment of individual 
step targets or recommendations (Pitta et al., 2006a; Watz et al., 2014).  
Disadvantages of using pedometers do exist, including the propensity to underestimate step 
counts and therefore energy expenditure at slow walking speeds, which in patients with COPD 
is a common phenomenon (Karpman & Benzo, 2014). Many of the devices are unable to store 
data, requiring individuals to periodically record the output of the assessment when multiple 
days of measurement are desired. These limitations may hinder the accuracy of pedometer 
recordings in certain interventions, however as a source of motivation to support the 
improvement of PA levels, this low burden instrument may be the most effective approach 
(Armstrong et al., 2019).  
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2.13.3 Accelerometers  
Accelerometers are portable electronic devices worn to detect acceleration and quantify 
activity counts that can be analysed to provide various PA variables including, an estimate of 
time spent above or below a pre-specified activity level (i.e. sedentary, light, MVPA), number 
of daily steps/day, movement intensity and energy expenditure (Pitta et al., 2006a; Van 
Remoortel et al., 2012b). As a result, accelerometers have received growing interest across 
research settings as they provide objective data that cannot be obtained from simple pedometers 
or questionnaires (Watz et al., 2014).  
Several factors are known to influence the outcome of accelerometers. Firstly, artificial 
vibrations (i.e. vehicle vibrations), can falsely elevate activity counts in some devices. With 
growing research and greater technology, this issue can be reduced through several filtering 
options and by altering the technical aspects of wearing/analysing the accelerometer (Cohen et 
al., 2012). Secondly, the number of valid assessment days and hours used for PA assessment 
are important factors to consider as they often influence the reliability of these activity monitors 
(Demeyer et al., 2014; Hecht, Ma, Porszasz, Casaburi, & Network, 2009; Watz et al., 2009). 
For instance, Sundays were found to report the lowest amount of activity counts across a 7 day 
week in GOLD stage I to III COPD patients (Watz et al., 2009). Former studies in healthy 
individuals have also found that Sundays report the least amount of PA across a 7-day week 
(Matthews, Ainsworth, Thompson, & Bassett, 2002; Tudor-Locke et al., 2005). Within the 
study of (Watz et al., 2009), it was demonstrated that the reliability of accelerometer data varied 
depending on disease severity and the number of days used for analysis. It was indicated that 
the variability of PA was higher in less severe COPD patients (GOLD stage I), with 5 days of 
measurement required to reliably measure PA in those patients (Watz et al., 2009). In previous 
studies that have cited the intra-class correlation coefficient for accelerometer measurements 
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in patients with COPD, early work from Steele et al. (2000) reported an intra-class correlation 
coefficient of 0.69 for statistical agreement of 3 days in patients with severe COPD. 
Meanwhile, Pitta et al. (2005a) reported that 2 days of weekday measurements were sufficient 
to achieve a ≥0.7 intra-class correlation coefficient.  
For the assessment of PA over longitudinal changes, 3-4 days were shown to be sufficient to 
demonstrate a treatment effect following PR in moderate-severe COPD patients, with 
weekends either included (Watz et al., 2009) or excluded (Demeyer et al., 2014). Further details 
regarding the assessment criteria implemented for PA assessment in this thesis are provided in 
Chapter 4.  
Although accelerometers present significant benefits to capturing PA levels over both step 
counters and questionnaires, they certainly present several limitations. For instance, little 
uniformity exist between types of accelerometers, making it difficult to compare studies that 
implemented difference devices (Butte, Ekelund, & Westerterp, 2012). Furthermore, slow 
walking speeds, often documented in patients with COPD, can influence the accuracy of 
activity counts and impede the estimation of energy expenditure (Troosters et al., 2010; Watz 
et al., 2009). Finally, purchase costs vary considerably between devices, many research 
projects with large sample sizes report difficulties purchasing sufficient numbers of 
accelerometer to meet research demands (Van Remoortel et al., 2012a). 
 
2.14 Capturing patients’ experiences of physical activity  
Research regarding PA in COPD primarily focuses on the frequency, intensity, duration and 
type of PA, quantified by means of activity monitor and/or self-reported questionnaires as 
detailed above (Van Remoortel et al., 2012b). However, qualitative research has continued to 
highlight the importance of patients experience of symptoms while conducting PA, and the 
impact this has on their lifestyle habits (Dobbels et al., 2014). Thus, questions are being asked 
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regarding why research studies have not incorporated a means of assessing patients qualitative 
experiences of symptoms while conducting PA, and the impact this has on their lifestyle habits 
(Dobbels et al., 2014). The primary reason for a lack of input regarding patients’ experiences 
of PA in research to date is that such patient centred concepts are not quantifiable through 
activity monitors or via available self-reported questionnaires.  
To overcome this issue, a novel approach from the “Framework of the European Union 
Innovative Medicines Initiative PROactive project”, namely the PROactive PA in COPD 
instruments (clinical and daily visit versions, C-PPAC and D-PPAC) has been constructed 
(Gimeno-Santos et al., 2015). In brief, the C-PPAC instrument consists of 12-items that capture 
both the amount and difficulty of PA, completed at the day of each study visit (i.e., pre & post), 
either online using an electronic device or using pen and paper, with a one-week recall 
(Gimeno-Santos et al., 2015). The D-PPAC instrument has 7-items with a daily recall and 
needs to be completed every day for a week using an electronic device (Gimeno-Santos et al., 
2015).  
The majority of Randomised Controlled Trial’s (RCT’s) have used the C-PPAC instrument 
because it is easier to implement with patients only needing to complete the instrument twice 
(pre & post). In terms of the C-PPAC instruments effectiveness, a recently published article 
from Garcia-Aymerich et al. (2021), documented the response of the C-PPAC instrument in 
three non-pharmacological interventions in patients with COPD (Arbillaga-Etxarri et al., 2018; 
Demeyer et al., 2017; Louvaris et al., 2016). Firstly, a 12-week high intensity interval exercise 
training programme delivered by Louvaris et al. (2016) highlighted significant improvements 
in the difficulty, amount, and total scores of the C-PPAC instrument. The remaining two non-
pharmacological interventions involved the use of PA counselling (Arbillaga-Etxarri et al., 
2018; Demeyer et al., 2017). Demeyer et al. (2017) provided 12- weeks of PA tele-coaching, 
of which patients received weekly semi-automated goals via a smartphone app which provided 
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encouragement to progressively undertake greater levels of PA. Following its completion, 
improvements in both the total and amount, but not in the difficulty dimension of the C-PPAC 
instrument were reported (Demeyer et al., 2017). Meanwhile Arbillaga-Etxarri et al. (2018) 
conducted a 12-month urban training programme that incorporated a behavioural and 
community-based exercise intervention in patients with COPD. The C-PPAC tool was able to 
detect significant improvements following the 12-month programme in both the amount and 
difficulty dimensions, although significant improvements between intervention and usual care 
groups was not documented (Arbillaga-Etxarri et al., 2018).  
Based on findings of Garcia-Aymerich et al. (2021), the C-PPAC instrument was effective at 
documenting patients’ experiences of PA and was responsive to both exercise training and PA 
counselling interventions. As a result, the C-PPAC instrument should be incorporated in future 
PA interventions to gauge an understanding of patients’ experiences of PA alongside more 
common quantitative measures of PA.  
 
2.15 Interventions to improve physical activity in COPD  
With the availability of growing research, a clear trend has developed highlighting the severity 
of physical inactivity in patients with COPD compared to healthy age matched controls. The 
severity of physical inactivity has significant implications for COPD patient’s health and 
wellbeing, with an increased risk of respiratory exacerbations, respiratory related 
hospitalisation, and overall mortality. As a result, the need for effective interventions to 
improve PA has never been greater.  
  
2.15.1 Pulmonary rehabilitation  
PR has now become a major tool for managing symptoms in COPD, with the latest American 
Thoracic Society and European Respiratory Society (ATS/ERS) statement defining PR as; “a 
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comprehensive intervention based on a thorough patient assessment followed by patient-
tailored therapies that include, but are not limited to, exercise training, education and 
behaviour change, designed to improve the physical and psychological conditions of people 
with chronic respiratory disease and to promote the long-term adherence to health-enhancing 
behaviours” (Spruit et al., 2013).  
PR itself consists of a multidisciplinary program, including supervised exercise training, 
education that is relevant to the needs and requirements of the individual COPD patient, 
nutritional counselling, psychological and social support (Bolton et al., 2013; Spruit et al., 
2013). Objectives of PR include reducing symptoms and improve both health-related quality 
of life and exercise capacity. In order to achieve these goals, PR covers a breadth of non-
respiratory problems including cardiovascular and muscle de-conditioning, anxiety and 
depression, social isolation, skeletal muscle wasting and weight loss (Bolton et al., 2013; Spruit 
et al., 2013). 
PR is well known to provide effective improvements to these outcomes (Egan et al., 2012; Ries 
et al., 2007; Verrill, Barton, Beasley, & Lippard, 2005). Specifically, a Cochrane review 
collating studies involving PR in COPD has shown both short- and long-term improvements 
in exercise capacity and health related quality of life (McCarthy et al., 2015). Moreover, there 
is significant evidence to show that PR is highly effective and safe intervention to reduce 
hospital admissions, mortality and health-related quality of life in patients who have recently 
suffered an exacerbation of COPD (Puhan, Gimeno‐Santos, Cates, & Troosters, 2016; Ryrsø 
et al., 2018; Sahin et al., 2018; Seymour et al., 2010; Spruit et al., 2013).     
With the benefits of exercise capacity and health related quality of life well documented 
following PR, it has often been proposed that such improvements should translate into 
improved levels of daily PA (Spruit et al., 2013). However, although there are effective 
improvements in measures of exercise capacity, improvements in daily PA are less convincing 
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(Cindy Ng et al., 2012; Spruit et al., 2015; Watz et al., 2014). A number of review articles have 
taken a closer look at this, with both Cindy Ng et al. (2012) and Spruit et al. (2015) investigating 
the effects of exercise training on PA levels. Cindy Ng et al. (2012) reported 7 studies with a 
total sample size of 472 patients, however none were RCT’s. Overall, they found limited effects 
of PR on PA levels, with significant heterogeneity amongst studies. The findings of Spruit et 
al. (2015) were similar, with the addition of 6 studies not included in the review of Cindy Ng 
et al. (2012). Again, results were inconsistent, with 3 studies reporting increased activity levels  
immediately following a PR programme (Mercken et al., 2005; Sewell, Singh, Williams, 
Collier, & Morgan, 2005; Walker et al., 2008), 5 studies documenting negative findings with 
no improvements in PA levels following PR (Coronado et al., 2003; Dallas et al., 2009; Mador, 
Patel, & Nadler, 2011; Saunders et al., 2015; Steele et al., 2003), and the remaining 3 reporting 
mixed results (Demeyer et al., 2014; Egan et al., 2012; Pitta et al., 2008b).  
This discrepancy in findings highlights the extensive knowledge that although PR improves 
exercise capacity and health related quality of life in patients with COPD, such improvements 
do not consistently portray into improvements in PA (Spruit et al., 2013). The reasons for this 
are still relatively unknown, with many believing that because a comprehensive PR programme 
arguably includes all the relevant tools to improve PA in COPD, improvements should be seen 
more often. However due to the complexity of PA as a health behaviour, it is likely that the 
addition of specific strategies that incorporate theoretical constructs to support behaviour 
change for PA are required (Burge et al., 2020; Lahham et al., 2016; Mantoani et al., 2016).  
 
2.15.2 Behaviour changes, feedback and physical activity counselling 
As highlighted in the previous section on PR, increasing exercise capacity alone in patients 
with COPD may be insufficient to increase participation in daily PA (Coronado et al., 2003; 
Dallas et al., 2009; de Blok et al., 2006; Egan et al., 2012; Mador et al., 2011; Mercken et al., 
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2005; Pitta et al., 2008b; Probst et al., 2011; Sewell et al., 2005; Steele et al., 2003; Walker et 
al., 2008). Widespread acknowledgment of this problem has led researchers to identify 
behavioural factors related to patient participation in daily PA and develop several 
interventions targeting these behavioural factors (Burge et al., 2020; Mantoani et al., 2016; 
Watz et al., 2014).  
Such interventions include combining self-monitoring of PA through activity monitors with 
behavioural counselling techniques in patient with COPD, which may have the potential to 
influence PA behaviour (Mantoani et al., 2016). Key components of behavioural interventions 
have been summarised and include mobilising social support using techniques of behaviour 
change and self-regulation (self-monitoring, problem solving, relapse prevention management, 
goal setting, self-reinforcement, performance feedback and developing action plans). 
Interestingly, although evidence is growing, the overall effectiveness of behavioural 
counselling interventions remain inconsistent, inhibiting its overall delivery across COPD 
(Burge et al., 2020; Lahham et al., 2016; Mantoani et al., 2016).  
 
2.15.2.1 Physical activity counselling  
PA counselling is a behavioural intervention employing several behavioural change 
interventions, including the identification of barriers, goal setting, self-efficacy, motivation, 
self-monitoring and feedback, to impact upon the vicious cycle of inactivity in COPD (de Blok 
et al., 2006). Patients receive counselling in order to modify their behaviour towards enhanced 
PA through the application of a pedometer, which allows patient monitoring and feedback of 
their daily steps along with frequently adjusted goal setting (Mantoani et al., 2016). This 
intervention can be delivered in several ways, including face-to-face contact between patients 
and clinicians, group contact during rehabilitation sessions and through electronic information 
and communication technologies (‘tele coaching’) (Demeyer et al., 2017).  Several review 
CHAPTER 2: LITERATURE REVIEW 
W13002500 30  
articles and a meta-analysis have been published assessing the overall effectiveness of this 
intervention (Lahham et al., 2016; Mantoani et al., 2016). In the first systematic review from 
Mantoani et al. (2016), evidence was gathered from 14 studies that included either, advice on 
PA (n=3) or a coaching programme towards a more active lifestyle (n=11), compared to usual 
care in COPD patients. The majority of studies (n=11) reported some level of improvement in 
PA, however generic advice on improving PA was not effective (Mantoani et al., 2016). 
Interestingly, they found that PA coaching that incorporated the use of pedometers was 
successful for increasing PA levels, although the included studies provided small sample sizes. 
In addition, they suggested that an intervention of PA counselling in combination with PR may 
provide significant improvements, with further research needed to explore this concept 
(Mantoani et al., 2016).  
Following this, a systematic review and meta-analysis from Lahham et al. (2016) was the first 
to incorporate studies that assessed PA counselling into a meta-analysis. Unlike Mantoani et 
al. (2016), they only included two studies assessing PA counselling compared to usual care. 
As a result, they found that providing individualised, pedometer-based counselling had no 
effect on improving PA levels (n=2 studies, SMD 0.23 [95% CI] [-0.26, 0.72]. However, they 
were the first to document a positive influence of PA counselling alongside exercise training 
as part of PR, with effective improvements in PA+PR compared to PR alone (n=4 studies, 0.47 
[0.02, 0.92]) (Lahham et al., 2016).  
Finally, a recent Cochrane review by Burge et al. (2020) collated the most up to date literature 
surrounding interventions for promoting PA in COPD. They found that the effectiveness of PA 
counselling to improve levels of PA remained widely inconsistent, highlighting that the 
identification of effective components of PA counselling was complex, with various 
programme durations, participant interfaces and intervention components used (Burge et al., 
2020). Furthermore, components of PA counselling that provided beneficial effects on PA were 
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not accompanied by improvements in health-related quality of life or exercise capacity, with 
further research needed to establish comprehensive improvements in PA, health-related quality 
of life and exercise capacity (Burge et al., 2020).  
 
2.15.2.2 Physical activity counselling alongside pulmonary rehabilitation 
One plausible solution was the incorporation of PA counselling to standard care PR 
programmes. Based on the recently published Cochrane review by Burge et al. (2020), the 
combination of PA counselling with PR has been the subject of numerous RCT’s, with negative 
studies reporting a lack of improvement in PA and clinical outcomes including health-related 
quality of life and exercise capacity (Burtin et al., 2015; Nolan et al., 2017). Meanwhile positive 
studies, including two published abstracts, were variably accompanied by improvements in 
exercise capacity and health-related quality of life (Loeckx, Rodrigues, Demeyer, Janssens, & 
Troosters, 2018b; Mantoani et al., 2018) or unaccompanied by improvements in such clinical 
outcomes (Altenburg et al., 2015; Cruz, Brooks, & Marques, 2014; Kawagoshi et al., 2015).  
Detailing the influence of PA counselling interventions combined with PR on PA levels, 
Lahham et al. (2016) was the first systematic review and meta-analysis to collate and report 
this variable. Specifically, Lahham et al. (2016) pooled together four RCT’s regarding PA 
counselling alongside PR. Overall, they demonstrated that this combined approach provided 
clinically important improvements in steps/day compared to PR alone, although such 
improvements did not achieve statistical significance. This may have been a result of the four 
RCT’s included in the meta-analysis consisting of small sample sizes that may have lowered 
statistical power (Lahham et al., 2016). However, the clinically important improvements in 
steps/day following PA counselling alongside PR reported by Lahham et al. (2016) were 
greater than alternative PA interventions (i.e. PA counselling alone, exercise training alone and 
health advise).  
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Since the publication of Lahham et al. (2016), a large scale RCT from Nolan et al. (2017) has 
been published questioning the overall effectiveness of PA counselling alongside PR, with 
improvements in PA greater following PR alone. These findings are important because they 
provide novel data regarding PA counselling alongside PR in the UK and were the first research 
group to present a large scale RCT with sufficient statistical power. Further details regarding 
this novel RCT are provided in Chapter 3 of this thesis.  
As detailed earlier, Burge et al. (2020) has provided the most up-to date analysis of 
interventions for promoting PA in people with COPD. Similar to PA counselling alone, they 
reported inconsistencies regarding the effectiveness of PA counselling alongside PR to 
improve levels of PA, suggesting that several areas were to consider. This included diversity 
in trial designs, delivery of PA counselling components and a lack of consistency in PA 
capturing tools.  
Therefore, it remains important to continue investigating the impact of behaviour change 
techniques, feedback and PA counselling alongside PR, with an emphasis placed on designing 
an effective PA behavioural modification intervention that can support PR to comprehensively 
improve levels of PA, exercise capacity and health-related quality of life in patients with 
COPD. One novel approach yet to be fully investigated is the influence of psychological 
behavioural modification tools alongside PR and/or PA counselling interventions to support 
patients with COPD. The following section will discuss this in further detail.  
 
2.15.3 Psychological behavioural modification tools  
Alongside the physical barriers influencing daily PA, the distressing nature of COPD has a 
significant impact on patients’ psychological wellbeing. Major focusing points for COPD 
patients are the sense of feeling unwell, the inability to perform everyday activities and the 
emotional consequences of the condition (Pumar et al., 2014; Yohannes & Alexopoulos, 2014). 
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These symptoms can promote psychological difficulties including anxiety and depression, 
which are prevalent in patients with COPD and are associated with, poorer treatment outcomes, 
and reduced survival (Ng et al., 2007; Pumar et al., 2014; Yohannes & Alexopoulos, 2014). 
Furthermore, patients with psychological difficulties are less able to manage symptoms (Thew, 
MacCallam, Salkovskis, & Suntharalingam, 2017), and are less likely to improve levels of PA 
(Yohannes & Alexopoulos, 2014) or attend management sessions such as PR (Bolton et al., 
2013).  
CBT is a psychological therapy delivered to patients with a ≥8 Hospital Anxiety and 
Depression Scale (HADS) score, focusing on understanding how experiences are interpreted, 
through a combination of behavioural and cognitive theories of behaviour (Benjamin et al., 
2011; Heslop & Foley, 2009).  Specifically, the term ‘cognitive’ relates to people’s thoughts, 
emotions, feelings, ideas, beliefs and values, while ‘Behaviour’ relates to what a person does 
or chooses not to do. The main concept of ‘therapy’ involves a person’s emotional reactions 
being influenced by what they ‘think’ (cognitions) or indeed what they ‘do’ (behaviour) 
(Westbrook & Kennerley, 2011). A diagram of the CBT model can be found in Figure 2.  
A core component of CBT is gaining an understanding that it is not the event, but what an 
individual makes of that event that is important (Heslop-Marshall & Burns, 2019). Patients 
may experience the same physical illness but interpret the experience in different ways. CBT 
provides an interaction between thoughts, mood, behaviour and physical sensations, which are 
intrinsically linked (Heslop-Marshall & Burns, 2019). Techniques used for anxiety included 
education on anxiety and COPD, distraction techniques, breathing control and relaxation. 
These techniques help to break the vicious cycle of anxiety and can reduce patients’ distress 
(Heslop-Marshall, 2018). Similar techniques for patients suffering mainly from depression 
included education about depression and inactivity and planning and recording activities each 
day, while rating these for achievement or pleasure. These techniques help to break patient 
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inactivity, which can lead to improved mood and physical condition. A key treatment for 
depression can involve encouragement to increase activities within the patients’ physical 
capabilities (Heslop-Marshall, 2018).  
 
 
 Figure 2. The CBT model, from (Westbrook & Kennerley, 2011) 
 
Heslop-Marshall et al. (2018) designed a pragmatic RCT with sufficient power to address the 
hypothesis that one-to-one CBT sessions, delivered by respiratory nurses, could lead to a 
reduction in anxiety symptoms and could be a cost-effective intervention. A total of 236 
patients completed the RCT, with 155 receiving one-to-one CBT sessions. Overall they 
reported clinically effective reductions in anxiety symptoms that were cost-effective, with 
reduced resource use, lower hospital admissions and reduced emergency department 
attendances (Heslop-Marshall et al., 2018).  
However, the implementation of CBT strategies alongside PR and PA behavioural 
modification intervention is yet to be fully investigated, with only the influence of CBT and 
PR currently under investigation by the TANDEM COPD trial (Sohanpal et al., 2020). In more 
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detail, the TANDEM group have developed a tailored, cognitive behavioural approach, which 
precedes and optimises the benefits of currently offered PR. They hypothesise that such a 
psychological intervention, delivered by training respiratory professionals, will provide 
improvements in mood in patients with mild to moderate anxiety and/or depression and 
encourage uptake and completion of PR. However, this investigation by the TANDEN COPD 
trial have failed to incorporate any assessment of PA, leaving the overall influence of CBT on 
PA open to further investigation.   
 
2.16 Importance of this thesis  
With the availability of growing research, a clear trend has developed highlighting the severity 
of physical inactivity in patients with COPD compared to healthy age matched controls. The 
severity of physical inactivity has significant implications for COPD patient’s health and 
wellbeing, with an increased risk of respiratory exacerbations, respiratory related 
hospitalisation, and overall mortality.  
Although PR has been extensively shown to provide improvements in both exercise capacity 
and health related quality of life, it often fails to have an influence on PA, due to PA being a 
complex health behaviour. Therefore, research has begun assessing the effectiveness of 
behaviour changes, feedback, and PA counselling as both an alternative intervention and in 
addition to PR to improve PA. The incorporation of PA behavioural modification strategies 
has provided the most effective avenues of success, especially alongside PR, but current 
findings remain inconclusive due to diversity in trial designs, leaving the true potential of this 
intervention poorly understood. The inclusion of psychological behavioural modification tools 
such as CBT, may have the potential to stimulate PA levels in specific patient groups alongside 
PR and PA counselling and hold the key to delivering consistent improvements in PA.   
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To gauge a comprehensive understanding of PA behavioural modification interventions and its 
effectiveness towards improving PA, the purpose of this thesis is to expand the existing body 
of knowledge and provide novel data by investigating the role of PA behavioural modification 
interventions to improve PA in COPD, specifically focusing on the impact of combining PA 
behavioural modification techniques, exercise training as part of PR and psychological 
behavioural modification tools in the form of CBT in those with significant anxiety and 
depression. The specific focus of each subsequent chapter is as follows.  
 
2.17 Chapter aims  
Chapter Three: A systematic review and meta-analysis to collate and assess the current 
literature surrounding PA counselling as a standalone intervention and alongside PR and 
investigate the optimal way of using these intervention to effectively improve PA in COPD.  
Chapter Four: Justification and rationale of general methods employed throughout this thesis.  
Chapter Five: Investigate the criterion validity and test-retest reliability of a commercially 
available pedometer.  
Chapter Six: Evaluate PA, muscular strength and endurance and levels of anxiety and 
depression in patients with COPD living in the North East of England compared with healthy 
age matched individuals from the same region of the United Kingdom and identify possible 
correlates associated with PA levels in these patients.  
Chapter Seven: Investigate the feasibility, acceptability and efficacy of a novel intervention 
combining PA behavioural modification strategies, PR and CBT in patients with COPD.  
Chapter Eight: An overall discussion interpreting and supporting the implications of the 
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3.1 Introduction 
Research regarding effective interventions to promote PA have become important in the 
management of COPD due to compelling evidence surrounding physical inactivity and the 
associated risk of increased hospitalisation and mortality (Garcia-Aymerich et al., 2006; 
Garcia-Aymerich et al., 2009; Garcia-Rio et al., 2012; Pitta et al., 2005b; Vaes et al., 2014; 
Waschki et al., 2011; Watz et al., 2014).  
It is well known that PR-induced improvements in exercise capacity often fail to translate into 
enhanced levels of PA in patients with COPD, leading many to identify alternative and adjunct 
interventions to PR to support the promotion of PA (Burge et al., 2020; Lahham et al., 2016; 
Mantoani et al., 2016; Qiu et al., 2018). PA counselling both as a standalone intervention and 
alongside PR has provided the most effective avenues of success, especially alongside PR. 
However, inconsistencies regarding diverse trial designs have left the true potential of this 
intervention poorly understood (Burge et al., 2020).  
Therefore, the purpose of this systematic review and meta-analysis was to collate the most 
recent collection of studies documenting the effects of PA counselling, both as a standalone 
intervention and alongside PR, to elucidate on the design of specific aspects of PA counselling 
related to the ways in which the intervention can be used to optimise PA in COPD patients. 
Specifically, this review investigated the optimal frequency of goal setting, type of patient 
feedback, optimal length of intervention, type of instrument used for assessing PA, and 
associations between baseline activity levels and the magnitude of improvement in daily PA.  
 
3.1.1 Review Objective 
To systematically review and meta-analyse aspects of PA counselling, specifically how the 
interventions are used to optimise PA through the incorporation of pedometers as a key 
component for improving levels of daily PA in patients with COPD.  
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3.2 Methods 
The Cochrane Handbook for Systematic Reviews of Interventions (Green & Higgins, 2005) 
and the preferred reporting items for Systematic Reviews and Meta-Analyses (Moher, Liberati, 
Tetzlaff, & Altman, 2009) guidelines for reporting systematic review and meta-analyses were 
followed when conducting and reporting this prospectively registered systematic review 
(CRD42018103893) https://www.crd.york.ac.uk/prospero/.    
 
3.2.1 Eligibility criteria 
The review team conducted a computerised literature search in the following databases, 
beginning in March 2018: Medline/PubMed, Cochrane Review, Web of Science and 
Cumulative Index to Nursing and Allied Health Literature (CINAHL). The original search of 
the literature ended on 18th January 2019, with an updated search of the literature commencing 
on 12th November 2020. Pre-piloted literature searches prior to the final search strategy were 
conducted based on two previously published systematic reviews on a related topic (Lahham 
et al., 2016; Qiu et al., 2018). An example search strategy can be found in Table 2. It included 
a wide range of modalities; using terms associated with “chronic obstructive pulmonary 
disease”, “physical exercise training”, “physical activity promotion, physical activity 
counselling” and “randomized controlled trial”. Bibliographic details of all articles from the 
different databases were stored in the reference software EndNote.   
On completion of the literature search, all stored references were exported from EndNote to 
the systematic review management software program Covidence. Eligible studies published in 
the English language were included if they fulfilled the pre-determined criteria based on 
population, intervention, comparison, outcomes and setting/study design (PICOS);  
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• Population: individuals with COPD defined by spirometry (i.e. FEV1/FVC <0.7).  
• Interventions or exposures: COPD patients who have been enrolled onto a PA 
intervention which included the use of a tool that provides real-time feedback on 
steps/day (i.e. pedometer screen). This included standalone interventions or those 
incorporated into PR. 
• Comparison or control groups: Patients not receiving any PA intervention. 
• Outcomes of interest: The effect of PA counselling on steps/day as a measure of daily 
PA.  
• Setting: certified research studies. 
•  Study design: RCT, pilot study and/or non-randomised. 
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Table 2. Example search criteria for computerised literature search conducted in PUBMED 
Search  Query  
1 (Chronic obstructive pulmonary disease [Text Word] OR COPD [Text Word] OR Chronic Lung Disease [Text Word] OR Chronic Obstructive Lung Disease [Text Word] OR 




(“exercise” [Text Word] OR “rehabilitation” [Text Word] OR "exercise training" [Text Word] OR "pulmonary exercise training" [Text Word] OR "physical exercise training" 
[Text Word] OR "pulmonary rehabilitation" [Text Word] OR "exercise rehabilitation" [Text Word] OR "cardiopulmonary rehabilitation" [Text Word] OR "rehabilitation 
program*" [Text Word] OR "exercise program*" [Text Word] OR "physical activity advice" [Text Word] OR "physical activity counselling" [Text Word] OR "physical 
activity promotion" [Text Word] OR "accelerometer*" [Text Word] OR "Pedometer*" [Text Word] OR "activity monitor*" [Text Word] OR "step count*" [Text Word] OR "" 




 “Activity” [Text Word] OR "Motor activity"[Text Word] OR " OR "physical inactivity"[Text Word] OR "risk factor"[Text Word] OR "outcome assessment"[Text Word] OR 








1 AND 2 AND 3 AND 4 
CHAPTER 3: SYSTEMATIC REVIEW AND META-ANALYSIS 
W13002500 42 
3.2.2 Data extraction  
After removing the duplicates and based on the inclusion criteria, two authors (MA and NK) 
independently and blinded, reviewed the title and abstract of studies and assessed the full text 
of studies. Any possible disagreement between both authors during the study selection process 
was discussed with a third author (IV) for resolution. 
For each eligible study, a predesigned standardised Excel (Microsoft, USA) form (Appendix 
3a) was used to collect data by a single author (MA) on the following subheadings: author 
information (including name of first author and date of publication), blindness, participant 
characteristics (including age, FEV1 % pred, FVC, 6MWD, baseline daily steps, Total Lung 
Capacity and Residual volume, intervention details, PA measurements, primary outcomes and 
results. Two blinded reviewers (MA and NK) screened all eligible studies independently, any 
disagreements were sent to a third independent author (IV) to make a majority agreement.    
 
3.2.3 Quality assessment 
Quality assessment was performed using the PEDro quality scale, which is an 11-item scale 
assessing internal and external validity of clinical trials (Maher, Sherrington, Herbert, Moseley, 
& Elkins, 2003). Two authors (MA and NK) independently reviewed the following domains 
employed by this scale: eligibility criteria, random allocation, concealed allocation, baseline 
similarity, blinding (subject, therapist, and assessor), and measures recorded from at least 85% 
of participants, full intention to treat, group comparison and point measure. The higher the 
given score, the better the quality. Cut points of the scale were excellent (9-10), good (6-8), 
fair (4-5) and poor (<3) (Maher et al., 2003).  
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3.2.4 Data synthesis 
Meta-analyses were undertaken using Review Manager (RevMan V5.3; Cochrane 
Collaboration, Oxford, UK). Change scores or end of intervention values with the 
corresponding pooled standard deviation for the outcomes of interest were used to obtain the 
overall effect size represented by standard mean difference with 95% confidence interval, with 
a threshold p <0.05 considered as significant.  Heterogeneity in this meta-analysis was assessed 
by I2 value, as follows: 0%-40%, might not be important; 30%-60%, moderate heterogeneity; 
50%-90% substantial heterogeneity; 75%-100% considerable heterogeneity (Higgins & Green, 
2011). A fixed-effects model was used for the meta-analysis; however, if statistical 
heterogeneity was noted (I2>40%), meta-analyses were performed using the random-effects 
model.  Sensitivity analysis was used if a substantial heterogeneity (I2>75%) was reported in 
meta-analyses.    
The clinically important improvement in steps/day referred to throughout this thesis was based 
on the findings of Demeyer et al. (2016). A clinically important improvement is defined as the 
‘smallest difference in score within a domain of interest which patients perceive as beneficial 
and which would mandate, in the absence of troublesome side effects and excessive costs, a 
change in patients’ management’ (Jaeschke, Singer, & Guyatt, 1989). Methods to determine 
clinically important improvements are typically divided into two well-defined categories: 
distribution-based and anchor-based approaches. However, distribution-based methods are 
often most effective when they are applied together with a meaningful external anchor 
(Wyrwich et al., 2005).  
Demeyer et al. (2016) based their calculations on several distribution-based techniques 
including 1) standard error of measurement, 2) empirical rule effect size, 3) Cohen’s effect size 
and 4) 0.5 times the standard deviation of the baseline measurements. In terms of the anchors 
used, the 6MWT distance and CRDQ total and dyspnea domains were chosen as they were 
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associated with levels of PA in cross sectional analyses (Gimeno-Santos et al., 2014) and 
related to changes in walking time after rehabilitation (Pitta et al., 2008b). Alongside anchors, 
a relevant clinical indicator, time for first hospital admission for an exacerbation of COPD 
following completion of PR, was included to assess the calculated clinical important 
improvement alongside a clinical outcome measure.  
The calculated clinically important improvement in steps/day varied depending on the 
distribution-based technique used i.e., 1) 599 steps/day, 2) 1029 steps/day, 3) 1072 steps/day 
and 4) 1131 steps/day respectively). Therefore, it was deemed that a clinically important 
improvement in steps/day would range from 599 to 1131 steps/day. Furthermore, patients who 
exceeded the clinically important improvement reported a lower number of hospital admissions 
in the first two years after rehabilitation, deeming the proposed difference clinically valid 
(Demeyer et al., 2016).  
 
3.3 Results 
During the initial search strategy (commenced March 2018 to January 2019), 2582 potentially 
relevant studies were found. After removing 714 duplicates and screening 1868 abstract/titles, 
55 studies remained for the full-text screening. On completion of full-text screening, 38 studies 
were excluded. Therefore, 17 studies were considered eligible for inclusion in this systematic 
review and meta-analysis. One study provided three different comparisons, resulting in three 
RCTs. An updated search strategy (commenced 12th November 2020) found a further 50 
potentially relevant studies. After removing 4 duplicates and screening 46 abstracts/titles, 8 
studies remained for the full-text screening. On completion of full-text screening, 6 studies 
were excluded. Therefore, 2 studies were added to the original pool of eligible studies included 
in this systematic review and meta-analysis. A full Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses (PRISMA) flow diagram of the screening process is shown in 
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Figure 3. Participants were individually randomised in all included trials (i.e. there were no 
cluster RCTs). Characteristics of included RCTs are summarised in appendix 3a and were all 
published between 2006 to 2020. 
 
3.3.1 Characteristics of included subjects 
All of the included trials (appendix 3a) comprised 1837 patients (53% female), with a median 
sample size of 72 (range 16-343). Included patients had a mean age of 67 years (range 54-75) 
and average FEV1%pred ranged from 34 to 78 indicative of severe to moderate COPD (Vestbo 
et al., 2013).  Patients were reported as physically inactive at baseline with an average mean 
value of 4450 steps/day (range 1557-7161 steps/day).  
 
3.3.2 Characteristics of included/excluded trials 
44 studies were excluded from this review on completion of full-text screening. The reasons 
for exclusion include the wrong intervention (n=17), duplicates (n=9), inappropriate study 
design (n=6), outcomes not meeting criteria (n=6), inappropriate comparators (n=2), no full 
text availability (n=2) and no reported data for daily steps (n=2).   
 
3.3.3 Quality assessment 
Table 3 provides a summary of the risk of bias decision made per category for the included 
studies. In line with the PEDro scale, quality of included studies ranged from good to excellent 
(mean PEDro score, [interquartile range] =7.3, suggesting a low risk of bias towards the main 
outcome measure (Maher et al., 2003).   
 
 
































Figure 3. PRISMA flow diagram for original and updated database search and study selection process 
Records identified through original 
and updated database searching 
(n =2632) 
Additional records identified through 
other sources  
(n =0) 
Records after duplicates removed  
(n =1914) 
Records screened  
(n = 1914) 
Records excluded  
(n =1851) 
Full-text articles assessed 
for eligibility  
(n = 63) 
Full-text articles excluded, 
with reasons  
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Table 3. Qualitative synthesis of included studies using PEDro scale for the quality of RCTs 
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Abbreviations: ITT: Intention to treat. *: yes, score = 1. The higher the given score, the better the quality. Cut-off points of the scale were: excellent (9-10), good (6-8), 
fair (4-5) and poor (3).  
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3.3.4 Meta-analyses of included studies 
When observing the effects of  PA counselling as a standalone intervention, there was a positive 
effect on steps/day compared to usual care (n=14 RCTs, standard mean difference [SMD] 0.49 
[95% CI 0.31, 0.66], p<0.00001); Figure 4 (Altenburg et al., 2015; Arbillaga-Etxarri et al., 
2018; Bender et al., 2016; Demeyer et al., 2017; Hornikx, Demeyer, Camillo, Janssens, & 
Troosters, 2015; Hospes, Bossenbroek, ten Hacken, van Hengel, & de Greef, 2009; 
Kohlbrenner et al., 2020; Mendoza et al., 2015; Moy et al., 2015; Tabak et al., 2014; Vorrink, 
Kort, Troosters, Zanen, & Lammers, 2016; Wan et al., 2017; Wootton et al., 2019) which 
equated to an improvement of 906 [536, 1277] steps/day. A positive effect on steps/day was 
also found when PA counselling was added to PR versus PR alone (n=7 RCTs, SMD 0.52 
[95% CI 0.18, 0.86], p=0.002); Figure 4 (Altenburg et al., 2015; Cruz, Brooks, & Marques, 
2016; de Blok et al., 2006; Holland et al., 2017; Kawagoshi et al., 2015; Nolan et al., 2017; 
Varas et al., 2018), which equated to an improvement of 1659 [506, 2811] steps/day. Both the 
pooled analysis of PA counselling compared to usual care and PA counselling alongside PR 
compared to PR alone reported moderate heterogeneity (I2=61% & 58%) respectively.  
Moreover, the SMD and improved steps/day induced by PA counselling were comparable 
among studies which provided: i) weekly or infrequent goal setting, ii) an intervention length 
less or more than 3 months, iii) remote or face-to-face contact, iv) accelerometer or pedometer 
measured PA (all p<0.05, Table 4). In contrast, studies reporting PA counselling alongside PR 
compared to PR alone were more effective in terms of SMD and steps/day in patients with 
greater baseline PA levels (>4000 steps/day) compared to those with lower baseline PA levels 
(≤4000 steps/day, Table 4). Specifically, only those with high baseline PA levels reported 
significant improvements in the SMD and steps/day of PA (n=3 RCTs, SMD 0.95 [95% CI 
0.22, 1.67], p<0.00001) compared to those with low baseline PA levels (n=3 RCTs, SMD 0.20 
[95% CI -0.02, 0.41], p<0.135). This equated to a clinically important improvement in 
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steps/day of 3130 [95% CI 1957, 4303] steps/day in patients with higher baseline PA compared 
to 115 [95% CI -68, 379] steps/day in those with low baseline PA. 





Figure 4. Effect sizes of physical activity counselling alone and alongside PR on steps/day. Abbreviations: SD, standard deviation; PA, physical activity; PR, 
pulmonary rehabilitation; CI, confidence interval 
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Table 4. Subgroup analysis on components of PA counselling of included studies and the effect size of steps/day 
Subgroups  Overall analysis PA counselling alone PA counselling + PR 
No. 
                           
Effect Size  Steps/day  No. Effect Size  Steps/day No.  Effect Size  Steps/day 
SMD  95% CI  MD 95% CI    SMD      95% CI  MD 95% CI SMD       95% CI  MD 95% CI 
Goal Setting 
Weekly 9 0.51** 0.25, 0.77 849** 348, 1350 6 0.44** 0.16, 0.71 663* 193, 1132 3 0.88 -0.03, 1.78 2137 -437, 4712 
Infrequent  12 0.48** 0.28, 0.67 1206** 684, 1728  8 0.53** 0.27, 0.78 1227** 582, 1872 4 0.29* 0.04, 0.54 980* 174, 1785 
Duration 
≤3 Months  16 0.53** 0.32, 0.73 1083** 616, 1550 1
1 
0.55** 0.27, 0.83 999** 450, 1548 5 0.63 0.11, 1.16 184
5* 
6, 3683 
>3 Months 5 0.36** 0.20, 0.51 835** 492, 1177 3 0.38** 0.20, 0.57 816** 443, 1189 2 0.35 -0.10, 0.80 135
7 
-505, 3220 
Type of Feedback 
Remote  12 0.46** 0.28, 0.64 797** 459, 1136 1
0 
0.46** 0.27, 0.64 730** 396, 1064 2 0.67 -0.32, 1.66 1818 -616, 4252 
Face-to-face 9 0.55* 0.22, 0.87 1759** 526, 2993 4 0.57 -0.06, 1.09 2023** 850, 3196 5 0.51* 0.08, 0.94 1686 -44, 3416 
Measure of PA  
Accelerometer 10 0.41** 0.18, 0.63 792* 291, 1293 6 0.39* 0.09, 0.68 664* 109, 1218 4 0.46 0.05, 0.87 1384* 76, 2692 
Pedometer 11 0.58** 0.37, 0.79 1304** 755, 1854 8 0.57** 0.34, 0.80 1158** 601, 1715 3 0.63 0.00, 1.26 2373** 1005, 3741 
Baseline PA Levels 
≤4000 steps 8 0.35** 0.20, 0.50 554* 192, 917 5 0.44** 0.24, 0.64 669* 253, 1085 3 0.20 -0.02, 0.41 155 -68, 379 
>4000 steps 
 
12 0.60** 0.36, 0.85 1411** 832, 1990 9 0.53** 0.27, 0.79 1116** 547, 1685 3 0.95** 0.22, 1.67 3130** 1957, 4303 
Abbreviations: SMD: Standard Mean Difference, MD: Mean Difference, CI: Confidence Interval, PR: Pulmonary Rehabilitation, PA: Physical Activity 




3.4.1 Summary of the main findings  
This systematic review and meta-analysis, including 21 RCTs, provides updated evidence 
regarding the effectiveness of PA counselling as both a standalone intervention compared to 
usual care and alongside PR compared to PR alone, with significant improvements in steps/day 
that exceeded the clinically important improvement of 599-1100 steps/day (Demeyer et al., 
2016). This increase in steps/day reported as a result of both PA counselling alone or alongside 
PR appears much larger than that from other methods including exercise training as part of PR, 
health monitoring, long term oxygen therapy or neuromuscular electrical stimulation (Lahham 
et al., 2016; Mantoani et al., 2016). In agreement with the findings of Lahham et al. (2016), PA 
counselling alongside PR was superior compared to PA counselling alone towards improving 
PA. However, important findings regarding the effectiveness of PA counselling in patients who 
report low baseline levels of PA were documented, with inferior improvements in steps/day 
documented in those studies that delivered PA counselling alongside PR in patients with 
baseline levels of PA ≤4000 steps/day.  
 
3.4.2 Interpretation of the results  
 
3.4.2.1 Physical activity counselling alone  
The meta-analysis of PA counselling alone in this study is the first to incorporate two recently 
published RCTs (Kohlbrenner et al., 2020; Wootton et al., 2019). The inclusion of these RCT’s 
has reported no changes in PA compared to data from the most recent meta-analysis of Qiu et 
al. (2018). Interestingly, the findings of both the current study and the review of Qiu et al. 
(2018) do not support the findings of Lahham et al. (2016), who demonstrated that PA 
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counselling was not an effective standalone intervention towards improving steps/day in 
patients with COPD. Several disparities are apparent between these review articles. Firstly, 
Lahham et al. (2016) based their analysis of PA counselling on a subgroup analysis of 
subjective and objectively derived PA (Lahham et al., 2016). In contrast, both the current meta-
analysis and that of Qiu et al. (2018) only included studies that were able to demonstrate PA 
which was objectively measured due to limited validity and reliability when measuring PA 
subjectively (Pitta et al., 2005a; Watz et al., 2014). Secondly, the number of included studies 
varied across separate meta-analyses. In this meta-analysis, a total of fourteen studies with an 
average sample size of 120 were included in the pooled analysis of PA counselling as a 
standalone intervention. Meanwhile, Lahham and colleagues only reported two studies 
documenting objectively measured PA, with an average total sample size of 17 (Lahham et al., 
2016). With the significant benefits of collecting and reporting objectively measured PA and a 
much greater sample size across pooled analyses, the current meta-analysis could be argued to 
have more valid findings than Lahham et al. (2016), therefore questioning the negative findings 
of their meta-analysis.   
In terms of the subgroup analysis, which provided a breakdown of the various components 
involved in PA counselling, similar improvements in steps/day were found irrespective of the 
way the intervention was designed or implemented. Interestingly, previous meta-analyses in 
both outpatient adults and patients with type 2 diabetes have demonstrated that step diary use 
for recording steps/day was an important predictor of increased PA levels, however this is yet 
to be documented in patients with COPD and was not demonstrated in the current study 
(Bravata et al., 2007).  
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3.4.2.2 Physical activity counselling alongside pulmonary rehabilitation  
When observing the effects of PA counselling alongside PR, the majority of available literature 
supports its effectiveness in terms of improving levels of PA (Altenburg et al., 2015; Cruz et 
al., 2016; de Blok et al., 2006; Holland et al., 2017; Kawagoshi et al., 2015; Varas et al., 2018). 
Specifically, the present meta-analysis, that includes a recently published RCT (Varas et al., 
2018), and the systematic review and meta-analyses of Lahham et al. (2016) and Qiu et al. 
(2018) have all shown statistically significant improvements in steps/day. Lahham et al. (2016), 
found that providing persistent and individualised feedback on activity levels in conjunction 
with PR, achieved significant effects that exceeded both PA counselling alone and PR alone. 
Furthermore, the present study was in agreement with Lahham et al. (2016) in that PA 
counselling alongside PR provided greater improvements in PA than PA counselling alone. 
Supporting those findings, Qiu et al. (2018) found that the addition of step counters as part of 
PA counselling alongside PR was able to enhance the effects of PR on both PA and exercise 
capacity.    
The publication of Lahham et al. (2016), did not report an important RCT from Nolan et al. 
(2017), which incorporated a PA counselling intervention alongside PR based in the UK. 
Following this twice-weekly, supervised, 8-week, outpatient PR programme alongside PA 
counselling, patients observed minimal improvements in PA following the completion of both 
the PR+PA and PR alone interventions, with neither group able to achieve clinically important 
improvements in steps/day. Based on these findings, they determined that the routine use of 
PA counselling should not be included in standard care PR (Nolan et al., 2017). The findings 
of this study are important as they provide novel data regarding PA counselling alongside PR 
in the UK and were the first research group to document negative findings regarding PA 
counselling alongside PR. Interestingly, the findings of Nolan et al. (2017) were based on a 
sufficiently powered sample size to show statistical significance and scored highly on the 
CHAPTER 3: SYSTEMATIC REVIEW AND META-ANALYSIS 
W13002500 56 
PEDro scale, suggesting it had a low level of bias and a high quality of evidence (Nolan et al., 
2017).  
A major finding of this study is that patients with greater baseline PA levels (>4000 steps/day) 
reported greater improvements in steps/day compared to those with lower baseline PA (≤4000 
steps/day) following PA counselling alongside PR in patients with COPD. Specifically, in 
studies that implemented PA counselling alongside PR, an improvement in steps/day was 
unable to reach the clinically important improvement of 599 steps/day in patients that 
documented baseline PA levels of ≤4000 steps/day (115 [-68, 379] steps/day, Table 4) (de Blok 
et al., 2006; Holland et al., 2017; Nolan et al., 2017). In comparison, significant improvements, 
greater than the clinically important improvement were reported following PA counselling 
alongside PR when patients had a baseline PA >4000 steps/day (3130 [1957, 4303] steps/day, 
Table 4) (Altenburg et al., 2015; Cruz et al., 2016; Varas et al., 2018). This finding may have 
significant implications for those with low baseline PA levels due to the increased risk of 
hospital admissions and mortality as a result of increased physical inactivity (Garcia-Aymerich 
et al., 2006; Garcia-Aymerich et al., 2009; Garcia-Rio et al., 2012; Vaes et al., 2014; Waschki 
et al., 2011). It must be recognised that there were only a small number of studies in this 
subgroup analysis with a small mean sample size, however such differences in steps/day 
warrants closer scrutiny. Within the meta-analysis of Qui and colleagues, they demonstrated 
similar findings, with severe COPD patients (FEV1 <50% Pred) more likely to see negative 
effects of pedometer PA counselling than with moderate severity patients (FEV1 >50% Pred) 
(Qiu et al., 2018). They speculate that this was a result of increased airflow limitation restricting 
the benefits of a pedometer. The choice to assess the severity of patients based on low and high 
baseline levels of PA instead of FEV1 in the current study was due to the association between 
worsening FEV1 and diminishing PA being only modest (Watz et al., 2014).     
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A further potential reason for this finding was proposed by Osadnik et al. (2018), reporting that 
patients with COPD who exhibit greater exercise capacity prior to PR were more likely to 
achieve greater improvements in daily PA. They reported clinically important improvements 
in steps/day in patients reporting a 6MWT >350m compared to ≤350m (707±1780 vs 157±1694 
steps/day respectively). This higher likelihood of improvement in PA in those with a greater 
exercise tolerance may also provide an explanation for those patients exhibiting a higher 
baseline PA level (Osadnik et al., 2018). However in contrast to this, a recent study from Gulart 
et al. (2019) suggested that patients with a lower FEV1 and baseline steps/day were more likely 
to achieve a clinically important improvement in steps/day. This finding was attributed to the 
belief that more severe patients have a greater potential for improvement as they are further 
from their “maximal” capacity, compared with patients with less severe disease (Gulart et al. 
(2019). However, this proposal requires further evidence before it can be considered a viable 
option. Future research may consider investigating the true effect of interventions to improve 
PA in patients with severe COPD vs moderate to low COPD and gauge a better understanding 
of the mechanisms associated with improved PA.  
 
3.4.3 Quality of the evidence 
The overall quality of evidence from included studies was good in line with the PEDro scale 
for quality assessment. The inability to blind subjects reduced the overall quality of evidence 
and increased the risk of bias towards the intervention procedure. Future research reporting the 
effects of PA counselling may improve quality scoring by blinding all subjects from the 
intervention procedure. However, a concern remains that blinding patients from the 
intervention would require a pedometer being issued to a control group, which may present the 
control group with a level of PA counselling as they are able to monitor their daily steps. A 
number of studies were unable to blind any members of the study from patient allocation 
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(Altenburg et al., 2015; Bender et al., 2016; Hornikx et al., 2015; Hospes et al., 2009; Moy et 
al., 2015; Tabak et al., 2014). In any clinical trial, blinding of at least the researcher is desirable 
and the blinding of subjects warranted thus to decrease bias within the findings. When blinding 
is not used or the subject group status is easily detectable, subjects will generally try to fulfil 
the perceived expectation of the researcher (Clark & Mulligan, 2011).  
 
3.4.4 Strengths and Limitations  
This systematic review and meta-analysis is the first to include three recently published RCTs 
reporting PA counselling implemented either alone (Arbillaga-Etxarri et al., 2018; Kohlbrenner 
et al., 2020) or alongside a combined PR programme (Varas et al., 2018). Moreover, it is the 
first to report on the various components involved in PA counselling interventions, highlighting 
that improvements in PA can exceed clinically important improvements with several different 
intervention approaches. Several limitations should be noted. Firstly, considerable 
heterogeneity continues to exist in interventions of this nature, which was partially explained 
by the findings on the components of PA counselling. Secondly, it cannot be determined 
without knowledge, the specific improvement a pedometer intervention can have alongside PR 
without knowing the exact progression of exercise training for individual patients during PR.  
Finally, despite a comprehensive search of the literature using the main scientific search 
databases, there remains a possibility that studies eligible for inclusion may have been missed. 
The search restriction on English written studies and the failure to search for unpublished 
studies and/or abstracts/conference papers may have resulted in selection and publication bias.  
 
3.4.5 Implications for future research  
Several implications for future research should be considered following the findings of this 
study. Firstly, researchers may wish to further investigate the reliability and technical aspects 
CHAPTER 3: SYSTEMATIC REVIEW AND META-ANALYSIS 
W13002500 59 
of PA monitoring to measure changes in PA when designing future interventions both in COPD 
and other populations. A study from van Schooten et al. (2015) investigated the assessment of 
PA monitoring in older adults, demonstrating that several factors may influence the reliability 
of accelerometer derived PA monitoring, including different daily activities and investigating 
PA on an individual vs group level. Specifically, a minimum of two consecutive days of 
accelerometer measurements were required to reliably assess PA outcomes at a group level, 
including ‘the duration of locomotion, sitting, standing and shuffling and movement intensity’. 
Meanwhile for lying and median locomotion bout duration, three and five days were required, 
respectively. Furthermore, when investigating PA on an individual level, a minimum of four 
days of PA measurements were required to achieve the smallest detectable difference (van 
Schooten et al., 2015). Based on these findings, it’s important that future studies investigate 
PA monitoring beyond the limits of steps/day that are demonstrated in this chapter. Specific 
details regarding the technical aspects of accelerometery used throughout this thesis are 
provided in Chapter 4. 
Secondly, considerations should be made prior to comparing any findings with a previously 
defined clinically important improvement. For example, if studies that define a clinically 
important improvement use a different PA device to monitor PA, this may have implications 
due to the validity and reliability of various PA monitoring devices. As a result, future research 
should only compare their findings to a clinically important improvement if a similar PA device 
is used to monitor PA levels.     
Thirdly, standard mean difference and absolute mean difference in steps/day were used instead 
of relative mean difference throughout the meta-analysis and subgroup analysis of this chapter. 
These measures were chosen as they relate to previously administered meta-analyses and 
allowed for simple comparisons to be made (Burge et al., 2020; Lahham et al., 2016; Qiu et 
al., 2018). However, it should be noted that relative mean difference expresses the absolute 
CHAPTER 3: SYSTEMATIC REVIEW AND META-ANALYSIS 
W13002500 60 
change as a percentage of the baseline value and may support a better comparison of 
improvements in steps/day across different interventions and populations. Therefore, future 
meta-analyses should consider the use of relative mean difference as an alternative to standard 
mean difference and/or absolute mean difference.   
 
3.5 Conclusion  
In conclusion, this study has shown that PA counselling promotes steps/day when it is used as 
an intervention alone or alongside PR, with improvements in steps/day greater following PA 
counselling alongside PR. Evidence delivered in this study can be incorporated into future 
study designs aiming to implement a PA behavioural modification intervention, providing 
specific thought towards the design and implementation of such interventions.  
Important evidence is provided in this study highlighting that patients benefit more from PA 
counselling when baseline levels of PA are greater than 4000 steps/day. This finding may have 
significant implications for those with low baseline PA levels due to the increased risk of 
hospital admissions and mortality as a result of increased physical inactivity (Garcia-Aymerich 
et al., 2006; Garcia-Aymerich et al., 2009; Garcia-Rio et al., 2012; Vaes et al., 2014; Waschki 
et al., 2011). Therefore, a greater emphasis on those with low levels of PA are urgently needed 
in order to suppress the decline in PA and promote a more physically activity lifestyle in these 
patients. Potential elements to this may include a greater understanding of patients baseline 
daily PA levels and/or exercise tolerance prior to designing and delivering future RCTs of this 
nature. In addition, future interventions of PA behavioural modification alongside PR, may 
wish to investigate the add-on effect of more complex psychological behavioural therapies (i.e. 
CBT) in those severe COPD patients who exhibit significant limitations in improving daily PA.   
Finally, this study has confirmed that only a single RCT (Nolan et al., 2017) reports on the 
effects of PA counselling alongside PR based in the UK. Intriguingly, it remains the only RCT 
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to report negative effects on PA levels alongside PR. Therefore, more evidence to understand 
the effects of PA behavioural modification interventions alongside PR that is prescribed in the 
UK are needed. Chapter 7 reports the efficacy of combining a PA behavioural modification 
intervention alongside a PR programme (and CBT in those with high levels of anxiety and 
depression) compared to PR alone on daily PA levels in COPD patients living in the North East 
of England with low baseline PA levels.  
 
 






 CHAPTER FOUR: Justification and rationale of general methods employed 





 CHAPTER FIVE: Investigate the criterion validity and test-retest reliability of a 
commercially available pedometer before its use in an intervention of PA behavioural 
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4.1 Introduction  
This chapter provides details on the general methods that were employed throughout this thesis 
with specific justification and rationale for the design and methods employed in:  
 
• Chapter 5: A criterion validity and test-retest reliability study of a commercially 
available pedometer to capture levels of PA in COPD patients.  
• Chapter 6: A case control and cross-sectional study assessing levels of PA in COPD 
patients compared to healthy age-matched controls and identifying correlates 
contributing to physical inactivity in patients with COPD.  
• Chapter 7: An RCT assessing a novel intervention combining PA behavioural 
modification strategies, PR, and CBT in patients with COPD.  
 
4.2 Ethical approvals  
The principles of research ethics state that the individual taking part in the research study 
should not be harmed in any way by the procedures taking place (Aita & Richer, 2005). To 
ensure safety, all measures taken throughout the studies of this thesis were conducted by trained 
researchers and relevant risk assessments were always in place, complying with the current 
health and safety legislations including “The Health and Safety at Work Act 1974” and the 
“Management of Health and Safety at Work Regulations 1999”.  
Research conducted as part of this thesis took place at both the University of Northumbria 
Newcastle and Newcastle upon Tyne Foundation NHS Healthcare Trust (NuTH), as such, 
ethical approval was required from both institutions and NHS committees.  
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4.2.1 University ethical approval  
Institutional ethical approval for Chapters 5 and 6 were submitted to Northumbria University 
Faculty of Health and Life Sciences Research Ethics Committee prior to the commencement 
of research (Appendix 4a). Given the nature of research, risk assessments were carried out and 
adhered to in line with ethical requirements. Ethical approval from Northumbria University 
Ethics Committee was provided (Ref: 12928) on 26/11/18. 
 
4.2.2 NHS ethical approval  
To begin the process of NHS ethical approval, the study protocol (Appendix 4b) was developed 
and submitted to the research and development (R&D) office within the NuTH (Ref no: 08968). 
An Integrated Research Application System (IRAS) project (Appendix 4c) was produced and 
applied for (IRAS ID: 248697) in order to begin the process for obtaining NHS ethical 
approval. Within the IRAS system, relevant documents were submitted and approved by the 
Health Research Authority (HRA) (Appendix 4d) and a favourable opinion received from the 
‘Yorkshire and The Humber- Sheffield’ Research Ethics Committee (REC) on 7th September 
2018 (Ref: 18/YH/0376) (Appendix 4e). Following ethical approval, the NuTH R&D 
department approved and granted permission for the study to commence and provided 
confirmation of capacity and capability (Appendix 4f). Given the nature of this research at an 
NHS site, a research passport and honorary contract/letter of access, was obtained (Appendix 
4g) enabling the researcher to have access to the NHS site and identifiable patient information. 
 
4.3 Data management  
All relevant data collection throughout this thesis conformed to institutional guidelines, the EU 
General Data Protection Regulations (GDPR) and Data Protection Act (2018). In accordance 
with the principles of Good Clinical Practice, essential trial documentation was kept in a trial 
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master file and investigator site file. All paper records including consent forms, clinical 
measurements and completed questionnaires were kept secure in a locked cabinet on the 
premises of the University of Northumbria campus. To conform with NHS research site 
regulations, a folder with relevant patient contact dates (i.e., date of interest shown, date of 
contact and date of consent), a copy of complete informed consent, a participant information 
sheet, a signed case report form, a complete GP letter (Appendix 4h) and an adverse events 
form were stored within the NHS Trust and relevant forms filed in medical records by the chief 
investigator.  
To ensure the quality of data throughout this thesis, all outcome data (i.e. questionnaires) were 
checked manually by the study coordinator (MA) for completeness, clarity of answers and 
consistency before being entered electronically into Microsoft Excel. Any discrepancies with 
data entry were performed by the outcome assessor, with checks against the original 
questionnaires and clinical measurement sheets made.    
Data saved electronically were stored on a password-protected computer and will be destroyed 
2 years following the conclusion of the study. Any identifiable data was destroyed/deleted as 
soon as possible. A complete backup of electronic data was performed monthly, via a password 




4.4.1 COPD patients 
A single cohort of COPD patients were recruited for this thesis from the NuTH Chest Clinic 
and PR waiting lists across both the Royal Victoria Infirmary (RVI) and Freeman hospital. 
Patients were initially approached by a healthcare professional (i.e., consultant respiratory 
physicians/specialist respiratory nurses/respiratory physiotherapists) who documented the 
study requirements and provided a participant information sheet (Appendix 4i) to patients who 
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expressed initial interest. Upon this, patients provided contact details to the healthcare 
professional which were subsequently passed to a member of the research team. A researcher 
contacted interested patients at least 24 hours after initial contact from the healthcare 
professional via telephone and delivered a screening assessment.  
The initial screening assessment was completed over telephone, with the nature and objectives 
of the study explained to the patient in more detail and an opportunity to ask any questions was 
given. Patients were asked to confirm eligibility to the study based on the inclusion/exclusion 
criteria outlined below. On confirmation of eligibility, patients were offered an invitation to 
attend a baseline assessment visit at either the RVI or the Freeman hospital depending on 
patient preference.  
Inclusion criteria: 
1. COPD confirmed by obstructive spirometry.  
2. Clinically stable male or female COPD patients aged 40 years or older.  
3. Optimised medical therapy.  
4. Able to provide informed consent. 
 
Exclusion criteria: 
1. Orthopaedic, neurological, or other concomitant diseases that significantly impair normal 
biomechanical movement patterns, as judged by the investigator. 
2. Moderate or severe acute exacerbation of COPD within 4 weeks.  
3. Unstable ischaemic heart disease, including myocardial infarction within 6 weeks.  
4. Moderate or severe aortic stenosis or hypertrophic obstructive cardiomyopathy.  
5. Uncontrolled hypertension and another condition likely to limit life expectancy to less than 
one year (principally metastatic malignancy). 
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Patients attended the physiotherapy department at either the RVI or Freeman hospital. On 
arrival, patients provided confirmation that they met the inclusion/exclusion criteria and written 
informed consent was obtained (Appendix 4j), conforming to the Medical Research Council 
(MRC) guidelines (Skivington, Matthews, Craig, Simpson, & Moore, 2018).  
 
4.4.2 Healthy participants 
Healthy participants were recruited for this thesis from a non-clinical population on a voluntary 
basis from around the University of Northumbria campus and local area. The recruitment of 
healthy participants was necessary to assess the validity and reliability of PA assessment tools 
(pedometer) via treadmill walking (Chapter 5) and compare PA levels with COPD patients 
from the same region (Chapter 6).  
 A number of recruitment methods were used including (1) a recruitment database of people 
who previously expressed interest in participating in research studies within the university, (2) 
advertisements via recruitment posters (Appendix 4k), (3) Word of mouth around the 
University campus. These recruitment methods were performed to generate a cross sectional 
representative selection of individuals living in the North East of England with diverse 
demographical and clinical characteristics.  
Following a response of interest from individuals, a participant information sheet (Appendix 
4l) was provided with at least 24 hours to consider the information given. Once verbal consent 
was received, the first visit to the Northumbria University laboratory was scheduled. During 
the first visit, individuals were fully informed of the study requirements and were screened for 
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Inclusion criteria: 
1. Normal spirometry results (FEV1/FVC >0.70 & FEV1 > 80% predicted).  
2. Sedentary males and females aged 50-75 years old. 
3. Stable condition with no comorbidities which would affect levels of daily physical 
activity/ability to walk on a treadmill. 
4. Able to provide informed consent. 
 
Exclusion criteria:  
1. Orthopaedic, neurological or other concomitant diseases that significantly impair 
normal biomechanical movement patterns, as judged by the investigator. 
2. Unstable ischaemic heart disease, including myocardial infarction within 6 weeks.  
3. Moderate or severe aortic stenosis or hypertrophic obstructive cardiomyopathy. 
4. Uncontrolled hypertension and another condition likely to limit life expectancy to less 
than one year (principally metastatic malignancy). 
 
Upon meeting the inclusion/exclusion criteria, patients signed an informed consent form 
(Appendix 4m) before being entered into the study and the data collection schedule planned. 
As per the consent form, all patients were free to withdraw from the study at any time.  
 
4.5 Study Design  
To establish sufficient evidence, several study designs were developed throughout this thesis, 
with the purpose of addressing the research aims and hypotheses outlined in Chapter 1. Below 
is a description of the study designs implemented for each chapter with a rationale of why they 
were conceived.  
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4.5.1 Chapter 5: Criterion validity and test-retest reliability.  
The effectiveness of pedometers to assess and promote PA in COPD is dependent on these 
devices being validated as an accurate and reliable measure of PA. Previous literature has 
confirmed the validity and reliability of several pedometers at walking speeds more commonly 
associated with healthy individuals (Kooiman et al., 2015; Takacs et al., 2014). However, at 
slower walking speeds, commonly found in COPD patients, pedometers often underestimate 
step counts (Crouter, Schneider, Karabulut, & Bassett Jr, 2003). As a result, it was important 
to determine the criterion validity and reliability of the pedometer (Fitbug, Fitbug Corporation, 
London, United Kingdom) used in this thesis to determine its ability to record PA at slower 
walking speeds.  
Criterion validity, which measures how well one measure predicts an outcome for another 
measure, was assessed by comparing the step count of the pedometer with visual step counts 
measured through a tally counter or video camera in line with previous validation studies 
(Kooiman et al., 2015; Takacs et al., 2014). Several statistical tests based on the same previous 
validation studies (Kooiman et al., 2015; Takacs et al., 2014)  were used, including (1) paired 
sample T-Test to assess systematic differences, (2) mean percentage error, (3) Bland Altman 
plots to assess the level of agreement and (4) Deming regression. Unlike previous validation 
studies, Deming regression was used as a tool to assess validity in Chapter 5 as both 
measurement tools (pedometer and visual counts) were subject to a degree of random error. 
Specifically, Deming regression is a term used to refer to linear regression analysis in which 
the random error of both methods of assessment are taken into account (Martin, 2000).  
Test-retest reliability, testing consistency over time, was assessed by comparing pedometer 
step count measurements at two time points. Two statistical tests based on previous literature 
(Kooiman et al., 2015; Takacs et al., 2014) were used, including (1) Intra-class correlation 
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coefficient (ICC) to assess inter-rater reliability and (2) Coefficient of variance to assess the 
stability of the pedometer across repeated trials.   
 
4.5.2 Chapter 6: Case control and Cross-sectional study 
As detailed in Chapter 2, levels of PA are significantly lower in patients with COPD compared 
to healthy age-matched individuals, with the severity of inactivity varying depending on study 
geographical location and study population (Boutou et al., 2019; Troosters et al., 2010).  
Several studies have highlighted the severity of physical inactivity in COPD patients compared 
to healthy age-matched controls in mainland Europe and North/South America (Pitta et al., 
2005b; Troosters et al., 2010), however, to our knowledge this has yet to be assessed in the 
UK, particularly on a regional basis. Therefore, it was necessary to gain an understanding of 
PA levels in both COPD patients and healthy age-matched controls living specifically in the 
North East of England. As a result, a case control design was undertaken.  
Its acknowledged that case control studies generate a high level of evidence and have the 
potential for a high external validity, enabling the data to be extrapolated to the wider COPD 
population (Schulz & Grimes, 2002). To control for confounding factors between the COPD 
and healthy populations, the principles of a matched case-control study were used (Dey, 
Mukherjee, & Chakraborty, 2020). Specifically, healthy controls were selected in a manner 
that matched for age (+/- 3 years) based on a previous study of a similar design in COPD 
patients (Troosters et al., 2010).  
Furthermore, it was important to gauge a consideration of baseline daily PA levels in COPD 
patients prior to their inclusion in Chapter 7, since earlier in this thesis it was detailed that 
patients were found to benefit more from PA counselling interventions when baseline levels of 
PA were greater than 4000 steps/day (Armstrong et al., 2019). Prior knowledge of patient’s 
baseline PA levels supported the design and delivery of the RCT in Chapter 7.  
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To identify factors that are associated with PA in patient with COPD, Spearman’s correlation 
coefficient and multiple linear regression analysis using a stepwise model were constructed 
based on a previous study in COPD patients (Troosters et al., 2010). Within these analyses, 
lung function, BMI, exercise capacity, health-related quality of life, anxiety and depression and 
symptoms of breathlessness were included as independent variables. In considering potential 
factors that may be related to PA, variables that have already been linked to the development 
of physical inactivity in COPD, as highlighted in both cross-sectional and longitudinal studies 
and the ERS statement on PA in COPD (Boutou et al., 2019; Pitta et al., 2005b; Troosters et 
al., 2010; Watz et al., 2014) were used.   
 
4.5.3 Chapter 7: RCT  
To date, previous literature has yet to explore the potential for a combined PA behavioural 
modification intervention, alongside PR and CBT in patients with COPD who report 
profoundly low baseline PA. To explore the effectiveness of this combined intervention, 
outcome measures (detailed below) were assessed within group (from baseline to post PR), and 
between groups (PR+PA vs PR alone), with differences assessed using a two-way repeated 
measures ANOVA. To support these findings, assessment of the feasibility of recruitment, 
randomisation and completion rates to patients assigned either to PR+PA or the PR alone 
groups, as well as the acceptability and adherence to the PA behavioural modification 
intervention was conducted.  
To define feasible rates of recruitment, randomisation and completion, a consultation with 
health care professionals involved in the delivery of PR and consideration of previous literature 
were held (Leon, Davis, & Kraemer, 2011; Ward et al., 2018). Following discussions, the 
following criteria were set (1) Recruitment of at least 30% of eligible patients, (2) 
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Randomisation of at least 80% of patients following informed consent, (3) At least 80% of 
randomised patients should complete the intervention period and post assessment visit.  
Assessing the acceptability is essential in the development, evaluation and implementation of 
interventions and may have a significant impact on the effectiveness of the intervention 
(Sekhon, Cartwright, & Francis, 2017). The acceptability of the PR+PA intervention was 
assessed through a qualitative project-tailored questionnaire. The project-tailored patient 
questionnaire administered was based on a previous questionnaire by Loeckx et al. (2018a) and 
specifically tailored to the PA behavioural modification intervention delivered (Appendix 4n).  
Adherence was assessed by examining the degree which components of the intervention were 
used by patients (Donkin et al., 2011). Specifically, actual usage was assessed by (1) The 
number of weekly goal setting targets met, based on a percentage of the 8 weekly step targets 
provided throughout the intervention, (2) Weekly completion of the step count diaries based 
on researcher’s observation of the patient’s diary twice weekly, (3) Pedometer wear time, based 
on a minimum of 70 steps for a valid day of wearing, in line with a previous study (Loeckx et 
al., 2018a) (4) Accelerometer wear time was based on a minimum of 8 hours recording time 
for a valid day of wearing (Demeyer et al., 2014). Furthermore, patients subjectively reported 
their usage of the step counter and step count diary using the project-tailored questionnaire.  
To gauge a better understanding of CBT added to a PA behavioural modification intervention, 
a subgroup analysis was undertaken in patients with HADS ≥8 who were provided with a 
session of CBT alongside their allocated group (PR+PA+CBT vs PR+CBT).    
 
4.6 Outcome measures  
All demographic and outcome assessment tool data for this thesis were collected between 
November 2018 and February 2021. A trained research team collected all data from the RVI 
and Freeman hospital NuTH sites and Northumbria University laboratories. Ethical approvals 
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and participant written informed consent were all confirmed before assessment measures were 
taken. Outcome measures are identified in Table 5 and described below.  
 
 






Table 5. Outcome measures assessed throughout this thesis  
Outcome measures Validity and reliability 
study 
(Chapter 5) 




Accelerometer derived PA   ✓ ✓ 
Pedometer derived PA  
Patient experience of PA (C-PPAC) 
✓  ✓ 
✓ 
Exercise capacity (6MWT)    ✓ 
Lower body muscle strength 
(QMVC) 
 ✓ ✓ 
Upper body muscle strength 
(HG) 
 ✓ ✓ 
Lower body muscle endurance 
(STS) 
 ✓ ✓ 
CAT   ✓ 
CCQ   ✓ 
HADS  ✓ ✓ 
MRC dyspnea scale    ✓ 
Abbreviations: 6MWT: Six Minute Walk Test, CAT: COPD Assessment Test, CCQ: Clinical COPD 
Questionnaire, HADS: Hospital Anxiety and Depression Scale, MRC: Medical Research Council, C-
PPAC: Clinical Visit of Proactive Physical Activity in COPD, QMVC: Quadriceps muscle voluntary 
capacity.  
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4.6.1 Assessment of Anthropometrics Measures 
Stature was measured to the nearest 0.1 cm in both COPD patients (Seca Ltd, Seca 220 
Stadiometer, Birmingham, UK) and healthy participants (stadiometer, SECA 217). Both 
populations followed the same instructions; individuals were asked to remove items of 
footwear, position themselves with their back and heels against the stadiometer. The research 
team member measuring would inform the individual to take a deep breath in and a 
measurement would be taken.  
Body mass was measured in COPD patients (Seca Ltd, Seca Scales 709, Birmingham, UK) and 
healthy participants (Avery scales, SECA 711) to the nearest 0.1 kg. All individuals were asked 
to remove any items from their pockets, remove all items of footwear and asked to stand in the 
centre of the scales. Body mass index (BMI) was calculated using the validated calculation 
(BMI = body mass [kg]/Stature [m2].  
 
4.6.2 Pulmonary function testing  
An objective measure of pulmonary function was performed in every COPD patient at the RVI 
Chest Clinic prior to inclusion in the study and was carried out by respiratory 
nurses/physiologists according to the latest guidelines from The Association for Respiratory 
Technology & Physiology (Sylvester et al., 2020).  
 
4.6.3 Recording of oxygen saturation  
Oxygen saturation (SpO2) was reported in several Chapters across this thesis using a pulse 
oximeter (Nonin, Palm SAT 2500, USA), placed on a finger of preference. Literature 
surrounding the placement of pulse oximetry found that measurements taken from the finger 
were more accurate than those taken from the ear (Jensen, Onyskiw, & Prasad, 1998). A meta-
analysis consisting of 21 oximeters found a correlation coefficient ranging from r = 0.986 to r 
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= 0.591. When SpO2 was measured within the range of 70-100%, the accuracy of most devices 
were found to be within 2-5% of in vitro oximetry (Jensen et al., 1998).  
 
4.6.4 Capturing physical activity 
Within this thesis, PA was captured using both a pedometer (Fitbug, Fitbug Corporation, 
London, United Kingdom, Figure 5) and a triaxial accelerometer (Actigraph wGT3X, 
Actigraph LLC, Pensacola, FL, USA, Figure 5). The Fitbug pedometer was used to record PA 
and self-motivate patients as part of the PA behavioural modification intervention in Chapter 
7. The validity and test-retest reliability of the Fitbug pedometer in both COPD patients and 
healthy controls is detailed in Chapter 5.  
.   
 
 
Figure 5. Fitbug pedometer and Actigraph triaxial accelerometer 
 
The Actigraph wGT3X (Actigraph LLC, Pensacola, FL, USA) is a triaxial accelerometer used 
to objectively capture daily PA throughout this thesis (Table 8) in both COPD patients and 
healthy individuals. Outcomes of the Actigraph wGT3X included step counts, vector 
magnitude units (to calculate movement intensity) and time spent in different intensities of 
activity (Table 6). The Actigraph wGT3X accelerometer was positioned above the anterior 
spine of the iliac crest in line with the anterior axillary line of the dominant hip. This placement 
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location has been reported to result in the highest accuracy (Swartz et al., 2000). All participants 
throughout this thesis were provided with a thorough description of the Actigraph 
accelerometer prior to initiation. This included information on i) correct positioning of the 
device; ii) the wearing period (e.g., wear the device from the moment you wake up until the 
moment you go to bed “wakefulness hours”), with instructions to keep on wearing the device 
even during sedentary time and illness; iii) when to take off the device (e.g. during bathing and 
showering) iv) date of when to stop assessment. A detailed explanation of the accelerometery 
data collection and processing conducted in this thesis is outlined below and condensed in 
Table 7.  
Table 6. MET Intensity Threshold and Cut Points 
  MET Intensity 
Thresholds (METs) 
 Cut Points  
(Activity Counts) 
Sedentary PA  
 
 <1.5  ≤100 
Light PA  
 
 ≥1.5 and <4  >100 and <2296 
Moderate PA  
 
 ≥4 and <6  ≥2296 and <4012 
Vigorous PA   ≥6  ≥4012 
Abbreviations: MET: Metabolic Equivalent Threshold.  
 
4.6.4.1 Sampling period 
Throughout this thesis individuals were required to wear the Actigraph accelerometer during 
waking hours (i.e. 07:00 to 22:00 hours) for 7 days. The Actigraph accelerometers were given 
to individuals in delay mode on day 0 and commenced logging on day one at 07:00 with a 
seven day stop time indicated. Previous research documents that PA measurements during 
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waking hours optimise the compliance between the individual and device, lower the burden 
and help to standardise the sampling period (Demeyer et al., 2014). Research into 
accelerometer derived PA most often use sampling periods of 24-hour assessment or waking 
hours (Demeyer et al., 2014; Furlanetto et al., 2017; Mesquita et al., 2017; Pitta et al., 2005b). 
In COPD patients, activities are typically performed between 7am and 8pm, with 90% of total 
daily steps taken by 8pm. This timeframe was found to be comparable in apparent healthy 
individuals of a similar age and was not affected by disease severity (Doherty et al., 2017; 
Mesquita et al., 2017).  
 
4.6.4.2 Number of assessment days 
In order to achieve a valid assessment of PA, a wearing period of 7 days was deemed 
appropriate throughout this thesis. Rabinovich et al. (2013) documented that patients with 
COPD were almost entirely willing to wear an accelerometer for a minimum of 7 days.  
 
4.6.4.3 Defining a valid day of assessment  
A valid day of assessment throughout this thesis was defined as a minimum of 8 hours of 
activity counts (480 minutes). In patients with COPD, previous literature has suggested the use 
of at least 8 hours of wearing time in order to gauge a clear representation of PA levels 
(Demeyer et al., 2014). Adjustments should be made on an individualised basis if night shift 
working, or variable sleeping patterns affected the sampling period. It is important to validate 
the assessment of PA based on the wear time of the device being used (Actigraph wGT3X), in 
order to ensure the results are representative of patients’ actual PA levels. 
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4.6.4.4 Type of days for analysis 
The type of days (weekdays vs weekends) used to assess PA vary depending on the precise 
aims of relevant Chapters in this thesis. To assess the PA levels of COPD patients in Chapter 
7, weekday levels of PA were analysed (Demeyer et al., 2014). Meanwhile when assessing PA 
levels of both COPD patients and healthy participants in Chapter 6, both weekdays and 
weekends were analysed. When measuring PA across numerous populations, studies have 
typically reported lower levels of PA during the weekend than during weekdays’ (Demeyer et 
al., 2014; Rabinovich et al., 2013; Watz et al., 2009). Importantly, when analysing these 
methods, adding weekend days has been found to increase the variability, but not the observed 
effect of outcomes (Demeyer et al., 2014). Therefore, excluding weekends when analysing the 
effect of an intervention on PA outcomes will support a smaller sample size and a greater 
observed effect (Demeyer et al., 2014). In contrast, when the aim of a study is to characterise 
the PA of a patient cohort with another disease or healthy comparator, including both weekdays 
and weekend days can present a more comprehensive analysis (Demeyer et al., 2014).  
 
4.6.4.5 Number of valid days for inclusion in analysis  
Likewise, with the types of days assessed (outlined above) the number of valid days required 
for inclusion vary across Chapters. In Chapter 7, the highest four weekday step counts were 
taken for the analysis. Demeyer et al. (2014) reported that more weekdays (up to 4) resulted in 
a decreased variability of outcome measures and a smaller sample needed to obtain statistical 
power (Demeyer et al., 2014). Therefore, in clinical trials, 4 weekdays of PA assessment were 
considered as the ideal assessment (Demeyer et al., 2014). In Chapter 6, five valid days 
including weekdays and weekends were required for analysis. Choosing to assess 5 valid days 
provides a greater overview of PA behaviour and increases the variability of data (Demeyer et 
al., 2014).  
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4.6.4.6 Validity and reliability  
Several studies have outlined the validity of the Actigraph wGT3X device for detecting levels 
of daily PA in patients with COPD (Rabinovich et al., 2013; Van Remoortel et al., 2012b). 
Using both ‘lab based’ and ‘real life’ approaches, the Actigraph GT3X was found to be one of 
two most valid and responsive monitors for use in COPD, when correlated with the gold 
standard assessment of energy expenditure (doubly labelled water) (Rabinovich et al., 2013; 
Van Remoortel et al., 2012b). In addition, monitors worn closer to the centre of mass of an 
individual (e.g. belt) provide higher validity compared to wrist worn monitors (Rabinovich et 
al., 2013; Van Remoortel et al., 2012b) 
 
Table 7. Details surrounding accelerometer data collection and processing 
Information  Details  
Accelerometer model 
Piezosensor orientation  
Data collection sample rate  
Deployment method  
Location worn  
Days of wear  
Initialisation  
 
Wear instructions  
Valid day criteria  
Valid recording  
Epoch length  
Actigraph wGT3X Version 5  
Tri-axial  
100 Hz  
Example of fitting provided by researcher (baseline)  
Dominant hip  
7 days (starting the day after visit 1)  
Deployed in delay mode during day 0 and commenced 
logging at 07:00 hrs with a 7 day stop time indicated.   
Wear during hours of wakefulness  
≥8 hours of valid wear time (480 minutes)  
At least 4 valid weekdays  
60 seconds  
Abbreviations: Hz: Hertz, hrs: Hours.   
 
CHAPTER 4: GENERAL METHODS 
W13002500 82 
4.6.4.7 Capturing patients’ physical activity experiences  
The C-PPAC instrument (Appendix 4o) was administered to capture patients’ experiences of 
PA in this thesis. Developed by the framework of the European Union Innovation Medicines 
Initiative (EU-IMI) PROactive project following recommendations from the US food and Drug 
administration, the C-PPAC instrument combines subjective questionnaire items and activity 
monitor variables to measure the amount of PA, difficulty completing PA and total PA 
experience (Gimeno-Santos et al., 2015). The C-PPAC instrument consisted of 12 subjective 
questions with a 7-day recall and was completed using paper and pen. Activity monitor data 
(steps/day and VMU) were taken from the Actigraph wGT3X accelerometer, which has been 
validated to be part of the C-PPAC instrument (Actigraph wGT3X, Actigraph LLC, Pensacola, 
FL, USA) (Gimeno-Santos et al., 2015). Overall C-PPAC scores were calculated by combining 
the 12 subjective questions regarding difficulty and amount of PA with two objective variables 
from the accelerometer (steps/day and VMU). Three scores were generated (amount of PA, 
difficulty of PA and total PA experience) ranging from 0 to 100, where higher numbers 
indicated a better score (Gimeno-Santos et al., 2015).  
A validation study found the C-PPAC instrument to be simple, reliable, and valid for measuring 
patients experiences of PA in COPD (Gimeno-Santos et al., 2015). Furthermore the C-PPAC 
instrument was reported as valid and reliable across sexes, age groups, COPD severity, 
countries, and languages (Gimeno-Santos et al., 2015).  
A recent study from Garcia-Aymerich et al. (2021) was the first to provide data on the 
responsiveness (response to intervention and ability to detect change) and minimal important 
difference following non-pharmacological interventions. Based on this data, authors suggested 
a minimum important difference of 6 for the amount and difficulty scores and 4 for the total 
scores of the C-PPAC instrument  (Garcia-Aymerich et al., 2021).  
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Table 8. Instruments used to capture PA 












Pensacola, FL, USA) 
 ✓ ✓ 
 










Clinical Visits of 
PROactive Physical 
Activity tool (C-PPAC)  
  ✓ 
 
 
4.6.5 Exercise capacity 
The exercise capacity of COPD patients was assessed using the 6MWT throughout this thesis 
(Table 5). The 6MWT is a self-paced test of exercise capacity, with patients required to walk 
as far as possible in six minutes along a 30-metre flat corridor (Holland et al., 2014). The test 
was performed at both hospital sites (RVI and Freeman hospital) over a marked 30 metre 
corridor in accordance to the ATS/ERS technical standards (Holland et al., 2014).  Prior to the 
test, a respiratory physiotherapist recorded measurements of SpO2 and measures of dyspnea 
and leg discomfort using the Modified Borg 1-10 Scale (Appendix 4p). Patients were then 
advised to walk the 30-metre corridor for six minutes at their own pace, taking rests when 
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required. Measurements of SpO2, dyspnea and leg discomfort were taken throughout the walk 
test and on its completion. The 6MWT has demonstrated a moderate-to-strong relationship 
(ICC 0.4 to 0.8 ) with peak VO2, measured using a cardiopulmonary exercise test (CPET) 
(Singh et al., 2014). Furthermore, a moderate to strong relationship has been documented 
between the 6MWT and objectively measured PA (ICC: 0.64-0.75) (Garcia-Rio et al., 2009; 
Hernandes et al., 2009; Pitta et al., 2005b).  
The 6MWT has been reported as a reliable measure of exercise capacity, with good to excellent 
correlation coefficients across a number of studies in COPD (ICC range: 0.72-0.99) (Singh et 
al., 2014). Despite the excellent reliability, there is strong evidence to suggest a learning effect 
can occur when two or more tests are conducted in close proximity of each other. Specifically, 
the percentage of COPD patients who walked further on the second 6MWT ranged from 50%-
87%, with 15% of those reporting a clinically significant improvement on their second walk 
(Sciurba et al., 2003). To reduce the influence of a learning effect on 6MWT outcomes, patients 
were required to perform a second 6MWT within 7 days of the first 6MWT at both pre- and 
post-PR assessments, with the best distance from the two pre and post 6MWT’s recorded 
(Holland et al., 2014).  
Available evidence suggests a clinically important improvement of 30 m for adult patients with 
chronic respiratory disease (Singh et al., 2014). Although some variability across studies and 
methods to determine the clinically important improvement exists, available evidence reports 
that it lies between 25 and 33 m (Singh et al., 2014).  
 
4.6.6 Lower body muscle strength 
Lower body muscle strength (QMVC) was measured using isometric maximal volitional limb 
muscle strength assessment, using a calibrated Myometer (MIE Medical Research Ltd., Leeds, 
UK) throughout this thesis (Table 5). Quadriceps muscle dysfunction has been recognised as a 
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major systemic manifestation of COPD (Barreiro & Gea, 2015), and therefore, it has been 
recommended that quadriceps muscle strength is assessed in COPD (Nyberg, Saey, Martin, & 
Maltais, 2018).  
Individuals sat in a purpose-built chair with an inextensible strap connecting the ankle of their 
dominate leg to a Myometer (MIE Medical Research Ltd., Leeds, UK). Care was taken to 
ensure that the participants knee was flexed to 90 ̊, and that the strain gauge and coupling were 
aligned to ensure an isometric contraction occurred. Participants performed three sustained 
maximal isometric quadriceps contractions of between a 3- and 5-seconds duration, with 
vigorous encouragement given throughout. A resting period of 30-60 seconds between each 
contraction was given to allow time to recover from each effort. The highest of three attempts 
was recorded (Edwards, Young, Hosking, & Jones, 1977).  
Isometric measurements of quadriceps muscle strength using a strain-gauge have been 
recommended over alternative strategies, due to its simplicity, availability and the quality of 
data outputs (Maltais et al., 2014). The test-retest reliability of isometric quadriceps muscle 
maximal strength in patients with COPD were high satisfactory, evident by high ICC (0.97 
[95% CI, 0.92-0.99]) and low coefficient of variance (3.2%) (Nyberg et al., 2018).  
A recently published article from Oliveira et al. (2021) has detailed an updated minimal 
clinically important difference for quadriceps muscle strength in people with COPD following 
completion of PR. The pooled minimal clinically important differences were 5.7kg and 26.9% 
of change for quadriceps one repetition maximal based on the pre-post PR difference (Oliveira 
et al., 2021).  
 
4.6.7 Upper body muscle strength 
Upper body muscle strength assessment was obtained by assessment of handgrip strength using 
a calibrated hand-dynamometer (Camry EH101, Camry Electronic CO. Ltd., Zhongshan, 
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China) throughout this thesis (Table 5). Upper body muscle strength has been associated with 
a higher risk of mortality in COPD patients (Puhan, Siebeling, Zoller, Muggensturm, & Ter 
Riet, 2013). As a result, handgrip strength assessment is recommended in this patient 
population (Puhan et al., 2013). Practice attempts and demonstrations were allowed for 
individuals to make them feel more comfortable about the procedure. Individuals were asked 
to position their elbow at a 90° angle from the side of their body, with the base of the handgrip 
dynamometer placed in the palm of the individuals’ hand. Researched informed the individual 
to grip the handle with maximum isometric effort for 5 seconds, with 30 seconds rest between 
attempts.  
Evidence reports good to excellent (r=0.80) test-retest reproducibility and excellent (r=0.98) 
interrater reliability in healthy volunteers (Mathiowetz, Weber, Volland, & Kashman, 1984; 
Peolsson, Hedlund, & Öberg, 2001). In addition the reliability of hand grip strength in COPD 
patients was identified as excellent, with a mean difference between tests of -0.05±5.97 kg and 
an ICC (0.81) (O’Shea, Taylor, & Paratz, 2007).  
 
4.6.8 Lower body muscle endurance  
The ability to get up from a seated position is essential to several everyday tasks and is 
necessary for autonomy, especially in older people and those with chronic disease (Hansen, 
Beyer, Frølich, Godtfredsen, & Bieler, 2018). The 30 second sit to stand test was therefore used 
to measure lower body muscular endurance across this thesis (Table 5). A straight-backed chair 
with a hard seat was stabilised by placing it against a wall. Floor to seat height was 
approximately 45-47 cm. Individuals were instructed to start in a seated position with their feet 
flat on the floor, back straight, with their upper limbs across the chest (Jones, Rikli, & Beam, 
1999). Prior to the test, a demonstration was given and then a practice attempt was provided to 
the participant to ensure a valid technique was being performed. Individuals started in the 
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seated position and, upon command, stood up and returned to sitting as many times as possible 
in a 30-second time period. The number of fully standing positions were recorded and if the 
individual was over halfway to standing when the 30 seconds had elapsed, this repetition was 
recorded (Jones et al., 1999).  
The 30 second sit to stand test was selected due to its extensive use throughout literature in 
COPD and its efficient nature in assessing lower body muscle endurance in a short period of 
time (Hansen et al., 2018; Zanini et al., 2015; Zanini et al., 2018). The 30 second sit to stand 
test was found to have good levels of agreement (ICC > 0.70) with other sit to stand protocols 
(5 rep test & 1 minute test) in COPD patients (Morita et al., 2015). Furthermore, the 
reproducibility of the 30 second sit to stand test was found to be excellent in COPD patients 
with high ICC (0.94) (Hansen et al., 2018). The minimum clinically important difference 
calculated for the 30 second sit to stand was a change of at least 2 repetitions following 
completion of a PR programme (Zanini et al., 2019).  
 
4.6.9 Hospital Anxiety and Depression Questionnaire 
The HADS questionnaire (Appendix 4q) is a patient-reported measure that examines the 
anxiety and depression of individuals and was used throughout this thesis (Table 5). Both 
depression and anxiety are highly prevalent in patients with COPD and should be assessed and 
treated in order to improve patient’s health related quality of life (Puhan, Frey, Büchi, & 
Schünemann, 2008). The scale consists of two distinct subscales assessing anxiety and 
depression across 7 specific items (Zigmond & Snaith, 1983). Each item is rated on a 0-3 Likert 
scale, with 0 representing ‘absence of that trait’ to 3 representing ‘extreme presence of that 
trait’. The overall scoring of the scale is defined as 0-7 normal; 8-10 borderline 
anxiety/depression; and 11-21 representative of clear anxiety and/or depression (Snaith, 2003). 
An updated systematic review reported on the validity and internal consistency of the HADS 
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questionnaire from studies assessing elderly patients with various chronic diseases. Based on 
15 studies, the Cronbach’s alpha coefficient of internal consistency varied from 0.67 to 0.93 
(mean 0.83), showing good consistency (Bjelland, Dahl, Haug, & Neckelmann, 2002). 
Recently published literature on the minimum clinically important difference for the HADS 
questionnaire proposes a decrease of between -1.8 and -1.3 points for HADS-Anxiety, and 
between -1.7 and -1.5 points for HADS-Depression (Smid et al., 2017).  
 
4.6.10 COPD Assessment Test   
The COPD Assessment Test (CAT) was administered at baseline and post-PR in Chapter 7 
(Table 5) to quantify the impact of COPD on patient’s health related quality of life (Appendix 
4r). This questionnaire was developed as a shorter tool which would be easier and quicker to 
complete and therefore more applicable in clinical settings than the St Georges Respiratory 
Questionnaire (Jones et al., 2009). It is a self-reported questionnaire taking around 5 minutes 
to complete, consisting of eight items that include; cough, phlegm, chest tightness, 
breathlessness, going up hills/stairs, activity limitation, confidence leaving home, sleep and 
energy. All points are scored from 0 to 5 giving a total score in the range of 0 to 40 (Jones et 
al., 2009). The development and validity of this questionnaire was assessed with very good 
validity (r=0.80) compared to the St Georges Respiratory Questionnaire in stable COPD 
patients (Jones et al., 2009). Recently published literature on the minimum clinically important 
difference for the CAT questionnaire proposes a decrease of between -3.0 and -2.0 points (Smid 
et al., 2017).  
 
4.6.11 Clinical COPD Questionnaire 
Likewise, with the CAT questionnaire, the Clinical COPD Questionnaire (CCQ) was 
developed as a shorter, easier tool for implementation in a clinical setting, and was 
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implemented at baseline and post-PR in Chapter 7 (Table 5, Appendix 4s). It provides a 
reflection of patient’s physical symptoms, emotional response and activity limitation to the 
disease. Based on a Likert scale (0 to 6), 10 questions are asked, reflecting symptoms, 
functional state and mental, with a maximum score of 15 indicating severe disability (Van der 
Molen et al., 2003). The reliability of the CCQ questionnaire was good across all domain levels; 
total (ICC) (0.85), symptoms (0.74), functional state (0.86) and mental state (0.83) (Ställberg, 
Nokela, Ehrs, Hjemdal, & Jonsson, 2009). Good intra-class correlations with the SGRQ was 
also reported, regardless of COPD severity (Ställberg et al., 2009). Recently published 
literature on the minimum clinically important difference for the CCQ total proposes a decrease 
of between -0.5 and -0.3 (Smid et al., 2017). 
 
4.6.12 Medical Research Council Dyspnea Scale 
The MRC Dyspnea scale (Appendix 4t) is a subjective measure used to quantify disability 
attributable to breathlessness in COPD patients and was implemented at baseline and post-PR 
in Chapter 7 (Table 5) (Fletcher, Elmes, Fairbairn, & Wood, 1959). It is based on five grades 
of increasing severity, rating the type and magnitude of dyspnea experienced. The five grading 
categories encompass the whole range of respiratory disability (from non to almost complete 
incapacity). It can be self-administered, and the score is the number that best fits the patient’s 
levels of activity. The MRC scale cannot quantify breathlessness itself, but the disability 
associated with activities of daily living. The MRC has been previously validated for use in 
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5.1 Introduction  
Subjective methods of PA assessment (e.g. recall questionnaires and diaries) are the most 
popular instruments for quantifying levels of PA in COPD patients, however, many are prone 
to recall bias, limiting the validity and reproducibility of these tools to assess and promote 
levels of PA (Watz et al., 2009). Objective methods, including pedometers and accelerometers 
are now becoming optimal for the quantification of the amount and intensity of PA (Reilly et 
al., 2008). Previous literature has documented the benefits of accelerometers to provide an 
objective, practical, accurate and reliable means of quantifying PA in various populations 
(Rabinovich et al., 2013; Van Remoortel et al., 2012b). Unfortunately,  the vast majority of 
accelerometer devices are unable to provide patients with direct feedback of PA levels, making 
these devices difficult to incorporate into PA counselling interventions (Armstrong et al., 2019; 
Qiu et al., 2018).  
Unlike accelerometer devices, pedometers provide more limited PA measurements, with 
step/day and calorie counts often the only information collected. Benefits of pedometer devices 
include their simplicity of use and cheap shelf price, with many having the beneficiary of a 
visual display, rendering them more accessible and user friendly. This has led to their increased 
use in interventions to promote PA, as the visual display provides direct feedback of activity 
levels, acting as a motivational tool to self-monitor PA behaviour (Armstrong et al., 2019; 
Burge et al., 2020; Mantoani et al., 2016). As detailed in Chapter 3, pedometers are an effective 
tool for promoting PA, either as a standalone intervention or alongside PR, inducing 
meaningful improvement in steps/day in patients with COPD (Armstrong et al., 2019).  
The effectiveness of pedometers to assess and promote PA in COPD patients is dependent on 
them being validated as an accurate and reliable measure of PA. Previous literature has 
confirmed the validity and reliability of numerous pedometers at walking speeds more 
commonly associated with healthy individuals (≥1.11 m/s) (Crouter et al., 2003; Feito, Bassett, 
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& Thompson, 2012; Hasson, Haller, Pober, Staudenmayer, & Freedson, 2009; Kooiman et al., 
2015; Takacs et al., 2014). However, at slower walking speeds (<1.0 m/s) pedometers often 
underestimate step counts as a result of less prominent vertical accelerations, limiting the 
ability to quantify movement (Crouter et al., 2003). In patients with COPD, it is common to 
ambulate at slower speeds than healthy individuals, therefore it is important to determine the 
validity and reliability of pedometers at slower walking speeds prior to their use in patients 
with COPD (Ilgin et al., 2011). 
Accordingly, the purpose of this study was to assess the criterion validity and test-retest 
reliability of the Fitbug pedometer (Fitbug Corporation, London, United Kingdom) in a 
controlled environment, prior to its inclusion in a PA behavioural modification intervention 
(Chapter 7), in patients with COPD and apparent healthy individuals, compared to direct 




5.2.1 Study design 
This cross-sectional investigation was conducted as two separate sub studies: (1) assessment 
of criterion validity in COPD patients while in a controlled hospital environment; (2) 
assessment of criterion validity and test re-test reliability in a group of apparent healthy 
individuals while in a controlled laboratory environment.   
 
5.2.2 Study participants 
A convenience sample of 24 healthy adults and 14 patients moderate to severe COPD were 
recruited to this study. Apparent healthy adults were recruited from a database of people who 
previous expressed interest in participating in research studies, and from advertisements within 
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the University of Northumbria at Newcastle. Meanwhile COPD patients were recruited as part 
of the RCT detailed in Chapter 7 (detailed in Chapter 4).  
5.2.3 Measurement Tools  
 
5.2.3.1 Step counter 
The Fitbug pedometer (Figure 6) is a small device containing a piezo-electric model to detect 
body movement. It can be carried on the waist using an adjustable strap or detachable clip and 
has a 2x3 cm LCD display to illustrate step counts, distance, calorie, and time functions. In 
addition, internal memory of the pedometer supports 14 days of step count history, limiting the 
amount of data lost and the expected battery life is 18-24 months making the device sustainable 




Figure 6. Fitbug pedometer  
 
 
5.2.3.2 Visual step counts 
Depending on the sub-study, direct observations of PA were recorded through (1) a video 
camera (Sony, Handycam HDR-CX240) attached to a tripod (Hama) in healthy participants or 
(2) tally counter manually operated by a researcher in COPD patients. Further details are 
provided below.  
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5.2.4 Study Protocol 1: COPD Patients 
To examine the criterion validity of the Fitbug pedometer in a controlled environment, patients 
with COPD were asked to wear the pedometer during a 6MWT at the conclusion of PR. The 
6MWT was performed by a respiratory physiotherapist according to the instructions of the 
ATS/ERS technical standards (Holland et al., 2014). Patients were required to walk repeatedly 
along a 30-metre corridor for 6 minutes, with the aim of walking as far as possible (detailed in 
Chapter 4). Data regarding stature, body mass and gender were entered into the pedometer prior 
to the start of the 6MWT. Following approval from the respiratory physiotherapist and patient, 
the pedometer was attached on the dominant hip at the mid-clavicular line using an elasticated 
waist band. Visual step counts were recorded by two researchers using a hand tally device.  
Pedometer step counts were recorded on completion of the 6MWT and compared to the visual 
step counts. To gain an understanding of the average walking speed of a COPD patient living 
in the North East of England, the following calculation was used: (Walking speed (m/s) = 
6MWT distance (m) / walking time (s)). For example, a 6MWT distance of 300 m during which 
a patient has an unintended stop (s) of a total duration of 40s, the 6MWT speed would be 0.94 
m/s (e.g. 300/320) (Cesari et al., 2005; Studenski et al., 2011).  
 
5.2.5 Study Protocol 2: Healthy participants  
To examine the criterion validity and test-retest reliability of the Fitbug pedometer in a 
controlled environment, healthy adults visited Northumbria University’s exercise laboratory 
on two separate occasions to perform a walking treadmill protocol. Upon arrival, demographic 
data was collected and stature, body mass and gender were entered onto the pedometer. 
Participants received verbal instruction on how to use the treadmill, followed by a 5-minute 
familiarisation/warm-up period to enable the participant to experience the different speeds 
during the protocol. In an identical manner to study protocol 1, the pedometer was attached on 
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the dominant hip at the mid-clavicular line using an elasticated waist band. The walking 
protocol consisted of four pre-defined speeds (0.69/0.83/0.97/1.11m/s), reflecting those 
commonly undertaken by patients with COPD both during the 6MWT (study protocol 1) and 
based on previous literature (Louvaris et al., 2013).  
Each speed was performed at a 0% gradient for a 2-minute duration. Participants received a 5 
second warning prior to completion of each speed and adequate rest was provided between 
speeds. Researchers recorded pedometer step counts between speeds and devices were reset to 
zero before proceeding to the next speed. Throughout the protocol, a video camera was focused 
on the participants lower limbs to visually record steps. Visit 2 was undertaken approximately 
8 days later, with the walking protocol repeated.   
 
5.2.6 Statistical analysis  
All statistical analyses were conducted using SPSS v26 (IBM Statistics) or GraphPad 5.03 with 
descriptive statistics used to characterise the sample. The criterion validity of the pedometer 
was calculated using several statistical tests; (1) Deming regression was employed to assess 
the agreement between Fitbug step counts and visual step counts. Agreement was confirmed if 
the 95% confidence interval for the slope contained 1 and the intercept contained 0 (Deming, 
1943); (2) Bland-Altman plots with associated limits of agreement (LOA) were constructed to 
visually inspect the data and to assess the agreement with the criterion measure (Bland & 
Altman, 1986). In the Bland-Altman plot, an average of the criterion measure and Fitbug were 
plotted against the difference between both measures to give an indication of agreement 
between the Fitbug and visual step counts; (3) Mean percentage errors between the Fitbug and 
criterion measure was also calculated using the following equation, “Fitbug step count-visual 
count / visual count x 100”, with values closer to zero indicating more accurate pedometer 
results. A percentage relative error exceeding 5% was considered as a practically relevant 
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difference (Middleton, Fritz, & Lusardi, 2015; Musto, Jacobs, Nash, DelRossi, & Perry, 2010). 
(4) The mean difference between two measures of step counts was measured using a paired 
sample T Test, with the Wilcoxon test used for non-normally distributed data. A rationale for 
the criterion validity statistical tests used are detailed in Chapter 4. The test-retest reliability of 
the Fitbug in healthy participants were calculated using ICC (two-way mixed, absolute 
agreement, average measures with a 95% confidence interval) between visit 1 and visit 2. 
Common cut-off points for the ICC assessment were used; >.90 (excellent), .75-.90 (good), 
.60-.75 (moderate), and < .60 (low) (Koo & Li, 2016). Using the ICC as a measure of relative 
reliability is well-accepted, however it is difficult to interpret ICC values due to their high 
dependence on the variable of the group being assessed. Therefore, to assess the absolute 
reliability, typical error expressed as a percentage of Coefficient of Variance (CV) was also 
calculated. A rationale for the test re-test reliability statistical tests used are detailed in Chapter 
4.  
 
5.3 Results  
5.3.1 Baseline characteristics  
Baseline characteristics of COPD patients and healthy adults are summarised in Table 9. A 
total of 14 COPD patients and 24 healthy adults volunteered to participate, 18 of whom were 
males and all of whom were of white ethnicity. A mean age of 73±7 and 58±17 years and a 
mean BMI of 26.5±5 and 26.2±8 were reported in COPD patients and healthy adults, 
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Table 9. Baseline characteristics  
 Healthy adults 
(n=24) 
 












Gender (M/F) 14/10 
 
5/9 0.188 
Stature (cm) 171±9 161±13  0.001 
Body Mass (kg) 78±16 69±17  0.103 
BMI (kg/m2) 26.5±5 26.2±8  0.882 
FEV1 (litres)  3.3±0.9 1.1±0.4 0.001 
FEV1 (% predicted)  110±10 50±20 0.0001 
FVC (litres)  4.0±1.1 2.3±0.7 0.001 
FEV1/FVC (%) 
 
80±10 48±14 0.001 
Abbreviations: M: Male, F: Female, cm: Centimetre, kg: Kilograms, BMI: Body Mass Index, 
m2: Metres squared, FEV1: Forced Expiratory Volume in 1 second, FVC: Forced Vital 
Capacity. 
Mean ± S.D are indicated for all columns unless stated.  
 
 
5.3.2 Criterion validity in COPD patients  
During the 6MWT, step counts were deemed consistent between the pedometer (566±66 step 
counts) and visual (566±65 step counts), with no significant differences (p>0.05). Bland-
Altman plot analysis were conducted to visually inspect the agreement between the pedometer 
and visual counts, upper and lower LOA were -33.41 to 32.41 and bias -0.50. Most of the points 
fall between the 95% LOA suggesting a normal distribution of differences (Figure 7). Deming 
regression analysis revealed no systematic [13.10 (-77.8 to 104.1) steps] or proportional bias 
[0.97 (0.82 to 1.13) steps] between the pedometer and visual step counts (Figure 10). The 
pedometer criterion validity was analysed further based on the average walking speed of COPD 
patients calculated during the 6MWT (0.85±0.17 m/s), with the analysis stratified by slower 
(≤0.85 m/s) and faster (>0.85 m/s) walking speeds. Step count recordings were deemed valid 
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between the pedometer and visual counts at ≤0.83 m/s (531±51 and 611±58)  and >0.85 m/s 
(529±53 and 614±46) respectively, with no significant differences (p>0.05). LOA were -13.06 
to 15.81, with a bias of 1.38 at slower walking speeds (Figure 8) and -52.74 to 46.74, with a 
bias of 0.83 at faster walking speeds (Figure 9). All data points fall between the 95% LOA 
suggesting a normal distribution of differences. Deming regression analysis revealed no 
systematic [-22.02 (-97.48 to 53.43) and 145.6 (-157.9 to 449.1) steps] or proportional bias 
[1.04 (0.90 to 1.18) and 0.77 (0.27 to 1.16) steps] between the pedometer and visual step counts 
at slower and faster walking speeds respectively (Figures 11 and 12).  
 
 




































Figure 7. Bland Altman limits of agreement for all COPD patients (red line indiciating the mean and 
dotted lines denoting the upper and lower limits of agreement)
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Figure 8. Bland Altman limits of agreement for COPD patients with slower walking speed (≤0.85 m/s), 
red line indiciating the mean and dotted lines denoting the upper and lower limits of agreement) 
 





































Figure 9. Bland Altman limits of agreement for COPD patients with faster walking speed (>0.85 m/s), 
red line indiciating the mean and dotted lines denoting the upper and lower limits of agreement)  
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Figure 11. Deming regression analysis for COPD patients with slower walking speed (≤0.85, solid line 
represents the line of identity) 
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Figure 12. Deming regression analysis for COPD patients with faster walking speed (>0.85, solid line 
represents the line of identity) 
 
 
5.3.3 Criterion validity in Healthy Participants  
The pedometer was deemed valid, with no significant differences (p>0.05) in step counts 
between the pedometer and visual counts across all four pre-defined treadmill speeds (0.69, 
0.83, 0.97 and 1.11m/s) (Figure 13). The mean percentage error of the pedometer at all 
treadmill walking speeds were less than 5.0% (Figure 14).   
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Figure 13. Difference between Fitbug and visual step counts at four pre-defined treadmill speeds in 




Figure 14. Mean percentage error of Fitbug pedometer at four pre-defined treadmill speeds in healthy 
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5.3.3.1 Treadmill walking speed (0.69 m/s) 
Bland-Altman plot analysis illustrated the upper and lower LOA at 0.69 m/s were -39.29 to 
33.20, with a bias of -3.04. Most of the points fall between the 95% LOA suggesting a normal 
distribution of difference (Figure 15). Deming regression analysis revealed no evidence of 
systematic [intercept (95% CI) = -10.38 (-84.89 to 64.14) steps] or proportional bias [slope 
(95% CI) = 1.04 (0.63 to 1.45) steps] between the pedometer and visual step counts at 0.69 m/s 
(Figure 16).  






































Figure 15. Bland Altman limits of agreement for healthy participants at 0.69 m/s (red line indicating 
the mean, black solid lines denoting the upper and lower limits of agreement & dashed lines indicating 
precision estimates 95% CI for the mean, upper and lower limits of agreement).  
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5.3.3.2 Treadmill walking speed (0.83 m/s) 
At 0.83 m/s, Bland-Altman plot analysis illustrated the upper and lower LOA were -17.22 to 
11.47, with a bias of -2.88. The majority of points fall between the 95% LOA suggesting a 
normal distribution of differences (Figure 17). Deming regression analysis revealed no 
systematic [2.96 (-26.87 to 32.80) steps] or proportional bias [0.97 (0.82 to 1.12) steps] 
between the pedometer and visual step counts, (Figure 18).  
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Figure 17. Bland Altman limits of agreement for healthy participants at 0.83 m/s (red line indicating 




























Figure 18. Deming regression analysis for healthy participants at 0.83 m/s (solid line represents the line 
of identity) 
 
CHAPTER 5: VALIDTY AND RELIABILITY 
W13002500 106 
5.3.3.3 Treadmill walking speed (0.97 m/s) 
At 0.97 m/s, Bland-Altman plot analysis illustrated the upper and lower LOA were -11.53 to 
15.70 and a bias of 2.08, with all but one data point falling between the 95% LOA suggesting 
a normal distribution of differences (Figure 19). Deming regression analysis revealed no 
systematic [-5.99 (-36.37 to 24.39) steps] or proportional bias [1.04 (0.89 to 1.19) steps] 
between the pedometer and visual step counts, (Figure 20).  
 




































Figure 19. Bland Altman limits of agreement for healthy participants at 0.97 m/s (red line indicating 
the mean and dotted line denoting the upper and lower limits of agreement) 
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5.3.3.4 Treadmill walking speed (1.11 m/s) 
The Bland-Altman plot analysis illustrated the upper and lower LOA were -10.02 to 10.85 and 
a bias of 0.42 at 1.11 m/s, with most of the data points falling between the 95% LOA suggesting 
a normal distribution of differences (Figure 21). Deming regression analysis revealed no 
systematic [-13.78 (-41.09 to 13.54) steps] or proportional bias [1.07 (0.94 to 1.19) steps] 
between the pedometer and visual step counts (Figure 22).  
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Figure 21. Bland Altman limits of agreement for healthy participants at 1.11 m/s (red line indicating 
the mean and dotted line denoting the upper and lower limits of agreement) 
 
 






















Figure 22. Deming regression analysis for healthy participants at 1.11 m/s (solid line represents the line 
of identity) 
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5.3.4 Test-retest reliability in Healthy participants   
The pedometer demonstrated moderate to excellent test-retest reliability at all treadmill 
walking speeds (ICC >0.81 and 95% CI >0.56). Absolute reliability was deemed good to 
excellent at all walking speeds, with CV% values of 9.2 (95% CI -7.4 to 2.0) %, 4.0 (3.3-5.1) 
%, 2.4 (2.0-3.1) % and 1.4 (1.1-1.8) % respectively (Table 10).   
 
 
Table 10. Test-retest reliability of the Fitbug pedometer 
Speed (m/s) Test 1 
Step counts 
Mean ± SD 
Test 2  
Step counts 
Mean ± SD 













0.81(0.56 to 0.92)  
0.94(0.84 to 0.97)  
0.97 (0.90 to 0.99) 
0.97 (0.93 to 0.98)  
9.2 (-7.4 to 2.0) 
4.0 (3.3 to 5.1) 
2.4 (2.0 to 3.1)  
1.4 (1.1 to 1.8)   
Abbreviations: CV: Coefficient of variance, SD: Standard Deviation, ICC: Intra-class correlation 
coefficient. Intra-class correlation coefficient values (ICC2,1 values) denote the intra-device reliability of 





















5.4.1 Summary of the main findings 
This study examined the criterion validity and test re-test reliability of step counts from a low 
cost, commercially available pedometer (Fitbug) in a controlled environment prior to its 
inclusion in a PA behavioural modification intervention (Chapter 7) as a tool to self-monitor 
PA. No systematic or proportional bias were reported between step count measurement tools 
in either a laboratory or hospital setting, regardless of walking speed. The test re-test reliability 
of the Fitbug pedometer was good to excellent across all standardised walking speeds in both 
treadmill walking and during the 6MWT. The findings of this study support the use of the 
Fitbug pedometer for the measurement of step counts throughout this thesis in patients with 
COPD with slow average walking speeds. In addition, these findings have practical 
implications for both researchers and healthcare providers who wish to quantify PA in a large 
population and/or monitor PA over the longevity of an intervention feasibly and affordably.  
 
5.4.2 Treadmill Validity and Reliability in Healthy Individuals   
Much of the literature surrounding pedometer validity and reliability predominantly covers 
walking speeds ranging from 0.88 to 1.80 m/s, albeit at walking speeds commonly associated 
with healthy individuals (Crouter et al., 2003; Feito et al., 2012; Hasson et al., 2009; Kooiman 
et al., 2015; Takacs et al., 2014). A study by Hasson et al. (2009) validated two commercially 
available pedometers (Omran and Yamax) across a range of walking speeds in healthy 
participants (1.12-1.56 m/s), detailing high validity (percent random error = 0.7-1.7) at walking 
speeds of 1.56 m/s and above. However, when assessing the validity of the Yamax pedometer 
at the slowest walking speed (1.12 m/s), the level of validity declined considerably (percent 
error = 16%) (Hasson et al., 2009). In contrast, the performance of the Fitbug used in this study 
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at a similar walking speed (1.11 m/s), reported much lower mean percent error than the Yamax 
(1.5%).  
The association between slower walking speeds and reduced validity is well documented in 
research surrounding pedometers. In a study assessing ten commercially available pedometers 
across various treadmill walking speeds, authors cited that 6 of the 10 models gave poor 
validity at speeds varying from 0.90 to 1.11 m/s (Crouter et al., 2003).  
It is thought that inconsistencies at primarily slow walking speeds are a result of less 
pronounced vertical accelerations at the hip (Crouter et al., 2003). These findings are 
commonly demonstrated in pedometers which use a spring-suspended lever arm mechanism. 
In such models, recordings are made through up and down movements of a lever arm in 
response to vertical acceleration at the hip. This momentum causes an electrical circuit, with 
electrical contacts translating into step counts (Crouter et al., 2005). With inferior vertical 
accelerations documented at slower walking speeds, the lever arm mechanism is unable to 
respond as accurately to movement, limiting the electrical contacts and therefore the translated 
number of step counts (Crouter et al., 2005). Alternatively, many modern pedometers, 
including the Fitbug, use a piezo-electric mechanism. This mechanism has been deemed more 
reliable at slower walking speeds due to a greater response to changes in vertical acceleration 
(Crouter et al., 2005). For example, piezo-electric pedometers have a horizontal cantilevered 
beam with a weight on the end, which causes compression on a piezo-electric crystal when 
acceleration commences, generating voltage. The generated voltage is proportionate to the 
acceleration of the individual, therefore the voltage oscillations formed are used to record step 
counts (Crouter et al., 2005).  
The Fitbit One (Fitbit Inc., San Francisco, CA) pedometer, which incorporates a 
microelectromechanical triaxial accelerometer, converting acceleration into step counts, 
reported similar validity and reliability to the Fitbug in healthy participants (Takacs et al., 
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2014). High validity and reliability at various walking speeds, including those below 1.11 m/s 
were reported. Percentage relative error were found to be similar, with values below 1.3% and 
ICC >0.95 for all tested walking speeds (Takacs et al., 2014). The validity and reliability of the 
Fitbit one was not assessed at the slowest walking speeds relevant for COPD patients in the 
North East of England (0.67 m/s), but it supports the growing evidence that pedometers of that 
nature (Fitbit and Fitbug) are becoming a more valid tool for usage in clinical populations with 
predominately slower walking speeds. The ability of pedometers like the Fitbug to provide 
valid step counts at these slow walking speeds are essential to support interventions aimed at 
promoting PA (Bravata et al., 2007). This is particularly important when considering PA 
interventions in COPD patients who report extremely slow walking speeds, reported by those 
living in the North East of England (see next chapter). Often interventions assessing PA require 
large sample sizes, with high consumable costs due to the long-term monitoring of PA levels. 
Incorporating complex monitors (i.e. accelerometer) that are well-validated are desirable, 
however, they present high consumable costs and do not allow for easy PA 
monitoring/feedback (Van Remoortel et al., 2012b). As a result, having access to valid and 
reliable pedometers, that are inexpensive and commercially available, makes monitoring and 
promoting PA in a research setting more feasible.  
 
5.4.3 6MWT Validity in COPD Patients  
Similar findings have been reported when validating pedometers in patients with chronic 
respiratory diseases (Turner, Houchen, Williams, & Singh, 2012). Statistical analysis at various 
walking speeds while undertaking an endurance shuttle walk test found significant differences 
(p<0.05) between the step counter and visual counts at slow (0.49 – 0.75 m/s) and medium 
(0.83 – 1.05 m/s) walking speeds, with valid step counts only reported in walking speeds 
greater than 1.14 m/s (Turner et al., 2012). This is contrary to the Fitbug which reported valid 
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step counts at walking speeds below and above 0.85 m/s in patients with COPD while 
undertaking a 6MWT. It should be noted that agreement between pedometer and visual step 
counts in the Turner et al. (2012) study was determined using a one-way ANOVA, which is a 
test of differences rather than agreement (Phatak & Nimbalkar, 2017).  
 
5.4.4 Strengths and Limitations 
This study focused on the validity and test re-test reliability of the Fitbug pedometer in both 
healthy adults and COPD patients in a controlled environment, with several strengths. Firstly, 
novel data regarding the validity and reliability of a commercially available pedometer (Fitbug) 
in slow walking speeds, commonly documented in patients with COPD living in the North East 
of England, was documented. Secondly, the validity of the Fitbug among COPD patients within 
a clinical setting was determined, with the inclusion of data at both slower and faster walking 
speeds.     
However, some limitations to the study should be noted. This study was unable to conduct the 
outcome measures in the same controlled conditions (exercise laboratory vs hospital) due to 
the complexity of ethical requirements and timeframes available.  
Due to the assessment of the Fitbug pedometer taking place on a treadmill and during a 6MWT, 
the current study was unable to assess the validity and test re-test reliability of the Fitbug 
pedometer in a free-living environment, which comes with several limitations. Firstly, the 
controlled environments in the laboratory (treadmill) and hospital (6MWT) settings only 
allowed for one type of activity to be examined (walking) and failed to consider different 
activities of daily living (stair climbing, walking at an incline and changes in direction). These 
additional activities of daily living may have impacted the overall validity and reliability of the 
pedometer and should be investigated further in future research (Kooiman et al., 2015). 
Furthermore, differences in walking gait have been documented between treadmill walking and 
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overground walking, which may have influenced the validity and reliability of step counts 
(Nagano, Begg, Sparrow, & Taylor, 2013).  
However, it was felt best to use a treadmill walking protocol to standardise the walking speeds 
to replicate those commonly implemented by COPD patients. To address these limitations, 
future studies should aim to investigate the validity and reliability of commercially available 
pedometers in free-living external environments to ensure their practical use during everyday 
activities of daily living. In free-living external environments, observing step counts as a 
criterion measure is typically not feasible. Therefore, several methods have been administered 
to act as a criterion measure including (1) the use of previously validated activity monitors in 
the population of interest (Bassett, Toth, LaMunion, & Crouter, 2017), (2) remote video 
devices including a GoPro (Dedic, 2017) and (3) wireless inertial measurement units (OPAL) 
(Hwang, Reh, Effenberg, & Blume, 2018; Van Thanh et al., 2017).  
The gold standard equivalent used for recording step counts was not standardised across testing 
locations. Throughout laboratory-based testing, a fixed video camera was used as a feasible 
gold standard tool to record step counts as the walking trials were administered on a fixed 
treadmill. This method was not possible in the hospital condition due to numerous 
complications. Firstly, the standardised corridor used for the 6MWT was narrow and didn’t 
provide adequate space for a video camera to be used. Secondly, the nature of patients walking 
up and down a corridor made it difficult for a fixed video camera to accurately monitor steps 
at either end of the corridor.  
Finally, increased levels of BMI and/or increased amounts of abdominal adipose tissue can 
have a negative influence on the accuracy of pedometers (Shepherd, Toloza, McClung, & 
Schmalzried, 1999). In the current study the majority of participants across both groups had a 
BMI ranging from 24-27, making it difficult to measure the influence of BMI on the validity 
of the Fitbug, which has been outlined in other step counters (Crouter et al., 2005). 
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5.5 Conclusion  
To conclude, agreement between the Fitbug pedometer and visual observations were good to 
strong at all treadmill walking speeds in healthy individuals and throughout the 6MWT in 
patient with COPD, with no systematic or proportional bias reported by Deming regression 
analysis. The test-retest reliability of the Fitbug pedometer was demonstrated as good at all 
walking speeds in healthy individuals. These findings support the use of the Fitbug pedometer 
in this thesis as a tool to provide feedback and form goals for improving PA levels in patients 
with COPD.  
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It is recommended that people of all ages complete a minimum of 30 minutes moderate 
intensity daily PA to maintain an acceptable level of physical fitness (World Health 
Organization, 2020). Those failing to meet this standard of activity are considered 
insufficiently active, which may lead to increased levels of disability and deconditioning, 
which are strong predictors of mortality (Erikssen, 2001). Therefore, quantifying levels of daily 
PA in sedentary individuals is of great importance.  
As detailed throughout this thesis, patients with COPD report significantly reduced levels of 
PA compared to age matched healthy controls, primarily due to high levels of breathlessness 
related to everyday activities of daily living (Hernandes et al., 2009; Pitta et al., 2005b; Singh 
& Morgan, 2001; Troosters et al., 2010; Vorrink et al., 2011; Walker et al., 2008; Waschki et 
al., 2012; Watz et al., 2009). A reduction in everyday activities forces patients into a downward 
spiral of symptom-induced inactivity, leading to deconditioning and muscle weakness, 
associated with the vicious cycle of inactivity detailed in Chapter 2 (Troosters et al., 2013). 
These factors are associated with increased risk of hospitalisation and mortality (Garcia-
Aymerich et al., 2006; Garcia-Aymerich et al., 2009; Garcia-Rio et al., 2012; Vaes et al., 2014; 
Waschki et al., 2011).  
Previous literature has objectively compared PA levels between patients with COPD and age-
matched healthy controls in both Europe and the UK (Pitta et al., 2005b; Troosters et al., 2010; 
Watz et al., 2009), however this has not been conducted on a regional basis, within the North 
East of England. Statistics from Public Health England report that the North East of England 
has the highest proportion of people with smoking and drinking habits, which are associated 
with a high sedentary lifestyle (Windsor-Shellard, 2019). Specifically, the region as a whole 
has the lowest percentage of physically active adults in the UK, increasing the need to observe 
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PA levels in this population. In addition, the prevalence of COPD and number of respiratory 
deaths in people aged over 65 is one of the highest of all UK regions (Snell et al., 2016). 
Therefore, it is plausible to believe, that patients with COPD living in the North East of 
England, may be increasingly deconditioned and portray a significantly inactive lifestyle in 
contrast to COPD patients of other regions in the UK and countries around the world. For many, 
this will present a greater risk of exacerbations, hospital admissions, morbidity and mortality 
(Garcia-Aymerich et al., 2006).   
As detailed in Chapter 3, patients demonstrating lower levels of PA at baseline are less likely 
to benefit from an intervention of PA counselling alongside PR (Armstrong et al., 2019). As a 
result, assessing the baseline PA habits of a specific COPD group, prior to their inclusion in a 
PA intervention, may help the design and implementation of such an intervention. Based on 
this concept, and the understanding that COPD patients living in the North East of England 
were likely to be increasingly deconditioned and living inactive lifestyles, it was important to 
determine the degree of baseline PA habits in this patient group. Furthermore, it was important 
to assess the functional impairment of these patients to comprehend their level of disability 
compared to healthy age-matched individuals, also living in the North East of England.  
Therefore, the objectives of this study were a) to evaluate PA levels, muscular function and 
anxiety and depression status in patients with COPD living in the North East of England in 
comparison to healthy age-matched individuals from the same region and b) to identify the 
possible correlates associated with physical inactivity in this group of COPD patients. 
 
6.2 Methods 
This case control and cross-sectional study was conducted to establish the daily PA habits of 
healthy individuals and patients with COPD living in the North East of England. For the case 
control section of this Chapter, 20 healthy individuals with no history of major medical illness 
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and not undertaking regular exercise were recruited on a first come basis and matched 
according to age (+/- 3 years) with moderate severe COPD patients who were recruited to PR 
as part of Chapter 7 in this thesis. Full details on recruitment and inclusion/exclusion criteria 
for this chapter are detailed in Chapter 4. The 20 healthy individuals attended the exercise 
laboratory at Northumbria University on two separate occasions to perform lung function and 
demographic measurements, collect/return an accelerometer and perform measurements of 
muscular strength and endurance (detailed in Chapter 4). Meanwhile, the 20 COPD patients 
that were recruited from PR, performed the same measurements as healthy individuals during 
their baseline assessment for PR.  
For the cross-sectional section of this Chapter, data was obtained from 60 COPD patients 
attending PR who consented to Chapter 7 of this thesis, with both secondary objectives and 
patient demographics evaluated to identify potential variables associated with physical 
inactivity.   
6.2.1 Procedure (Visit 1) 
 
6.2.1.1 Healthy individuals  
Demographic data including age, sex, body mass and stature were obtained. Eligibility to the 
study was then confirmed based upon the inclusion and exclusion criteria detailed in Chapter 
4 and written informed consent was obtained. Following this, an assessment of spirometry and 
arterial oxygen saturation measurements were conducted (detailed in Chapter 4). The HADS 
self-reported questionnaire was issued to determine anxiety and depression status. Following 
completion, participants were provided with an accelerometer (Actigraph GT3X; Actigraph 
LLC, Pensacola, FL, USA) and guided to wear the device for 7 consecutive days during waking 
hours (8:00-22:00) around the waist to measure daily PA levels (detailed in Chapter 4).  
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6.2.1.2 COPD patients  
COPD patients attended PR at either the RVI or Freeman hospitals, providing demographic 
data including age, gender, stature (cm), body mass (kg) and BMI. Measures of spirometry had 
previously been conducted as part of routine clinical care in chest clinic, in which data were 
collected from patient notes (detailed in Chapter 4). Eligibility to the study was then confirmed 
based upon the eligibility criteria and written informed consent was obtained (detailed in 
Chapter 4). The HADS self-reported questionnaire was issued, to determine anxiety and 
depression status. COPD patients were then provided with an accelerometer (Actigraph GT3X; 
Actigraph LLC, Pensacola, FL, USA) and guided to wear the device for 7 consecutive days 
during waking hours (8:00-22:00) around the waist, to measure daily PA levels. Assessment of 
both muscular strength and endurance were then performed, including a 30 second sit-to-stand 
test and assessment of handgrip and quadriceps strength (detailed in Chapter 4).  
 
6.2.2 Procedure (Visit 2) 
 
6.2.2.1 Healthy individuals  
Following 7 consecutive days of wearing the accelerometer, participants attended (+/- 1 day) 
the exercise laboratory at Northumbria University to undertake muscular function measures 
including a 30 second sit-to-stand test and assessment of handgrip and quadriceps muscle 
strength (detailed in Chapter 4).  
 
6.2.2.2 COPD patients  
After wearing the accelerometer for 7 consecutive days, COPD patients returned the 
accelerometer to the hospital PR programme.  
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6.2.3 Outcome Measures 
 
6.2.3.1 Primary Outcome Measure 
Accelerometer derived PA was determined using the Actigraph wGT3X triaxial accelerometer 
(Actigraph wGT3X, Actigraph LLC, Pensacola, FL, USA), with measures of steps/day, VMU 
and time spent in different domains of PA reported (detailed in Chapter 4).  
 
6.2.3.2 Secondary Outcome Measures 
- Muscular strength and endurance were evaluated by isometric maximal volitional limb 
muscle strength assessment (lower body strength), hand grip (upper body strength) and 
the 30 second sit to stand test (lower body muscle endurance) (detailed in Chapter 4).  
- Levels of anxiety and depression were evaluated using the HADS questionnaire 
(detailed in Chapter 4).  
 
6.2.4 Sample size justification 
The minimum sample size for the case control study was based upon a study comparing 
steps/day recorded in COPD patients (n=19) with healthy age-matched volunteers (n=10), 
using the mean difference in steps/day (1995) and standard deviation (2088), calculated based 
upon 80% power and a two-sided 0.05 significance level (Latimer, 2019). A minimum total 
sample size of 20 participants required to detail significant differences in daily PA (steps/day) 
between COPD patients and healthy age matched controls was required.  
 
6.2.5 Statistical Analysis  
Data for both analyses were collected, coded and inputted into Microsoft Excel. SPSS version 
26, (IBM Corp., Armonk, NY, USA) was used for all statistical analyses. Descriptive statistics 
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are reported as mean±SD unless otherwise specified. Prior to analysis, the assumption of 
normality for all outcomes were assessed using the Shapiro Wilks test, with a p value >0.05 
indicating normally distributed data.  
 
6.2.5.1 Case control  
Throughout this study, between-group data was reported as mean; 95% CI unless stated 
otherwise. To assess the between-group effect of outcome variables in COPD patients 
compared to healthy age-matched individuals, an independent t-tests or Mann-Whitney U test, 
if data was non-normally distributed, was used. To assess the linear trend in PA across GOLD 
stages, a repeated measures ANOVA, with appropriate post hoc analysis, was used.  
 
6.2.5.2 Cross sectional  
Following the Shapiro Wilks test, PA variables including steps per day, VMU and MVPA were 
found to be non-normally distributed. As a result, Spearman’s correlation coefficient was 
implemented to assess for correlations between PA variables, secondary variables and 
demographic data. Following this, a multiple linear regression model, using a backward 
stepwise method, was constructed to assess the variability of all variables that were 
significantly associated with PA. 
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6.3 Results 
Of the 42 healthy individuals who expressed interest, 32 returned the eligibility form and were 
assessed against the inclusion criteria. Following confirmation of the inclusion criteria, 20 
healthy participants matched the age (+/- 3 years) of the 20 COPD patients and were recruited 
to the study. The most common reasons for exclusion were not matching the age criteria (n=9). 
Other reasons included smokers (n=2) and musculoskeletal implications (n=1). Participant 
flow through this study is presented in Figure 23.  
 
6.3.1 Baseline characteristics 
Baseline characteristics of healthy individuals and COPD patients are included in Table 11. Of 
the overall sample, 26 (65%) were male and 14 were female (35%), with all 
participants/patients of white ethnicity. Healthy individuals (n=20) had a mean age of 66±7, 
with a range of ages from 52-75 years. Just under half of the healthy individuals were in part- 
or full-time employment while the remaining individuals were retired. Clinical characteristics 
of the healthy individuals included a mean BMI of 27.8±5 kg/m2, resting heart rate of 70±12 
beats/min and resting oxygen saturation of 98±1%. Lung function characteristics included a 
FEV1 of 111±13% predicted. COPD patients (n=20) had a mean age of 68±5, with a similarly 
wide age range of 52-76 years. Most patients were retired (87%) with the rest in part-time 
employment. Clinical characteristics of the COPD patients included a mean BMI of 25.3±6 
kg/m2, resting heart rate of 81±11 beats/min and resting oxygen saturation of 93±1%. 




































42 healthy individuals 
expressed interest in taking part 
32 healthy individuals returned 
eligibility forms 
20 aged matched healthy 
individuals provided consent 
20 healthy individuals 
completed the study 
10 healthy individuals failed to 
return eligibility form 
12 healthy individuals excluded: 
 
Did not meet age criteria = 9 
Smokers = 2 
Musculoskeletal implications = 1 
20 COPD patients  
20 COPD patients 
completed the study 
Healthy individuals 
COPD patients  
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Abbreviations: WB: White British, cm: Centimetres, kg: Kilograms, BMI: Body Mass Index, m2: 
Metres squared, HR: Heart Rate, SPO2: oxygen saturation, FEV1: Forced Expiratory Volume in 1 
second, FVC: Forced Vital Capacity. MRC: Medical Research Council Dyspnea scale, 6MWD: Six 
Minute Walk Distance, m: Metres, n/a: data not available.  
Mean ± S.D are indicated for all columns unless stated. 
 
 
6.3.2 Outcome measures  
6.3.2.1 Physical activity  
All PA outcome measures between COPD patients and healthy controls are provided in Table 
12. Compared to healthy individuals, COPD patients reported significantly lower step/day (by 
-4833 steps/day; 95% CI -6862 to -2802 steps/day, p = 0.000) and movement intensity (by -
361 VMU; 95% CI -490 to -233 VMU, p = 0.001). In addition, time spent in activities of 
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MVPA were significantly lower in COPD patients than healthy individuals (by -34 mins; 95% 
CI -45 to -22 mins, p = 0.001). When comparing PA levels across GOLD stages, Figure 24 
illustrated a gradual reduction in steps/day, movement intensity and MVPA with increased 
disease severity. Specifically, step/day was reduced by -60±62%, -63±68% and -76±63% 
across GOLD stages II to IV, respectively. Both the movement intensity and time spent in 
MVPA in COPD patients were also reduced by -48±42%, -57±53%, and -69±60% VMU and 
-75±61, -83±65, and -94±87% min in GOLD stages II, III and IV, respectively (Figure 24). 
These differences all reached statistical significance as of GOLD stage II (p <0.05).  
 
 
Table 12. PA outcome measures in COPD patients and healthy age-matched individuals 
 
PA outcome measures 
COPD n = 20 Healthy n = 20   




Movement Intensity (VMU)  
 
Sedentary PA (<1.5 METs) mins 
 
Light PA (1.5-3.0 METs) mins 
 































Abbreviations: METS: Metabolic equivalents, PA: Physical Activity, mins: Minutes.  
Mean ± S.D are indicated for all columns unless stated. 





Figure 24. Change in (A) steps/day (B) MVPA (C) Movement intensity in both healthy individuals and 
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6.3.2.2 Muscular strength and endurance  
All muscular strength and endurance outcome measures between COPD patients and healthy 
controls are provided in Table 13. COPD patients reported significantly reduced lower body 
muscle strength (by -20.2; 95% CI -27.1 to -14.8 kg, p = 0.001), strength (by -12.9; 95% CI -
18.9 to -6.8 kg, p = 0.001) and sit to stand repetitions (by -8; 95% CI -11 to -6 reps, p =0.0001) 
compared to healthy age-matched individuals. 
 
6.3.2.3 Anxiety and Depression  
Anxiety and depression scores determined using the HADS questionnaire between COPD 
patients and healthy controls are provided in Table 13. COPD patients experienced 
significantly higher levels of both anxiety and depression in comparison to healthy individuals 
(by 8; 6 to 11 points, p = 0.000 and by 8; 6 to 10 points, p = 0.001) respectively. Across GOLD 
stages of COPD, both HADS anxiety and depression were significantly lower as of GOLD 
stage II compared with healthy individuals, with anxiety scores being higher by 7±5, 9±6 and 
9±3 points, respectively and depression scores being higher by 6±4, 9±6 and 9±5 points in 




















6.3.3 Correlates of physical activity in COPD patients  
Table 14 provides a detailed overview of the single correlations observed between PA outcome 
measures, namely steps/day, VMU and MVPA, with various secondary outcomes and baseline 
demographics of 60 COPD patients. Steps/day were significantly associated with pulmonary 
function variables (FEV1, FEV1 % Pred, FVC and FEV1/FVC %), 6MWD, QMVC, domains 
of the CCQ questionnaire, HADS depression, MRC and Gold stage of COPD.   
VMU was significantly associated with pulmonary function variables (FEV1, FEV1 % Pred, 
FVC and FEV1/FVC %), 6MWD, CCQ total, symptom and functional domains, HADS 
depression, MRC and Gold stage of COPD.  
Finally, the time COPD patients spent in MVPA was significantly associated with both FEV1 
and FEV1/FVC %, 6MWD, QMVC, CCQ symptoms, MRC and Gold stage of COPD.  
Further analysis of our data through a final multivariable linear regression model provided in 
Table 15 showed that, in patients with COPD living in the North East of England, FEV1 % 
predicted and the functional domain of the CCQ accounted for most of the variability in the 
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Abbreviations: QMVC: Quadriceps Muscle Voluntary Contraction, HG: Hand Grip.  
Mean ± S.D are indicated for all columns unless stated. 
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stepwise multiple regression model for steps per day (adjusted R2 = 30%). In terms of VMU, 
MRC dyspnea scale and FEV1 % predicted accounted for most of the variability in the stepwise 
multiple regression model (adjusted R2 = 24%). Finally, FEV1 % predicted and QMVC 
accounted for the most variability in the stepwise multiple regression model for MVPA 
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Table 14. Spearman’s correlation of PA (steps/day) with outcomes in COPD patients 
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Abbreviations: BMI: Body Mass Index, FEV1: Forced Expiratory Volume in 1 second, FVC: Forced Vital 
Capacity, 6MWD: Six Minute Walk Distance, s: Seconds, kg: Kilograms, CAT: COPD Assessment Test, 
CCQ: Clinical COPD questionnaire, HADS: Hospital Anxiety and Depression Scale, MRC: Medical 
Research Council dyspnea scale.  
*. Significance <0.05, **. Significance <0.01  
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Table 15. Final multivariable linear regression models for PA outcome measures 
  Unstandardised coefficients Standardised coefficients   
PA   B Std. Error Beta t Sig 
Steps/day (Constant) 2816.071 795.077  3.542 0.001* 
 FEV1% predicted 
 
1446.415 465.805 .350 3.105 0.003* 
 CCQ F -444.346 143.625 -.349 -3.094 0.003* 

























MVPA (Constant)  -4.375 2.447  -1.787 0.079 
  























       
Abbreviations: FEV1: Forced Expiratory Volume in 1 second, CCQ: Clinical COPD questionnaire, MRC: Medical Research Council dyspnea scale, QMVC: 
Quadriceps muscle voluntary contraction.  
*. Correlation is significant at the 0.05 level (2-tailed)  
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6.4 Discussion  
 
6.4.1 Summary of main findings  
The findings of this study identified that COPD patients living in the North East of England 
had significantly lower levels of daily PA, impaired upper and lower body muscular strength 
and lower body muscular endurance and elevated anxiety and depression compared to healthy 
age-matched individuals living in the North East of England. To our knowledge, this is the first 
study to assess PA levels in COPD patients living in the North East of England region, 
providing novel data that can be used to compare the activity levels of COPD patients across 
various regions of the UK and Europe. Furthermore, this study has documented a gradual 
reduction in PA outcomes across GOLD-stages, delivering additional evidence that more 
severe COPD patients are at greater risk of physical inactivity and the associated risks that 
follow (Garcia-Aymerich et al., 2006). Given the diminished levels of PA documented in 
COPD patients living in the North East of England and the associated risk factors, as well as 
the North East of England presenting one of the highest prevalence’s of respiratory deaths 
nationally (Snell et al., 2016), the requirement for PA behavioural modification interventions 
to support these patients at regional level has never been greater.  
 
6.4.2 Physical activity outcomes 
The overall results of this study demonstrate that COPD patients living in the North East of 
England have significantly lower PA levels than healthy age-matched individuals living in the 
same region of the UK. These findings support several single and multi-centre studies that have 
objectively measured PA in COPD patients (Coronado et al., 2003; Hernandes et al., 2009; 
Mercken et al., 2005; Pitta et al., 2005b; Schonhofer et al., 1997; Singh & Morgan, 2001; 
Troosters et al., 2010; Walker et al., 2008; Waschki et al., 2012; Watz et al., 2009).  
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In terms of steps/day, an outcome which is conventionally assessed using pedometers and 
accelerometers, two multi-centre studies (Troosters et al., 2010; Waschki et al., 2012), reported 
a reduced number of steps/day equating to -40% and -54% respectively in COPD patients 
compared to healthy controls (Troosters et al., 2010; Waschki et al., 2012). In contrast, the 
current study reports a greater reduction in steps/day of -65% between COPD patients and 
healthy individuals, suggesting that COPD patients living in the North East of England were at 
greater risk of decline in steps/day compared to their healthy counterparts. These differences 
could be explained by the severity of COPD patients across the various studies. For instance, 
the 70 COPD patients recruited from outpatient clinics in the Troosters et al. (2010) study 
reported a greater baseline FEV1 % Pred (54±23%) than documented in the current study 
(41±15%), which may have postulated the lower steps/day. Interestingly, when looking at the 
study of Waschki et al. (2012), FEV1 was matched, however baseline steps/day were 
considerably lower in the current study. This contrast may have been a result of several factors, 
including superior exercise capacity and lower MRC dyspnea scores in the Waschki et al. 
(2012) study. As discussed earlier in this thesis, the association between greater levels of PA 
and more preserved functional exercise tolerance, consistent with the idea of “functional 
reserve”, has been reported previously (Osadnik et al., 2018). Therefore, COPD patients living 
in the North East of England may be less capable of maintaining greater levels of PA due to an 
inhibitory ceiling limitation caused by the low functional reserve (Osadnik et al., 2018). 
Meanwhile, a number of studies including that of Waschki et al. (2012) have confirmed a 
significant association between higher MRC dyspnea scores and lower PA levels (Watz et al., 
2009). 
Regarding the time spent in MVPA, significant reductions were documented in COPD patients 
compared to healthy age matched controls. Both Troosters et al. (2010) and Watz et al. (2009) 
reported reductions in MVPA in patients with COPD when compared to healthy age-matched 
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individuals. However, time spent in MVPA was considerably lower in the current study than 
both other studies (Troosters et al., 2010; Watz et al., 2009). Notably, it is emphasised by the 
WHO that those over the age of 65 years should target a minimum of 150 minutes of moderate 
intensity aerobic activity or 75 minutes of vigorous intensity per week in order to protect 
cardiovascular health in adults (World Health Organization, 2020). Based on these 
recommendations, it is clearly shown that COPD patients living in the North East of England 
do not meet the WHO guidelines.   
With an obvious deterioration of daily PA levels in COPD patients living in the North East of 
England, it was important to understand how these PA levels compare with patients living in 
other residential location in mainland Europe and the UK. Specifically, data from this study 
was compared to data from the multicentre study of Boutou et al. (2019). Interestingly, a 
significant reduction in steps/day (-42%) was reported when data from the North East of 
England was compared to five other European cities (Athens, Edinburgh, Leuven, London and 
Groningen) (Boutou et al., 2019). On closer analysis with cities in the UK, patients living in 
the North East of England continued to experience significant reductions in daily PA levels 
compared to those living in both London (-41%) and Edinburgh (-25%) (Boutou et al., 2019). 
Potential factors that have been shown to influence PA levels across geographical locations 
include; climate (rainfall, daylight & temperature), socio-cultural, socio-economic and 
micro/macro environments of the area of living (Boutou et al., 2019). When looking 
specifically at patients living in the North East of England, one could assume that many of 
these potential factors that are documented to reduce levels of PA may have had an impact on 
this patient population. 
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6.4.3 Gold stages of COPD and PA  
Another major finding of this study was the significant gradual reduction in PA levels with 
increasing COPD severity. Although a weak correlation between PA and lung function has 
previously been demonstrated (Watz et al., 2014), data from the current study clearly 
demonstrated a significant association between FEV1% Pred and PA variables, meaning the 
PA levels of COPD patients living in the North East of England are reduced with greater 
severity of COPD. These findings are similar to three other studies that implemented a similar 
methodology for assessing daily PA levels (Troosters et al., 2010; Watz et al., 2008; Watz et 
al., 2009). Specifically, an accumulation of steps/day across the three previous studies 
decreased by 69%, 71%, 65% and 76% from GOLD stage I to GOLD stage IV, respectively 
compared to healthy controls (Troosters et al., 2010; Watz et al., 2008; Watz et al., 2009). 
Interestingly, compared to the other studies (Troosters et al., 2010; Watz et al., 2008; Watz et 
al., 2009), healthy individuals from the current study reported the lowest number of steps/days, 
which alongside the greatest reduction in steps/day from healthy to GOLD stage IV, continues 
to highlight the diminished level of PA in individuals living in the North East of England, 
regardless of health status. These findings may present an opportunity to tailor future PA 
interventions based on the severity of patients and the associated levels of PA. For instance, 
less severe COPD patients with a sustained level of PA at baseline may find exercise training, 
as part of PR, effective in order to maintain and support a gradual gain in daily PA levels. 
Whereas those more severe COPD patients with diminished baseline PA levels, may require a 
multifaceted approach incorporating aspects of exercise, behavioural support and motivation 
(Spruit et al., 2015).  
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6.4.4 Muscular Function  
This study identified that COPD patients living in the North East of England reported 
significant impairment in upper and lower body muscular strength and lower body muscular 
endurance compared to healthy age matched individuals, suggesting that overall muscle 
function in patients with COPD living in the North East of England is majorly diminished.  
Early work from Serres, Gautier, Varray, and Prefaut (1998) aimed to determine whether 
COPD patients had impaired skeletal muscle performance (i.e. maximal strength and 
endurance) compared to healthy controls. Their analysis of peripheral muscle performance 
reported no significant differences in maximal muscle strength between groups, while muscular 
endurance was significantly decreased compared to healthy controls (Serres et al., 1998). They 
suggested that reduced muscular endurance was a result of abnormal muscle metabolism, with 
such changes consistent with the metabolic changes commonly observed in skeletal muscle of 
COPD patients.  
Since these findings, research regarding muscular function in COPD has evolved. In a review 
article from Donaldson, Maddocks, Martolini, Polkey, and Man (2012), they documented that 
compared with age and gender matched healthy controls, isometric quadriceps strength was 
reduced by around 20%-30% in patients with COPD (Bernard et al., 1998; Man et al., 2005). 
In terms of quadriceps endurance, they found that studies reported an increased susceptibility 
to fatigue, with a rapid decline in quadriceps performance during both continuous (Allaire et 
al., 2004; Man et al., 2003) and repeated bouts of exercise (Coronell et al., 2004; Mador, Deniz, 
Aggarwal, & Kufel, 2003). Such reductions in muscle strength were largely explained by a 
comparable reduction in quadriceps cross-sectional area and mass, assessed by magnetic 
resonance imaging and ultrasound or computed tomography (Marquis et al., 2002; Mathur, 
Takai, MacIntyre, & Reid, 2008; Seymour et al., 2009). Meanwhile the reductions in 
CHAPTER 6: CASE CONTROL AND CROSS-SECTIONAL 
W13002500 139 
quadriceps endurance were more likely related to the loss of fatigue-resistant type I fibres and 
subsequent reduction in oxidative capacity (Gosker et al., 2007).  
 
 6.3.5 Anxiety and Depression 
Anxiety and depression measured via the HADS questionnaire was impaired in patients with 
COPD compared to healthy controls. Remarkably, to our knowledge this is the first study to 
assess levels of anxiety and depression in COPD patients compared to healthy individuals. 
Contrary to this lack of research, elevated levels of anxiety and depression have been reported 
in 40% and 25% of COPD patients respectively (Panagioti, Scott, Blakemore, & Coventry, 
2014). Furthermore, anxiety and depression may have a considerable impact on PA levels, with 
reductions in steps/day greater than the clinically important difference in patients with COPD 
who reported elevated levels of anxiety and depression via the HADS questionnaire (Boutou 
et al., 2019).  
 
6.3.6 Correlates of physical activity parameters in patients with COPD 
As well as understanding the severity of physical inactivity in COPD patients in the North East 
of England, it was necessary to understand the factors associated with physical inactivity, in 
order to consider these aspects when designing and implementing a PA behavioural 
modification intervention. Results from this study demonstrated several statistically significant 
correlates of steps/day, VMU and MVPA, including several demographic variables, pulmonary 
function variables, 6MWD, QMVC, quality of life domains (CCQ), depression and dyspnea. 
Further analysis confirmed that FEV1 (% predicted) alongside MRC, CCQ F and QMVC 
provided the largest variability in steps/day, VMU and MVPA, respectively. However, these 
coefficients only accounted for around 22-30% of the variability and further evaluation of the 
potential association between variables of PA and patient demographics are necessary.  
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Several previous studies have explored such relationships in COPD patients, particularly the 
response of FEV1 values (Belza et al., 2001; Pitta et al., 2005b; Schonhofer et al., 1997; Singh 
& Morgan, 2001; Steele et al., 2000; Troosters et al., 2010; Waschki et al., 2012). Both the 
findings of Troosters et al. (2010) and Waschki et al. (2012) reported a positively association 
between lung function and steps/day in COPD patients. On the other hand, Pitta et al. (2008a) 
documented that FEV1 provided no correlation with steps/day or any domains of PA for that 
matter. Intriguingly, they did report that measures of Inspiratory Capacity and Maximum 
Voluntary Ventilation were significantly correlated with all PA variables. They suggested that 
this association may be a result of Maximum Voluntary Ventilation providing a reflection of 
the ventilatory reserve available to respond to increased physiological demands of PA (Pitta et 
al., 2008a). Furthermore, Inspiratory Capacity measurements estimate levels of dynamic 
hyperinflation, which has been well documented to influence levels of PA in COPD patients 
(Garcia-Rio et al., 2009).  
In terms of exercise capacity, the majority of studies report a common association between the 
results of a 6MWT and PA (Altenburg et al., 2013; Belza et al., 2001; Eliason, Zakrisson, Piehl-
Aulin, & Hurtig-Wennlöf, 2011; Garcia-Aymerich et al., 2009; Pitta et al., 2005b; Waschki et 
al., 2012; Watz et al., 2009), with it generally hypothesised that variations in exercise capacity 
and PA levels are similar (Altenburg et al., 2013).  
Limited associations between peripheral muscle weakness and PA were documented in this 
study, with only QMVC and the PA outcomes; steps/day and MVPA reporting an association. 
Pitta et al. (2005b) reported a moderate correlation between measures of handgrip and 
quadriceps muscle strength with levels of PA using a bivariate model. However, an association 
between handgrip muscle weakness and physical inactivity was not confirmed using a 
multivariate model analysis in this study. Early findings from Gosselink, Troosters, and 
Decramer (1996) provided evidence that isometric quadricep strength was a significant 
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predictor of exercise limitation, which could provide evidence of a similar trend in relation to 
daily PA levels. Therefore, it seems plausible that levels of PA are influenced by quadriceps 
muscle strength. 
Knowledge regarding PA, health related quality of life and psychological variables remains 
unclear. In this study, it was shown that reduced CCQ scores relating to symptoms, functional 
and mental state as well as reduced depression symptoms were associated with greater 
steps/day and VMU, with only CCQ symptoms associated with MVPA. Specifically, it was 
shown that the functional domain of the CCQ, which provides a subjective analysis of patient’s 
limitation towards different activities of daily living due to lung disease (Sundh, Janson, 
Lisspers, Montgomery, & Ställberg, 2012), accounted for the second highest variability in 
steps/day through a multiple regression model. It could be assumed that such an association 
may link to the fact PA is a complex health behaviour that involves both physiological and 
psychological traits of an individual patient (Bauman et al., 2012). Similar findings were 
reported by Altenburg et al. (2013) who studied variables affecting PA levels in 155 COPD 
patients. Both the CCQ functional score and depression were inversely associated with greater 
PA. However, a multiple regression analysis in this study failed to report a large amount of 
variability with the CCQ functional score. 
With respect to levels of depression, the findings of the current study and that of Altenburg et 
al. (2013) do not compare with two earlier studies (Moy, Matthess, Stolzmann, Reilly, & 
Garshick, 2009; Watz et al., 2009). This disparity may be the result of a different questionnaire 
used to assess depression (Beck depression scale) (Moy et al., 2009; Watz et al., 2009) or a 
smaller sample size (Moy et al., 2009).   
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6.4.7 Strengths and limitations  
A major strength of this study was the novelty of several findings. Firstly, to our knowledge, 
data from this study was the first to have assessed the PA levels of COPD patients on a regional 
basis in the UK compared to healthy age-matched individuals. Secondly, it was able to compare 
levels of anxiety and depression in COPD patients compared to healthy age-matched controls. 
With the ever-increasing knowledge surrounding mental health and its association with 
physiological variables, it was felt that this was an important area of research in chronic 
diseases. Finally, this chapter has provided updated research surrounding correlates of daily 
PA levels, which are essential in order to progress PA behavioural modification interventions 
in this population in the future.  
The study did have some limitations that are worth noting. Firstly, the study consisted of a 
single centre study that was performed in patients who were interested in research and taking 
part in an RCT (chapter 7). These factors may have limited the applicability across difference 
centres and clinical settings. Secondly, the analysis of daily PA levels was not conducted across 
all seasons due to the timescale of data collection. Previous literature has documented that 
limited PA assessment in winter months may positively influence findings (Boutou et al., 
2019), however we feel that this did not affect the overall findings of the current study. Thirdly, 
due to constraints with the location of data collection for healthy participants, we were unable 
to conduct the 6MWT, meaning we were unable to compare exercise capacity across groups. 
However, as we were able to collect data on lower and upper muscle strength and endurance, 
it was felt that a sufficient analysis of exercise capacity was included in this study. Fourthly, 
both type I error (rejecting a null hypothesis) and type II error (not rejecting a null hypothesis) 
should be considered. Specifically, type I error involves rejecting a null hypothesis when it is 
true and may have been exemplified in table 14 spearman’s correlation due to many variables 
in one analysis that may skew the overall findings. Finally, the implementation of a cross-
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sectional design to determine the correlates of PA levels was another limitation of the study, 
as correlation does not necessarily imply causation, therefore further research is required to 
determine a causal relationship.  
 
6.5 Conclusion 
In conclusion, the present case control and cross-sectional study reported for the first time that 
levels of PA in patients with COPD living in the North East of England are significantly lower 
than healthy age-matched individuals living in the same region. Furthermore, PA variables 
including steps/day, VMU and MVPA were found to significantly decrease with increasing 
COPD severity. This study has been able to strengthen the evidence base regarding variables 
that significantly influence levels of PA in patients with COPD, providing valuable evidence 
that can support the implementation of future PA behavioural modification interventions in 
COPD.  
A major concern arising from this study is the substantial deterioration in levels of daily PA 
documented in patients living in the North East of England compared to COPD patients living 
in other regions of the UK and Europe. Considering the increased risk of hospital admissions 
and mortality as a result of increased physical inactivity, these findings provide vital evidence 
that PA behavioural modification related interventions are urgently needed in order to supress 
the decline in daily PA levels and promote a more physically active lifestyle for COPD patients 
living in the North East of England.     
With the findings of Chapter 3 highlighting that PA counselling interventions are more 
effective in COPD patients who exhibit greater baseline PA levels, its apparent that COPD 
patients living in the North East of England may require additional support to improve the 
outcomes of PA counselling interventions.  
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Therefore, the next chapter of this thesis will use these novel findings to assess the feasibility 
and efficacy of combining PA behavioural modification strategies, PR and psychological 
behavioural modification through CBT, in patients with COPD living in the North East of 
England, to investigate whether additional support to improve the outcomes of PA counselling 


































As detailed in Chapter 6, patients with COPD living in the North East of England reported 
significantly lower PA levels (steps/day) compared to both healthy age-matched individuals 
living in the same region and patients with COPD living in other regions of the UK and across 
Europe (Boutou et al., 2019). These findings are important due to the association between low 
levels of PA and increased risk of hospitalisation and mortality (Garcia-Aymerich et al., 2006; 
Garcia-Aymerich et al., 2009; Garcia-Rio et al., 2012; Vaes et al., 2014; Waschki et al., 2011). 
Therefore, behavioural modification interventions to achieve a sustained improvement in PA 
are urgently needed to supress the decline in PA in this geographical group of patients.  
PA counselling has been employed to address the complex behaviour of PA, with the majority 
of previous studies demonstrating improvements in PA (steps/day) both as a standalone 
intervention and alongside PR in patients with COPD (Armstrong et al., 2019). This is 
accomplished by stimulating patients to increase their PA levels by incorporating lifestyle 
activities into daily life in conjunction with patient monitoring and feedback of their daily steps 
alongside frequently adjusted goal setting (Mantoani et al., 2016). However, as previously 
reported, those patients with low baseline levels of PA (≤4000 steps/day), failed to achieve a 
clinically important change in PA following PA counselling interventions alongside PR 
(Armstrong et al., 2019). As a result, COPD patients living the North East of England would 
likely fail to benefit from interventions of this nature. Consequently, investigating the potential 
of comprehensive behavioural modification approaches to increase PA alongside PR in this 
COPD population is necessary.   
In addition, the behavioural modification approach involves the incorporation of a 
psychological behavioural modification tool, namely CBT, as an intervention to support COPD 
patients with profound psychological difficulties such as anxiety and depression (Heslop & 
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Foley, 2009; Heslop-Marshall et al., 2018). Importantly, many of these patients are less able to 
manage symptoms of anxiety and depression (Thew et al., 2017), and are therefore less likely 
to improve levels of PA (Yohannes & Alexopoulos, 2014). CBT focuses on understanding how 
experiences are interpreted and provides an understanding of the interaction between thoughts, 
mood, behaviour and physical sensation, which are intrinsically linked (Heslop & Foley, 2009). 
Many of the techniques used in CBT help to break patient inactivity, which can lead to 
improved mood and better physical conditioning (Dueñas-Espín et al., 2016; Yohannes & 
Alexopoulos, 2014). Across the NuTH, CBT is administered to those patients with elevated 
levels of anxiety and depression as part of standard care PR, making it feasible to incorporate 
CBT as part of PR alongside a PA behavioural modification intervention. This combined 
approach may support an improved mood, better physical conditioning and improved PA levels 
in those patients with elevated levels of anxiety and depression who are typically less able to 
manage symptoms and improve levels of PA (Thew et al., 2017; Yohannes & Alexopoulos, 
2014).  
To date, studies investigating PA counselling interventions in patients with COPD have 
focused primarily on the frequency, intensity, duration and type of PA, which are quantified 
by means of activity monitors (Van Remoortel et al., 2012a). This method of assessment, 
however, fails to fully capture patients’ experiences of PA (Gimeno-Santos et al., 2015). 
Qualitative research has indicated that while patients engage in daily physical activities, they 
experience symptoms which adversely impact on their lifestyle (Dobbels et al., 2014). In order 
to gauge a better understanding of these symptoms and experiences of PA during a PA 
behavioural modification intervention alongside PR, the C-PPAC instrument was incorporated 
in this thesis, combining subjective questions regarding the amount and difficulty of PA 
alongside objective measures of steps/day and movement intensity (VMU) (Gimeno-Santos et 
al., 2015).  
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Therefore, this chapter investigated whether a PA behavioural modification intervention 
alongside PR in patients with COPD reporting low baseline PA levels was effective in term of 
improving PA levels and patients’ experiences of PA, exercise capacity, quality of life, 
symptoms, and wellbeing. As this novel behavioural modification intervention alongside 
standard care PR in COPD patients with profoundly low PA levels had yet to be investigated, 
it was important to establish patient acceptability and compliance to the components of this 
behavioural modification intervention and assess whether recruitment and retention was 
affected by adding this behavioural modification intervention to PR compared to PR alone.  
It was hypothesised that the PA behavioural modification intervention incorporating 
motivational interviewing, face-to-face twice weekly goal setting, step count monitoring and 
feedback, combined with PR, would be superior to PR alone in improving all aspects of PA.  
 
7.2 Methods  
 
7.2.1 Study design  
This chapter consists of a prospective, single centre, two parallel-group, RCT. Following 
baseline assessment (visit 1-pre-PR) patients were randomly allocated 1:1 to either standard 
care 8-week PR (PR alone) or standard care 8-week PR alongside a PA behavioural 
modification intervention (PR+PA) (Figure 25). Patients were stratified by 6MWT data 
(6MWT ≤ 300 m or 6MWT >300 m) and the average HADS score for anxiety and depression 
(< 8 points or ≥8 points) using a block size of 4 at the onset of the PR programme. Following 
randomisation, those patients documenting elevated levels of HADS anxiety and/or depression 
score (≥8) received CBT alongside either PR alone or PR+PA intervention. All trial outcomes 
were conducted at baseline and following 8-weeks of PR (post-PR).  
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7.2.2 Trial setting and recruitment 
As detailed in Chapter 4, patients with COPD were recruited from NuTH Chest Clinic and PR 
waiting lists across both the RVI and Freeman hospital sites. Patients were initially approached 
by a healthcare professional associated with either the Chest Clinic or PR programme (i.e., 
consultant respiratory physicians, specialist respiratory nurses, respiratory physiotherapists) 
who documented the study requirements and provided a participant information sheet to any 
patient who expressed an initial interest in the trial. With agreement, patients provided contact 
details to the healthcare professional which were subsequently passed to a member of the 
research team. Following a 24-hour period allocated to allow interested patients time to read 
the participant information sheet and consider their options regarding the trial, a researcher 
contacted the patients over telephone and delivered a screening assessment, as outlined below. 
 
7.2.3 Screening telephone assessment 
The initial screening assessment was completed over telephone, with the nature and objectives 
of the study explained to the patient in more detail and an opportunity to ask any questions to 
the research team was provided. Patients were asked to confirm eligibility to the study based 
on the inclusion/exclusion criteria outlined below. On confirmation of eligibility, patients were 
offered an invitation to attend a baseline assessment visit at either the RVI or the Freeman 
hospital sites depending on patient preference.  
Patient inclusion and exclusion criteria are detailed below. 
 
Inclusion criteria:  
1. COPD confirmed by obstructive spirometry.  
2. Clinically stable male or female COPD patients aged 40 years or older.  
3. Optimised medical therapy 
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4. Able to provide informed consent  
Exclusion criteria:  
1. Orthopaedic, neurological or other concomitant diseases that significantly impair normal 
biomechanical movement patterns, as judged by the investigator. 
2. Moderate or severe acute exacerbation of COPD within 4 weeks.  
3. Unstable ischaemic heart disease, including myocardial infarction within 6 weeks.  
4. Moderate or severe aortic stenosis or hypertrophic obstructive cardiomyopathy.  
5. Uncontrolled hypertension and another condition likely to limit life expectancy to less than 
one year (principally metastatic malignancy). 
 
7.2.4 Baseline assessment visit 1 (pre-PR) 
Patients attended the physiotherapy department at either the RVI or Freeman hospital sites. On 
arrival, patients provided confirmation that they met the inclusion/exclusion criteria and written 
informed consent was obtained, conforming to the MRC guidelines (Skivington et al., 2018). 
Demographic data including age, sex, body mass and stature were obtained. Lung function 
measurements were recorded from patient notes, and were unavailable, spirometry was 
performed (detailed in Chapter 4). Data were collected from patient notes on pharmacological 
therapy and medication. Baseline outcome measures (detailed below) were completed and 
upon completion, an Actigraph accelerometer was provided to patients (detailed in Chapter 4).  
 
7.2.5 Baseline assessment visit 2 (PR session 1)  
Following a 7-day period of wearing the Actigraph accelerometer, patients returned to the 
physiotherapy department to attend their 1st session of PR. Prior to the start of PR, 
accelerometer data was analysed, and confirmation of valid accelerometer data was ensured. 
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Following this, patients were allocated an appointment for CBT based on a HADS anxiety 
and/or depression score of ≥8.  
 
7.2.6 Randomisation and allocation 
Following confirmation of valid accelerometer data, patients were randomly assigned 1:1 to 
either PR+PA or PR alone (Figure 25). An online randomisation programme 
(www.randomization.com) was used by a researcher, who took no part in the recruitment 
process of the study, to generate the randomisation sequence. Stratification was based on 
6MWT data (6MWT ≤ 300 m or 6MWT >300 m), (Camillo et al., 2016) and the average HADS 
score for anxiety and depression (< 8 points or ≥8 points) (Nowak et al., 2014) to ensure a 
balanced sample size between the two study groups. Balanced group allocation blocks were 
conducted by a researcher at Northumbria University who was independent of the research 
team.  
 
7.2.7 Final pulmonary rehabilitation session  
The same procedure as baseline visit 1 (pre-PR) with patients issued an Actigraph 
accelerometer to be worn for 7 days (detailed in chapter 4). Patients in the PR+PA intervention 
returned their pedometer and remaining step diaries and were asked to complete a project 
tailored satisfaction questionnaire anonymously at home.   
 
7.2.8 Post assessment visit (1-week post-PR) 
On arrival at the post assessment visit (at least 7 days following final PR session), patients 
provided their Actigraph accelerometer and anonymously handed their satisfaction 
questionnaire into the PR team. The same procedures as baseline visit 1 (pre-PR) were 
implemented with all outcome measures completed.   
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7.2.9 Physical activity behavioural modification intervention added to pulmonary 
rehabilitation (PR+PA)  
Patients assigned to the behavioural modification intervention (PR+PA) received 8-week 
standard care PR (detailed below) alongside an additional PA behavioural modification 
intervention comprising motivational interviews, monitoring and feedback using a pedometer 
and goal setting.  
Prior to the start of the PR+PA intervention, patients received a one-to-one semi-structured 
motivational interview with a member of the research team discussing motivation issues, 
favourite activities, facilitators and barriers to PA and strategies to become more physically 
active (Miller & Rollnick, 2002). Motivational interviewing is defined as “a collaborative, 
person-centred form of guiding to elicit and strengthen motivation for change” and involved 
creating an atmosphere in which the patient became the main advocate and primary agent for 
change (Miller & Rollnick, 2002). The motivational interviews delivered in this study were 
based on the general principles taken from Miller and Rollnick (2002) including, (1) expressing 
empathy (2) developing discrepancy (3) avoiding argumentation (4) rolling with resistance and 
(5) supporting self-efficacy. Specifically, the researcher focused on engaging with the patient’s 
thoughts and feeling regarding their levels of PA, focusing on a clear direction and goal towards 
improving PA, evoking a patient’s own internal motivations for change, based on the goals 
identified in the focusing process, and planning, that encompasses both developing a 
commitment to change and formulating a specific action plan to build upon. To support the 
implementation of these processes, the basic skills of Open questions, Affirmations, 
Reflections, and Summarisations, (OARS) were used throughout (Miller & Rollnick, 2002). 
On completion of the motivational interview, each patient created 3 concrete actions that were 
used throughout the PR+PA intervention to stimulate patient’s self-motivation and self-
efficacy towards achieving greater levels of PA.  
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The overall design of this PA behavioural modification intervention was based on the findings 
of Chapter 3, which reported that irrespective of the way the intervention was designed or 
implemented (i.e. frequency of goal setting, duration, type of feedback & measure of PA), 
improvements in PA were of a similar magnitude. Specifically, the PA behavioural 
modification intervention delivered in this study incorporated the provision of a pedometer 
(Fitbug, Camden, London), an individualised daily step count target, and a daily step count 
diary provided weekly during the 8-week PR programme. The pedometer used in this study 
has shown good validity and test-retest reliability in a controlled environment at walking speeds 
adopted by COPD patients ranging from 0.69-1.11 m/s, as detailed in Chapter 5.  
The first week’s step count target was based on baseline Actigraph accelerometer step count 
data, with a 10% increase in step counts calculated (e.g. 100 additional steps from a baseline 
step count of 1000 steps). During subsequent weeks, the 10% increase in step counts was based 
on pedometer (Fitbug) step count data, retrieved from the daily step count diary. Patients were 
encouraged to discuss the daily step count target with the researcher if they felt it was 
unrealistic as an individualised approach was promoted for every target. A weekly step-count 
increase of 10% in the current study was chosen based on the study from Nolan et al. (2017), 
that did not result in any meaningful improvements in PA alongside PR with a 5% weekly step-
count increase. Once confirmed, the daily step count target was documented on the daily step 
count diary and support was provided at every PR session (twice weekly) to achieve the 
prescribed daily target. Patients were asked to note their daily step count using the daily step 
count diary at the end of each day, making note of whether the daily target was achieved. 
Furthermore, patients were asked to document their daily wellbeing on the daily step count 
diary via a simple 3 face tool (1-smiley face, 2- satisfied face and 3- sad face). 
Prior to each PR session (twice weekly), patients provided the step diary to the researcher, who 
was not involved in the PR programme delivery. Face-to-face advice and support to achieve 
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current and future goals were given to patients during each PR session and a new daily step-
count target was provided at every other PR session (once weekly). In addition, the researcher 
assessed the adherence to components of the intervention through means detailed earlier in this 
chapter. If the patient missed a recording on their diary step count diary, this was retrieved 
from the pedometer memory function. However, for the analysis of adherence, it was reported 
as a missing data point. If the patient did not attend PR in person, the weekly target was 
prescribed by telephone.  
During each face-to-face PA review session, the patient and researcher discussed the 
importance of achieving the weekly step-count target and advice on how to increase PA levels 
was given. Each session was patient led with a focus on discussing the barriers and 
opportunities facing each patient and considerations were made towards the 3 concrete actions 
set during the motivational interview. An emphasis was placed on several behaviour 
modification techniques, including goal setting, action planning and guidance on self-
monitoring and management. Such behavioural components have been shown to benefit COPD 
patients’ readiness, motivation and confidence to engage in PA and were associated with 
significant improvements in PA behaviour (Bourbeau et al., 2021). The aims of a greater face-
to-face component were to use the techniques detailed above to empower and motivate patients 
to engage in more daily PA, to support greater improvements in overall PA.  
 
7.2.10 Standard care pulmonary rehabilitation 
All patients enrolled to the study attended the same centre-based PR programme at either the 
RVI or Freeman hospital sites. Both hospital sites ran a symmetrical programme delivered in 
accordance to the BTS guidelines for PR (Bolton et al., 2013). Specifically, patients attended 
a group programme twice weekly for 8 weeks (16 sessions) for approximately 60 minutes of 
exercise and 20 minutes of education or relaxation between November 2018 and February 
CHAPTER 7: RANDOMISED CONTROLLED TRIAL 
W13002500 156 
2021. Due to the COVID-19 pandemic, 6 patients (n=3 in the PR alone control and n=3 in the 
PR+PA intervention) completed one exercise session under socially distanced supervision and 
one unsupervised session at home. Respiratory physiotherapists supervised the exercise 
programme which involved an individually tailored programme of aerobic continuous and 
interval exercises (cycling and walking) and strengthening exercises (machines and free 
weights). Initial endurance cycling using a cycle ergometer was set at a workload to achieve 
level 4 on the Modified Borg Dyspnea scale (1-10 scale). The ATS/ERS guidelines for PR 
(Spruit et al., 2013) were used to prescribe lower body resistance exercises. Examples of 
resistance exercises include seated leg press, leg extensions, sit to stand and step ups with 
appropriate free weights and leg weights. Upper body resistance training exercises included 
bicep curls, punches and shoulder press using free weights. The duration and intensity of lower 
and upper body exercises were monitored after every exercise using the Modified Borg 
Dyspnea scale (1-10 scale). For patients to be exercising at both an effective as well as feasible 
intensity, they were expected to aim for a perceived exertion on the Modified Borg Dyspnea 
scale of 4 (moderately to moderately severe), with the intensity and/or duration increased when 
Borg scale levels were below 4 (Spruit et al., 2013). Patients from both groups received a home 
exercise programme with example exercises and a recording section, enabling physiotherapists 
to monitor and support additional home exercises during the PR programme.  
The education components were delivered by a multidisciplinary team, including 
physiotherapists, dieticians, psychologists, respiratory nurses, respiratory consultants, social 
workers, speech and language therapists and occupational therapists. The aim of these sessions 
were to develop patients understanding and management of their disease, as well as topics 
including smoking cessation, PA and exercise, medication use, diet, relaxation, coping 
strategies, as well as rescue medication and community support (Bolton et al., 2013; Spruit et 
al., 2013). Regardless of group allocation in the study, generic advice on improving PA was 
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provided with an emphasis on barriers and facilitators to improving levels of PA. Furthermore, 
each patient received a British Lung Foundation exercise handbook which provided added 
support regarding the educational sessions as well as resources to record exercise and PA 
conducted outside of the weekly PR sessions. 
7.2.11 Cognitive Behavioural Therapy (CBT) 
CBT was administered by respiratory nurses as part of standard care PR at the RVI and 
Freeman hospital sites for patients who presented a HADS score ≥8. CBT sessions were 
conducted either in the Chest Clinic at the RVI or at home, lasting around 30 minutes. The 
protocol used to deliver CBT in this study was in accordance with a previously published RCT 
from Heslop-Marshall et al. (2018). The number of CBT sessions suggested and timescale for 
such sessions were co-developed with the patients depending on their individual response to 
treatment and managing symptoms based on their subjective feedback, HADS questionnaire 
results and patient preference (Heslop-Marshall et al., 2018). CBT focused on understanding 
how experiences were interpreted, made up of four elements: behaviour, cognition/thoughts, 
feelings/emotions, and physical sensations (Greenberger & Padesky, 1995). A number of 
techniques were used to aid symptoms of anxiety and depression including education on 
anxiety and depression and COPD, distraction techniques, breathing control, relaxation and 
rating achievement/pleasure of PA (Heslop-Marshall et al., 2018).    
 
7.2.12 Targets for recruitment, randomisation and completion rates   
To assess patient recruitment, patient randomisation and completion rates this study aimed at 
achieving the following criteria: (1) Recruitment of at least 30% of eligible patients (2) 
Randomisation of at least 80% of patients following informed consent (3) At least 80% of 
randomised patients should complete the intervention period and post assessment visit. The 
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criteria were based on consultations with health care professionals involved in the delivery of 
PR and on previous literature (Leon et al., 2011; Ward et al., 2018).    
 
7.2.13 Assessment of patient acceptability to the physical activity behavioural modification 
intervention 
The acceptability of the PR+PA intervention was assessed through a qualitative project-tailored 
questionnaire previously administered by (Loeckx et al., 2018a). During the final PR visit, 
patients were provided with the questionnaire and asked to complete at home. The anonymised, 
self-administered, project tailored, questionnaire involved questions regarding patient 
experiences with the PR+PA intervention and asked the usefulness of its components. In the 
final part of the questionnaire, patients were asked to comment on which components of the 
intervention they would change in the future and provide any final comments regarding their 
experiences of the intervention. Patients returned the questionnaire to the physiotherapy 
department (post-assessment visit). A member of the research team collated and anonymised 
answers into an excel file, which was subsequently used for analysis.    
 
7.2.14 Assessment of adherence to physical activity behavioural modification components   
Adherence was assessed through the degree which components of the intervention were used 
by patients (Donkin et al., 2011). Specifically, it was assessed by (1) The number of weekly 
goal setting targets met, based on a percentage of the 8 weekly step targets provided throughout 
the intervention, (2) Weekly completion of the daily step count diaries based on researcher’s 
observation of patient diaries twice weekly, (3) Pedometer wear time, based on a minimum of 
70 steps for a valid day of wearing, in line with a previous study (Loeckx et al., 2018a), (4) 
Accelerometer wear time based on a minimum of 8 hours recording time for a valid day of 
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wearing (Demeyer et al., 2014). Furthermore, patients subjectively reported their usage of the 
step counter and step count diary using the project-tailored questionnaire.  
 
7.2.15 Primary outcome measure  
 
7.2.15.1 Patients physical activity experiences  
The Clinical PROactive C-PPAC instrument, which was previously validated for use in patients 
with COPD (Dobbels et al., 2014), required both questionnaire and accelerometer-derived PA 
data (Actigraph wGT3X, Actigraph LLC, Pensacola, FL, USA) and was implemented one 
week prior to the onset of the PR programme and one week following completion of the PR 
programme. The C-PPAC questionnaire included 12-items with a 7-day recall and was 
completed using paper and pen. Patients were also instructed to wear the Actigraph 
accelerometer, that has previously been validated to be part of the C-PPAC tool (Gimeno-
Santos et al., 2015). C-PPAC scores were calculated by combining questionnaire items with 
two objective variables from the activity monitor (steps/day and VMU). Three scores were 
generated (amount of PA, difficulty of PA and total PA experience) ranging from 0 to 100, 
where higher numbers indicated a better score (Gimeno-Santos et al., 2015).  
 
7.2.16 Secondary outcome measures  
 
7.2.16.1 Physical activity outcomes  
Levels of daily PA were collected at baseline and following completion of PR, using the 
Actigraph accelerometer (Actigraph wGT3X, Actigraph LLC, Pensacola, FL, USA), with PA 
outcome measures including steps/day, VMU, sedentary time, light time, MVPA time. The 
Actigraph accelerometer was positioned above the anterior spine of the iliac crest in line with 
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the anterior axillary line of the dominant hip. This placement location has been reported to 
result in the highest accuracy (Swartz et al., 2000). All patients were instructed on how to use 
the Actigraph accelerometer prior to initiation. This included information on (1) correct 
positioning of the device; (2) the period worn for (e.g., device worn the moment you woke up 
until the moment you went to bed “wakefulness hours”), with instructions to keep on wearing 
the device even during sedentary time and illness; (3) when to take off the device (e.g., during 
water activities, bathing and showering); (4) date of when to stop assessment. A detailed 
explanation of accelerometery data collection, processing, validity and reliability are provided 
in Chapter 4. 
 
7.2.16.2 Exercise capacity  
The 6MWT was administered to assess exercise capacity at baseline and following completion 
of PR. The test was completed over a marked 30-metre corridor in accordance to the ATS/ERS 
technical standards (Holland et al., 2014). Measurements of SpO2 and heart rate using an 
oximeter and sensation of dyspnea and leg discomfort using the Modified Borg scale were 
taken prior to the test, after 3 minutes, on completion of the test and 2 minutes following the 
completion of the test. Further details on the 6MWT are provided in Chapter 4. 
 
7.2.16.3 Upper and lower body muscle strength and endurance  
Upper and lower body muscle strength and lower body muscle endurance were assessed at 
baseline and following completion of PR. Upper body muscle strength was assessed by 
handgrip strength using a calibrated hand-dynamometer (Camry EH101, Camry Electronic CO. 
Ltd., Zhongshan, China). Lower body muscle strength (QMVC) was assessed by isometric 
maximal volitional limb muscle strength assessment at baseline and following PR using a 
calibrated myometer (MIE Medical Research Ltd., Leeds, UK). Lower body muscle endurance 
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was assessed using the 30-second sit to stand test at baseline and following completion of PR. 
A detailed explanation of the set-up, implementation, analysis, validity and reliability of all 
muscle strength and endurance measures are detailed in Chapter 4.  
 
7.2.16.4 Health related quality of life   
Health related quality of life was assessed using two questionnaires, namely the CCQ and CAT 
questionnaires at baseline and following completion of PR. A detailed explanation of both the 
CCQ and CAT questionnaires and their validity and reliability in COPD are provided in 
Chapter 4.  
 
7.2.16.5 Anxiety and depression  
Both anxiety and depression were assessed using the HADS questionnaire at baseline and 
following completion of PR. A detailed explanation of the HADS questionnaire and its validity 
and reliability in COPD are provided in Chapter 4.  
 
7.2.16.6 Breathlessness  
The degree of breathlessness was assessed using the MRC Dyspnea scale at baseline and 
following completion of PR. A detailed explanation of the MRC Dyspnea scale and its validity 
and reliability in COPD are provided in Chapter 4. 
 
7.2.17 Subgroup analysis for patients with ≥8 HADS 
The subgroup analysis gauged a better understanding of the overall effectiveness of the PR+PA 
versus PR alone in patients with HADS ≥ 8 who were provided with CBT alongside their 
allocated group (either PR+PA+CBT or PR+CBT).  
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7.2.18 Statistical analysis and sample size calculation 
All statistical analyses were performed using the SPSS version 25 (IBM Corporation, UK). 
Descriptive statistics were reported as mean±SD unless otherwise specified. Prior to analysis, 
the assumption of normality for all outcomes were assessed using the Shapiro Wilks test, with 
a p value >0.05 indicating normally distributed data. Continuous variables were expressed as 
means±SD or means  (95% CI) (normal distribution) or as medians (25th-75th percentiles [P25-
P75]; skewed distribution), unless otherwise stated. Categorical variables were expressed as 
percentages, unless otherwise stated. The level of significance was set at 0.05 for all statistical 
tests.  
Data from the project-tailored questionnaire were scored as categorical variables and reported 
as frequencies and percentages (i.e., number of patients indicating each answer), except for the 
usefulness ratings of the project-tailored questionnaire, which were expressed as median (P25-
P75).  
Within and between group differences pre- to post PR for both groups for all outcome measures 
were reported as mean, (95% CI). Independent sample t tests were implemented to compare 
baseline group characteristics. A two-way repeated measures ANOVA was implemented for 
all outcome variables to identify differences between the two interventions followed by 
appropriate post hoc analysis when ANOVA revealed significant difference. Statistical 
significance was set at p < 0.05 for all analyses. The intention-to-treat principle was used to 
analyse the primary outcome measure (C-PPAC) and the per-protocol principle was used to 
analyse all secondary outcome measures.  
Verification of the sample size was based on the study by Louvaris et al. (2016) comparing PR 
to control. Based on the mean difference in the C-PPAC total score (7.4 units) between PR and 
control and observed SD (8.5 units), an alpha significance level of 0.05 (2-sided) and 80% 
power, a minimum sample of 24 patients per group was considered to be sufficient to detect 
CHAPTER 7: RANDOMISED CONTROLLED TRIAL 
W13002500 163 
significant differences in the total C-PPAC score between PR+PA and PR. Based on previous 
studies on similar PR programmes in the UK (Nolan et al., 2017), considering an attrition rate 
of 20% the total sample size was increased to 58 patients.  
 
7.2.19 Blinding 
Due to the nature of the intervention, members of the research team and enrolled patients were 
aware of their group allocation. However, to reduce the risk of bias physiotherapists running 
the PR sessions and the respiratory nurses running the CBT sessions were blinded to patient 
allocation. Patients were asked to conceal their intervention arm to the physiotherapists and 
CBT nurses, which was adhered to by all patients. 
 
7.3 Results  
 
7.3.1 Targets for recruitment, randomisation, and completion rates 
Of the 350 patients referred to the NuTH PR unit during the study period, 155 (56%) were 
diagnosed with COPD and therefore screened for inclusion in this RCT. The 195 patients 
excluded were diagnosed with other respiratory diseases: ILD (n = 45), Asthma (n = 84), 
Bronchiectasis (n = 50), other respiratory condition (n = 16). The 155 eligible patients 
comprised of 84 females (54%) and 71 males (46%). Figure 26 provides the gender and age 
distribution of the screened patients.  
Patient flow through the trial is presented in Figure 27. Of the 155 COPD patients who were 
screened for inclusion, 35 (23%) patients declined to participate when approached by a 
healthcare professional, 13 (8%) patients did not meet the specific study eligibility criteria and 
37 (24%) patients did not wish to attend the PR sessions following their PR screening visit. 
Therefore 70 (45%) patients agreed to participate in this RCT and signed the informed consent. 
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Of these, 10 patients were not randomised due to 5 patients not able to provide 4 valid days of 
PA assessment, 4 patients failing to attend the first PR session and 1 patient not wishing to 
continue the study. Therefore, following the informed consent of 70 patients, 60 (86%) patients 
were randomised to either the PR+PA intervention (n = 31) or PR alone control (n = 29). Of 
the 60 patients randomised, 33 (55%) patients reported elevated levels of anxiety and/or 
depression (≥8 HADS) and were allocated a session of CBT alongside their allocated PR+PA 
(n=17) or PA alone (n=16) group.  
Forty-eight (80%) patients attended the follow-up appointment post PR (n = 24 PR+PA and n 
= 24 PR alone). 7 (24%) patients in the PR+PA group and 5 (17%) patients in the PR alone 
group were lost to the end of PR. Reasons for withdrawal are shown in Figure 28.  Of the 48 
patients who attended the follow up appointment post PR, 23 (48%) had received a session of 
CBT alongside their allocated PR+PA (n=11) or PR alone (n=12) group. 
 































































Figure 27. Consolidation Standards of Reporting Trials diagram 
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7.3.2 Baseline patient characteristics  
Baseline demographic information and disease characteristics of patients consented to the study 
are summarised in Table 16. Of the 60 randomised patients, 22 (37%) were male and 38 (63%) 
were female, the majority of patients were of white ethnicity (98%) with a mean age of 71±9 
years/old and a mean BMI of 26.4±6.2 kg/m2. Most patients were retired (92%), with the 
remaining patients still in full/part time employment (8%). The majority of patients lived with 
family/partner (70%) and were grandparents (72%). Overall, 75% of patients were former 
smokers and the remaining patients were still smoking (25%).  
No differences in clinical characteristics were observed between the groups at baseline (p > 
0.05). Patients reported a mean MRC dyspnea grade of 3 and pulmonary function measures of 
FEV1 % pred (49±18%) and FEV1/FVC % (52±14%) which demonstrated moderate-severe 
severity of COPD in the 60 patients. The majority of patients were taking long (70%) and/or 
short-acting bronchodilators (80%) at the onset of the trial and 23% of patients required 
ambulatory oxygen at home. In addition, 18% of patients required long-term oxygen therapy 
throughout the study.  
Patients had low baseline PA levels in terms of steps/day (3171±1858) and MVPA (5.8±7.2 
mins) reported from an accelerometer as well as low baseline exercise capacity via the 6MWT 
(282±92 m). Self-reported health-related quality of life reported via the CAT questionnaire was 
poor in patients (27±6). 
 
7.3.3 Follow-up characteristics  
For the 48 patients who completed the trial, 15 (31%) were male and 33 (69%) were female, 
with a mean age of 73±8 years/old and a mean BMI of 27±5. The baseline PA of those who 
completed the trial was not different in terms of steps/day (3293±2000 steps/day) and MVPA 
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(6.4±8.3 mins) compared to the total group at baseline. Both exercise capacity and QoL were 
























CHAPTER 7: RANDOMISED CONTROLLED TRIAL 
W13002500 169 
Table 16. Baseline patient characteristics for the whole group and group allocation 
Variable Whole Group 
(n=60) 
PR + PA  
(n=31)  
PR alone  
(n=29) 
P value  
Age, years 
Male gender (%)  
Female gender (%) 
BMI, kg/m2 






































FEV1 % Pred 





































Medication, n (%) 
Long-acting bronchodilators  
Short-acting bronchodilators  
Inhaled corticosteroids  
Oral steroids (maintenance)  






























Walking aids, n (%) 
None 
Walking stick  
Walking frame  































Exercise capacity  
6MWT, m 































Abbreviations: BMI: Body Mass Index, kg/m2: kilograms/metres squared, SPO2: oxygen saturation, FEV1: Forced 
Expiratory Volume in 1 second, FVC: Forced Vital Capacity. MRC: Medical Research Council Dyspnea scale, 6MWT: 
Six Minute Walk Test, MVPA: Moderate Vigorous Physical Activity, CAT: COPD Assessment Test.  
Mean ± S.D are indicated for all columns unless stated. 
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7.3.4 Patient Acceptability to the PA behavioural modification intervention 
Overall, the PA behavioural modification intervention was well received by the patients as 75% 
(18/24) indicated that they “Liked it a lot” when asked how much they enjoyed taking part in 
the study. Furthermore, most patients (58%, 14/24) claimed that the PA behavioural 
modification intervention “helped them a lot”, to coach themselves to increase PA outside of 
PR. Most of the patients (79%, 19/24) experienced the proposed weekly increases in step goals 
as “reasonable”, whereas 21% (5/24) of patients experienced these increases as “a little too 
high” or “a little too low”. The usability of the step counter/pedometer was deemed “very easy” 
in 96% (23/24) of patients, with one patient documenting the step counter/pedometer as “easy” 
to use.  
Patients rated the usefulness of components of the PA behavioural modification intervention 
with scores based on a 0-10 satisfaction scale (0 terrible to 10 perfect); with the step 
counter/pedometer (median [P25-P75]; 9 [8-10]), daily step goals (8.5 [8-9]), feedback from 
researchers (9 [8-10]), CBT sessions (those with ≥8 HADS only) (8 [7-9]) and the step diary 
(10 [9-10]) all deemed useful parts of the intervention (Figure 29).  
Patients were asked to document how often they performed the following actions: “look at your 
step counter/pedometer” and “look and use your daily step diary”. Most patients (71%, 17/24) 
interacted with their step counter/pedometer “several times a day”, while the remaining patients 
used their step counter/pedometer “once daily” (21%, 5/24) or “sometimes, but not every day” 
(8%, 2/24) (Figure 30). In terms of using the daily step diary, 42% (10/24) used the step diary 
“several times per day”, 29% (7/24) “once per day”, 25% (6/24) “sometimes, but not every 
day” and one patient “once or twice per week” (Figure 30).    
When patients were asked to name which parts of the intervention, they would be willing to 
use further in the future, 58% (14/24) of patients chose all aspects of the intervention (step 
counter/daily step diary/PR sessions). The remaining 42% (10/24) of patients said they would 
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use the step counter/pedometer and daily step count diary again. Patients with ≥8 HADS who 
received the CBT session were asked whether they would recommend CBT to future patients 
in a similar position, 72% (8/11) said they would recommend.   
Finally, patient’s wellbeing while completing the PA behavioural modification intervention 
was deemed good at baseline and was found to improve as patient’s pedometer step counts 





Figure 29. Usefulness of components of the PA intervention. Minimum, median, interquartile range 















Figure 30. How often patients (A) looked and used their daily step diary (B) looked at their pedometer. 
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Figure 31. Fitbug pedometer mean steps/day (solid line) alongside self-reported patient wellbeing 
scores (dotted line) taken from step diaries (1 being excellent, 3 being poor) in the group undertaking 




7.3.5 Adherence to PA behavioural modification components  
The average number of days a pedometer was worn across the 8-week programme was 54 days 
(96%), representing a median (IQR) number of 6.6 (6.2-7) days worn per week (Figure 32). 
The Actigraph accelerometer was worn for a median (IQR) number of 10.4 (8.4-12.7) hours 
per day at baseline and post PR. Adherence to the step count diary to self-report daily step 
counts was high (93±17%), with a median (IQR) number of 55 (49-56) recorded days over the 
8 weeks (Figure 33). The number of weekly step goal targets met throughout the 8 weeks were 
good, with an average 67±12% of step goals achieved (Figure 34). Furthermore, patients in the 
PR+PA intervention did not increase their target step goal by 10% on a mean±SD of 3±1 
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Figure 34. Adherence of achieving weekly step goal targets across the 8-week PR+PA intervention. 
Dashed red line represents average.  
  
7.3.6 Primary outcome measure  
7.3.6.1 Patients experiences of physical activity  
The effect of the PR+PA intervention compared to the PR alone control on all dimensions of 
the C-PPAC instrument for each individual patient is shown in Figure 37. Following PR, the 
total score of the C-PPAC instrument improved by a significant and clinically important 
margin in those who undertook the PR+PA intervention (by 9 points; 95% CI 6 to 11 points, p 
= 0.001, Table 17) compared with those who undertook the PR alone control (by 2 point; 95% 
CI -1 to 4 points, p = 0.193, Table 17). A between group difference of 7 points (95% CI 4 to 
11 points, p =0.001, Table 17) was both statistically signifcant  and clinically important. In 
regard to the difficulty score of the C-PPAC instrument, significant and clinically important 
improvements were reported in those who undertook the PR+PA intervention (by 7 points; 
95% CI 3 to 10 points, p = 0.001, Table 17) compared with those who undertook the PR alone 
control (by -2 point; 95% CI -4 to 4 points, p = 0.743, Table 17). A between group difference 
of 9 points (95% CI 3 to 15 points, p =0.002, Table 17), was both statistically significant and 
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score of the C-PPAC tool were reported in those who undertook the PR+PA intervention (by 
11 points; 95% CI 7 to 15 points, p = 0.001, Table 17) compared to those who undertook the 
PR alone control (by 3 points; 95 CI -2 to 6 points, p = 0.378, Table 17).  A between group 
difference of 8 points (95% CI 2 to 11 points, p = 0.004, Table 17) was both statistically 





















CHAPTER 7: RANDOMISED CONTROLLED TRIAL 
W13002500 177 
Table 17. Change in primary outcome measures using ITT in the PR+PA (n = 31) and PR alone (n = 29) interventions 
 Group  Baseline  Post PR Within Group Mean Difference  P value Between Group Difference P value  
C-PPAC  
Total score  
PR+PA 61±16  70±16 9 (6 to 11) * 0.001 7 (4 to 11) * 0.001 
PR alone  59±14 61±15 2 (-1 to 4)  0.193   
C-PPAC  
Difficulty score  
PR+PA  62±15 69±15 7 (3 to 10)*  0.001 9 (3 to 15)* 0.002 
PR alone  62±16 60±15 -2 (-4 to 4)  0.734   
C-PPAC  
Amount score 
PR+PA  59±20 70±20 11 (7 to 15)*  0.001 8 (2 to 11)* 0.004 
PR alone  56±19 59±21 3 (-2 to 6)  0.378   
Abbreviations: C-PPAC = Clinical visit-PROactive physical activity in COPD, Min = Minutes, PA = Physical activity, PR = pulmonary rehabilitation, MVPA = moderate to vigorous 
physical activity, ITT = Intention-To-Treat.  Values are means.  Within and between group differences are reported with 95% confidence intervals (CI). *Clinically important 
improvement  
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Figure 37. Individual responses to the C-PPAC instrument for: total score PR+PA (Top left), total score 
PR alone (Top right),  amount score PR+PA (Middle left), amount score PR alone (Middle right), 
difficulty score PR+PA (Bottom left), difficulty score PR alone (Bottom right). (Red dashed line 
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7.3.7 Secondary outcome measures  
 
7.3.7.1 Physical activity outcomes 
The effect of PR+PA compared to PR alone on PA outcome measures are shown in Table 17 
and individual responses to steps/day are shown in Figure 35. Following PR, significant and 
clinically important improvements in accelerometer steps/day were demonstrated in those who 
undertook the PR+PA intervention (by 976 steps/day; 95% CI 651 to 1300 steps/day, p = 0.001, 
Table 17), but not in those who undertook the PR alone control (by -40 steps/day; 95% CI -365 
to 284 steps/day, p = 0.805, Table 17). A between group difference of 1016 steps/day (95% CI 
556 to 1474 steps/day, p =0.001, Table 17) was both statistically significant and clinically 
important. Following PR, significant improvements in accelerometer movement intensity 
(VMU) were demonstrated in those who undertook the PR+PA intervention (by 73 VMU; 95% 
CI 37 to 109 VMU, p = 0.001, Table 17), but not in those who undertook the PA alone control 
(by -20 VMU; 95% CI -57 to 17 VMU, p= 0.281, Table 17). A between group difference of 
93 VMU (95% CI 41 to 145 VMU, p =0.001, Table 17) was statistically significant. 
Following PR, a significant decrease in time spent in sedentary PA was demonstrated in those 
who undertook the PR+PA intervention (by -37 mins; 95% CI 12 to 62, p = 0.005, Table 17), 
but not in those who undertook the PR alone control (by -22 mins; 95% CI -48 to 3 mins, p = 
0.088, Table 17). A between group difference in time spent in sedentary PA of -15 (95% CI -
51 to 21, p = 0.406, Table 17) was demonstrated. A significant improvement in time spent in 
light PA was demonstrated in those who undertook the PR+PA intervention (by 20 mins; 95% 
CI 6 to 35 mins, p = 0.006, Table 17), but not in those who undertook the PR alone control (by 
-2 mins; 95% CI -17 to 12 mins, p = 0.741, Table 17). A between group difference in time 
spent in light PA of 22 mins (95% CI 2 to 43 mins, p = 0.030, Table 17) was statistically 
significant. Finally, a significant improvement in time spent in MVPA was demonstrated in 
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those who undertook the PR+PA intervention (by 3 mins; 95% CI 0 to 6 mins, p = 0.041, Table 
17) but not in those who undertook the PR alone control (by 0 mins; 95% CI -3 to 3 mins, p = 
0.791, Table 17). A between group difference of 3 mins (95% CI -1 to 7 mins, p = 0.185, Table 
17) was demonstrated in time spent in MVPA.  
Patients randomised to the PR+PA intervention were provided with a pedometer to monitor 
steps/day throughout the trial. Significant and clinically important improvements in pedometer 
derived steps/day following completion of PR were reported (by 1566; 95% CI 684 to 2357 




Figure 35. Individual steps/day responses (Actigraph) to the PR+PA intervention (Left panel) and PR 
alone (Right panel). Dashed red line indicates average response in steps/day (Actigraph), orange line 
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Table 17. Change in secondary outcome measures for PA outcomes in the PR+PA (n = 24) and PR alone (n = 24) interventions 
 Group  Baseline  Post PR Within Group Mean Difference  P value Between Group Difference P value  
Steps/day  PR+PA  3450±2168 4426±2577 976 (651 to 1300)*  0.001 1016 (556 to 1474)* 0.001  
PR alone  3446±2342 3406±2095 -40 (-365 to 284)  0.805   
Movement intensity 
(VMU)  
PR+PA  337±154 410±231 73 (37 to 109) 0.001 93 (41 to 145) 0.001 
PR alone  307±170 287±133 -20 (-57 to 17) 0.281   
Sedentary time (min)   PR+PA 495±84 458±111 -37 (12 to 62) 0.005 -15 (-51 to 21) 0.406 
PR alone 541±90 519±103 -22 (-48 to 3) 0.088   
Light time (min)  PR+PA 167±56 187±73 20 (6 to 35) 0.006 22 (2 to 43)* 0.030 
PR alone 135±57 133±48 -2 (-17 to 12) 0.741   
MVPA (min) PR+PA 7±8 10±14 3 (0 to 6) 0.041 3 (-1 to 7) 0.185 
PR alone 7±10 7±8 0 (-3 to 3) 0.791   
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7.3.7.2 Exercise capacity  
Following PR, significant and clinically important improvements (>30m) in exercise capacity 
measured by the 6MWT were demonstrated in those who undertook the PR+PA intervention 
(by 54 m; 95% CI 36 to 72 m, p =0.001, Table 18) and PR alone control (by 38 m; 95% CI 20 
to 57 m, p =0.001, Table 18). A between group difference of 16 m (95% CI -10 to 41 m, P 
=0.236, Table 18) was demonstrated.  
 
7.3.7.3 Upper and lower body muscular strength and endurance  
Following PR, significant improvements in lower body muscle strength (QMVC) were 
demonstrated in those who undertook the PR+PA intervention (by 5.0 kg; 95% CI 3.4 to 6.8 
kg, p =0.001, Table 18) and PR alone control (by 2.5 kg; 95% CI 0.8 to 4.2 kg, p =0.005, Table 
18). A between group difference of 2.5 kg (95% CI 0.2 to 4.9 kg, p = 0.033, Table 18) was 
statistically significant. 
Significant improvements were demonstrated in upper body muscle strength in those who 
undertook the PR+PA intervention (by 3.3 kg; 95% CI 2.1 to 4.5 kg, p =0.001, Table 18) but 
not in the those who undertook the PR alone control (by 1.2 kg; 95% CI 0.2 to 2.5, p=0.083, 
Table 18). A between group difference of 2.1 kg (95% CI 0.3 to 3.9 kg, p =0.022, Table 18) 
was statistically significant. Significant and clinically important improvements (≥2 reps) in 
lower body muscle endurance were reported in those who undertook the PR+PA intervention 
(by 3 reps; 95% CI 2 to 4 reps, p =0.001, Table 18) and those who undertook PR alone control 
(by 2 reps; 95% CI 1 to 3reps, p =0.001, Table 18) A between group difference of 1 rep (95% 
CI -1 to 2 reps, p =0.446, Table 18) was demonstrated.  
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7.3.7.4 Health-related quality of life  
Following PR, significant and clinically important improvements (> -2 units) in health-related 
quality of life measured by the CAT questionnaire were demonstrated in those who undertook 
the PR+PA intervention (by -4; 95% CI -5 to -3 points, p = 0.001, Table 18) and those 
undertook the PR alone control (by -2.; 95% CI -3 to -1 points, p = 0.002, Table 18). A between 
group difference of -2 points (95% CI -4 to 0 points, p =0.025, Table 18) was both statistically 
significant and clinically important. No differences in health-related quality of life were 
demonstrated by the CCQ questionnaire using the following domains in the PR+PA 
intervention or PR alone control, following PR; total score (by -0.3; 95% CI -0.6 to 0.1, p 
=0.068 vs -0.1; 95% CI -0.4 to 0.2, p =0.599, Table 18), symptoms score (by -0.3; 95% CI -0.7 
to 0.1, p =0.169 vs -0.1; 95% CI -0.5 to 0.4, p =0.805, Table 18), functional score (by -0.3; 
95% CI -0.7 to 0.1, p =0.134 vs -0.2; 95% CI -0.6 to 0.2, p =0.326, Table 18) and mental score 
(by -0.1; 95% CI -0.5 to 0.8, p =0.677 vs 0; 95% CI -0.7 to 0.6, p =0.859, Table 18). No between 
group difference were demonstrated for any CCQ domains (p >0.05, Table 18).  
 
7.3.7.5 Anxiety and depression  
Following PR, no reductions in HADS Anxiety were demonstrated in those who undertook the 
PR+PA intervention (by -1; 95% CI -2 to 0 units, p =0.065, Table 18) or those who undertook 
the PR alone control (by 0; 95% CI -2 to 1 units, p =0.461, Table 18). A between group 
difference of -1 units (95% CI -2 to 1 units, p = 0.421, Table 18) was demonstrated.  
Following PR, significant reductions in HADS depression were demonstrated in those who 
undertook the PR+PA intervention (by -1; 95% CI -2 to 0 units, p =0.004, Table 18) and those 
who undertook the PR alone control (by -1; 95% CI -2 to -1 units, p =0.036, Table 18). A 
between group difference of 0 units (95% CI -2 to 1 units, p = 0.527, Table 18) was 
demonstrated. 
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7.3.7.6 Breathlessness  
Following PR, no mean differences in MRC breathlessness were demonstrated in either the 
PR+PA intervention or PR alone control (Table 18). 
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Table 18. Change in exercise capacity, muscular strength/endurance, health-related quality of life and anxiety and depression outcome measures in the PR+PA 
(n = 24) and PR alone (n = 24) interventions 
 Group  Baseline Post PR Within Group Mean Difference  P value Between Group Difference P value  
6MWT (m) PR+PA 285±92 339±90 54 (36 to 72)* 0.001 16 (-10 to 41) 0.236 
 PR alone 276±92 314±99 38 (20 to 57)* 0.001   
HG (kg) PR+PA 22.7±8.9 26.0±9.2 3.3 (2.1 to 4.5) 0.001 2.1 (0.3 to 3.9) 0.022 
 PR alone 18.3±6.1 19.5±7.3 1.2 (0.2 to 2.5)  0.083   
QMVC (kg) PR+PA 24.6±8.7 29.6±9.7 5.0 (3.4 to 6.8) 
0.001 
2.5 (0.2 to 4.9)  0.033 
 PR alone 21.0±10.2 23.5±10.7 2.5 (0.8 to 4.2) 
0.005 
  
Sit to Stand (reps) PR+PA 10±3 13±4 3 (2 to 4)* 
0.001 
1 (-1 to 2) 0.446 
 PR alone 11±4 13±5 2 (1 to 3)* 
0.001 
  
CCQ (T) PR+PA 2.5±1.1 2.2±1.1 -0.3 (-0.6 to 0.1) 0.068 -0.2 (-0.7 to 0.2) 0.349 
 PR alone 2.5±1.3 2.4±1.3 -0.1 (-0.4 to 0.2) 0.599   
CCQ (S) PR+PA 2.5±1.2 2.2±1.1 -0.3 (-0.7 to 0.1) 0.169 -0.2 (-0.9 to 0.4) 0.435 
 PR alone 2.7±1.2 2.6±1.4 -0.1 (-0.5 to 0.4) 0.805   
CCQ (F) PR+PA 2.4±1.2 2.1±1.3 -0.3 (-0.7 to 0.1) 0.134 -0.1 (-0.7 to 0.5)  0.722 
PR alone 2.4±1.4 2.2±1.4 -0.2 (-0.6 to 0.2)  0.326   
CCQ (M) PR+PA 1.8±1.5 1.7±1.6 -0.1 (-0.5 to 0.8) 0.677 -0.1 (-1.0 to 0.8)  0.869 
 PR alone 1.9±1.5 1.9±1.5 -0 (-0.7 to 0.6)  0.859   
CAT PR+PA 26±6 22±6 -4 (-5 to -3)* 0.001 -2 (-4 to -0)*  0.025 
 PR alone 27±6 25±7 -2 (-3 to -1)*  0.002   
HADS (A) PR+PA 7±6 6±4 -1 (-2 to 0)  0.065 -1 (-2 to 1) 0.421 
 PR alone 7±4 7±4 0 (-2 to 1)  0.461   
HADS (D) PR+PA 6±6 5±4 -1 (-2 to 0) 0.004 0 (-2 to 1) 0.527 
PR alone 7±4 6±3 -1 (-2 to -1)  0.036   
MRC  PR+PA 3±1 3±1 0 (-1 to 1) 0.345 0 (-1 to 1) 0.345 
PR alone 3±1 3±1 0 (-1 to 1) 0.345   
Abbreviations: 6MWT = Six Minute Walk Test, HG = Hand grip strength, QMVC = Quadriceps Muscle Voluntary Capacity, CCQ = Clinical COPD Questionnaire, T = Total, 
S = Symptoms, F = Functional, M = Mental, CAT = COPD Assessment Test, HADS = Hospital Anxiety and Depression Scale, A = Anxiety, D = Depression, m = Metres, PA 
= Physical activity, PR = Pulmonary Rehabilitation.  Values are mean±SD.  Within and between group differences are reported with 95% confidence intervals (CI). 
*Clinically important improvement  
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7.3.8 Subgroup analysis of  patients with ≥8 HADS score at baseline 
Baseline characteristics of those included in the subgroup analysis (≥8 HADS) and those who 
weren’t (<8 HADS) for patients who completed PR (n=48) are documented in table 19.  
 
 
Table 19. Baseline characteristics of PR completers with ≥8 HADS and <8 HADS in both PR+PA 
and PR alone groups 
Variable Patients ≥8 HADS  
(n= 23) 





FEV1 % Pred 





































Abbreviations: BMI = Body Mass Index, FEV1 = Forced Expiratory Volume in the 1st  second, L = Litres, FVC 
= Forced Vital Capacity, 6MWD = Six Minute Walk Distance, m = metres, MVPA = Moderate Vigorous 




7.3.8.1 Physical activity outcomes 
The effect of PR+CBT+PA compared to PR+CBT on PA outcome measures are shown in 
Table 20 and individual responses to steps/day are shown in Figure 38. Following PR, 
significant and clinically important improvements in steps/day data were demonstrated in those 
who undertook PR+CBT+PA (by 1065 steps/day; 95% CI 498 to 1631 steps/day, p = 0.001, 
Table 20), but not in those who undertook PR+CBT (by 113 steps/day; 95% CI -429 to 655 
steps/day, p = 0.669, Table 20). A between group difference of 952 steps/day (95% CI 167 to 
1736 points, p = 0.020, Table 20) was both statistically signifcant and clinically important. 
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Following PR, positive, non-significant improvements in movement intensity were 
demonstrated in those who undertook PR+CBT+PA (by 67 VMU; 95% CI -2 to 134 VMU, p 
= 0.056, Table 20), while a decrease in those who undertook PR+CBT was demonstrated (by -
36 VMU; 95% CI -101 to 29 VMU, p= 0.267, Table 20). A between group difference of 103 
VMU (95% CI 8 to 196 VMU, p =0.035, Table 20) was statistically signifcant. 
In terms of the time spent in different domains of PA, following PR, a significant reduction in 
time spent in sedentary PA was demonstrated in those who undertook PR+CBT+PA (by -48 
mins; 95% CI -91 to -5 mins, p = 0.030, Table 20), but not in those who undertook PR+CBT 
(by -15 mins; 95% CI -56 to 26 mins, p = 0.442, Table 20). A between group difference of -33 
mins (95% CI -92 to 27 mins, p =0.269, Table 20) was demonstrated. No significant 
improvements in light PA time were demonstrated in those who undertook PR+CBT+PA (by 
19 mins; 95% CI -7 to 44 mins, p = 0.148, Table 20) or PR+CBT (by -1 min; 95% CI -26 to 
23 mins, p = 0.908, Table 20). A between group difference of 20 mins (95% CI -16 to 55 mins, 
p =0.256, Table 20) was demonstrated. Finally, following PR, no improvements in time spent 
in MVPA were demonstrated in those who undertook PR+CBT+PA (by 0 mins; 95% CI -3 to 
4 mins, p = 0.760, Table 20), or PR+CBT (by 1 min; 95% CI -2 to 4, p = 0.566, Table 20). A 
between group difference of -1 mins (95% CI -5 to 4 mins, p =0.850, Table 20) was 
demonstrated.  
Patients randomised to the PR+CBT+PA group were provided with a pedometer to monitor 
steps/day throughout the trial. Significant and clinically important improvements in pedometer 
derived steps/day following completion of PR were reported (by 1354; 95% CI 344 to 2364 
steps/day, p = 0.014).  
 
CHAPTER 7: RANDOMISED CONTROLLED TRIAL 
W13002500 189 
 
Figure 38. Indiviudal responses to the PR+CBT+PA (Left Panel) and PR+CBT (Right Panel) based 
on change in steps/day in patients reporting elevated anxiety and depression. (Red dashed line 
indicates average response in steps/day [Actigraph]). 
 
7.3.8.2 Patient experiences of physical activity  
The effect of PR+CBT+PA compared to PR+CBT on all dimensions of the C-PPAC instrument 
are shown in Table 20. Following PR, the total score of the C-PPAC instrument improved by 
a significant and clinically important margin in those who undertook PR+CBT+PA (by 8 
points; 95% CI 3 to 14 points, p = 0.004, Table 20) compared with those who undertook 
PR+CBT (by 1 point; 95% CI -4 to 6 points, p = 0.698, Table 20). A between group difference 
of 7 points (95% CI 1 to 15 points, p =0.047, Table 20) was both statistically signifcant and 
clinically important. In regard to the difficulty score of the C-PPAC instrument, significant and 
clinically important improvements were reported in those who undertook PR+CBT+PA (by 8 
points; 95% CI 1 to 16 points, p = 0.034, Table 20) and clinically important improvements in 
those who undertook PR+CBT (by 6 point; 95% CI -1 to 14 points, p = 0.097, Table 20). A 
between group difference of 2 points (95% CI -9 to 13 points, p =0.664, Table 20), was 
demonstrated. Finally, significant and clinically important improvements in the amount score 
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2 to 14 points, p = 0.010, table 20) compared to those who undertook PR+CBT (by -4 points; 
95 CI -10 to 1 points, p = 0.131, Table 20). A between group difference of 12 points (95% CI 
4 to 21 points, p = 0.005, Table 20) was both statistically significant and clinically important. 
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Table 20. Change in PA outcome measures in the PR+CBT+PA (n = 11) and PR+CBT (n = 12) interventions. 
 Group  Baseline Post PR Within Group Mean Difference  P values Between Group Difference P values 
C-PPAC  
Total score  
PR+CBT+PA 54±14 62±12 8 (3 to 14)  0.004* 7 (1 to 15)  0.047* 
PR+CBT 58±11 59±12 1 (-4 to 6)  0.698   
C-PPAC Difficulty 
score  
PR+CBT+PA 56±15 64±16 8 (1 to 16)  0.034* 2 (-9 to 13)  0.664 
PR+CBT 52±18 58±19 6 (-1 to 14)  0.097   
C-PPAC  
Amount score 
PR+CBT+PA 52±17 60±11 8 (2 to 14)  0.010* 12 (4 to 21)  0.005* 
PR+CBT 65±11 61±11 -4 (-10 to 1)  0.131   
Steps/day  PR+CBT+PA 3180±1714 4245±2034 1065 (498 to 1631)  0.001* 952 (167 to 1736)  0.020* 
PR+CBT 2632±1877 2745±1933 113 (-429 to 655) 0.669   
Movement intensity 
(VMU)  
PR+CBT+PA 325±109 392±225 67 (-2 to 134)  0.056 103 (8 to 196)  0.035* 
PR+CBT 281±189 245±134 -36 (-101 to 29)  0.267   
Sedentary time (min)   PR+CBT+PA 511±83 463±102 -48 (-91 to -5)  0.030* -33 (-92 to 27)  0.269 
PR+CBT 544±73 529±89 -15 (-56 to 26) 0.442   
Light time (min)  PR+CBT+PA 153±43 172±73 19 (-7 to 44)  0.148 20 (-16 to 55)  0.256 
PR+CBT 129±57 128±46 -1 (-26 to 23)  0.908   
MVPA (min) PR+CBT+PA 7±6 7±5 0 (-3 to 4)  0.760 -1 (-5 to 4)  0.850 
PR+CBT 5±7 6±7 1 (-2 to 4)  0.556   
Abbreviations: C-PPAC = Clinical visit-PROactive physical activity in COPD, Mins = Minutes, PA = Physical activity, PR = Pulmonary Rehabilitation.  Values are mean±SD.  
Within and between group differences are reported with 95% confidence intervals (CI). *Clinically important improvement 
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7.3.8.3 Exercise capacity  
Following PR, significant and clinically important improvements (>30m) in exercise capacity 
measured by the 6MWT were demonstrated in those who undertook PR+CBT+PA (by 59m; 
95% CI 37 to 82 m, p =0.001, Table 21) and PR+CBT (by 30m; 95% CI 8 to 52m, p =0.010, 
Table). A between group difference of 29m (95% CI -2 to 61m, p =0.067, Table 21) was 
demonstrated.  
 
7.3.8.4 Upper and lower body muscular strength and endurance 
Significant improvements in lower body muscle strength (QMVC) were demonstrated 
following PR in those who undertook PR+CBT+PA (by 4.6 kg; 95% CI 2.2 to 7.1 kg, p =0.001, 
Table 21) and PR+CBT (by 3.9 kg; 95% CI 0.4 to 7.3 kg, p =0.026, Table 21). A between 
group difference of 0.7 kg (95% CI -3.3 to 4.9 kg, p =0.676, Table 21) was demonstrated. 
Significant improvements were also demonstrated in upper body muscle strength (HG) in those 
who undertook PR+CBT+PA (by 4.7 kg; 95% CI 2.9 to 6.5 kg, p =0.001, Table 21) but not in 
the those who undertook PR+CBT (by 0.5 kg; 95% CI -2.5 to 1.4, p =0.587, Table 21). A 
between group difference of 4.2 kg (95% CI 1.6 to 6.9 kg, p =0,003, Table 21) was statistically 
signifcant. Finally, in terms of lower body muscle endurance (STS), significant and clinically 
important improvements (≥2 reps) following PR were reported in  those who undertook 
PR+CBT+PA (by 2 reps; 95% CI 2 to 4 reps, p =0.001, Table 21) but not  in those who 
undertook PR+CBT (by 1 rep; 95% CI 0 to 3 reps, p=0.121, Table 21). A between group 
difference of 1 rep (95% CI 0 to 3 reps, p =0.125, Table 21) was demonstrated.  
 
7.3.8.5 Health related quality of life  
Significant and clinically important reductions (>-2 units) in health-related quality of life 
measured by the CAT questionnaire were demonstrated following PR in those who undertook 
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PR+CBT+PA (by -5 points; 95% CI -7 to -3 points, p = 0.001, Table 21) and those who 
undertook PR+CBT (by -2 points; 95% CI -4 to 0 points, p = 0.028, Table 21). A between 
group difference of -3 points (95% CI -6 to 1 points, p =0.075, Table 21) was demonstrated.  
Significant reductions in health-related quality of life measured by the CCQ questionnaire were 
demonstrated in the following domains following PR in those who undertook PR+CBT+PA; 
total score (by -0.6 points; 95% CI -1.1 to -0.1 points, p = 0.015, Table 21), symptom score ( 
by -0.4 points; 95% CI -0.8 to -0.1, p = 0.032, Table 21) and functional score (by -0.7 points; 
95% CI -1.3 to 0.0, 0.050, Table 21). In additon, a non significant reduction in mental score 
was demonstrated (by -0.9 points; 95% CI -1.8 to 0.1, p = 0.051, Table 21). No reductions in 
those who undertook PR+CBT were demonstrated in the total score (by -0.1; 95% CI -0.5 to 
0.5, p = 0.965, Table 21), symptom score (by -0.2; 95% CI -0.6 to 0.3, p = 0.445, Table), 
functional score (by-0.3; 95% CI -1.0 to 0.4, p = 0.375, Table 21) and mental score (by 0.1 
points; 95% CI -1.0 to 0.9, p =0.874, Table 21). No between group difference were reported 
for any CCQ domains (p >0.05).  
 
7.3.8.6 Anxiety and depression  
A significant and clinically important reduction (<1.5 units) in HADS anxiety following PR 
was demonstrated in those who undertook PR+CBT+PA (by -3 units; 95% CI -5 to -1 units, p 
=0.024, Table 21) but not in those who undertook PR+CBT (by -1 unit; 95% CI -4 to 1 units, 
p = 0.214, Table 21). A between group difference of 2 units (95% CI -4 to 2 units, p =0.397, 
Table 21) was demonstrated. 
A significant and clinically important reduction in HADS depression following PR was 
demonstrated in those who undertook PR+CBT+PA (by -2 units; 95% CI -4 to -1 units, p = 
0.002, Table 21) and those who undertook PR+CBT (by -3; 95% CI -3 to -1 units, p =0.002, 
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No mean differences in MRC breathlessness were reported following PR in those who 
undertook PR+PA+CBT or PR+CBT (Table 21).  
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Table 21. Change in exercise capacity, muscular strength/endurance, health-related quality of life and anxiety and depression outcome measures in the PR+CBT+PA 
(n = 11) and PR+CBT (n = 12) interventions. 
 Group  Baseline Post PR Within Group Mean Difference  P value Between Group Mean Difference  P value 
6MWT (m) PR+CBT+PA 265±95 324±88 59 (37 to 82)  0.001* 29 (-2 to 61)  0.067 
 PR+CBT 245±84 275±85 30 (8 to 52) 0.010*   
HG (kg) PR+CBT+PA 18.7±6.4 23.4±8.2 4.7 (2.9 to 6.5) 0.001* 4.2 (1.6 to 6.9) 0.003* 
 PR+CBT 19.6±5.2 20.1±7.3 0.5 (-2.5 to 1.4) 0.587   
QMVC (kg) PR+CBT+PA 22.7±6.2 27.3±8.1 4.6 (2.2 to 7.1)  0.001* 0.7 (-3.3 to 4.9) 0.676 
 PR+CBT 20.6±9.0 24.5±10.0 3.9 (0.4 to 7.3)  0.026*   
Sit to Stand (reps) PR+CBT+PA 10±3 12±5 2 (2 to 4) 0.001* 1 (0 to 3)  0.125 
 PR+CBT 10±2 11±3 1 (0 to 3)  0.121   
CCQ (T) PR+CBT+PA 2.9±1.2 2.3±1.3 -0.6 (-1.1 to -0.1)  0.015* -0.5 (-1.2 to 0.1) 0.074 
 PR+CBT 3.3±1.2 3.3±1.2 -0.1 (-0.5 to 0.5) 0.965   
CCQ (S) PR+CBT+PA 2.7±1.1 2.3±1.2 -0.4 (-0.8 to -0.1) 0.032* -0.2 (-0.9 to 0.3) 0.308 
 PR+CBT 3.5±1.0 3.4±1.4 -0.2 (-0.6 to 0.3) 0.455   
CCQ (F) PR+CBT+PA 2.8±1.9 2.1±1.4 -0.7 (-1.3 to 0.0)  0.050* -0.4 (-1.3 to 0.6) 0.442 
PR+CBT 3.3±1.2 3.0±1.3 -0.3 (-1.0 to 0.4)  0.375   
CCQ (M) PR+CBT+PA 2.5±1.9 1.6±1.6 -0.9 (-1.8 to 0.1) 0.051 1.0 (-2.3 to 0.4) 0.137 
 PR+CBT 2.8±1.6 2.8±1.6 0.1 (-1.0 to 0.9)  0.874   
CAT PR+CBT+PA 29±4 24±4 -5 (-7 to -3)  0.001* -3 (-6 to 1)  0.075 
 PR+CBT 31±5 29±6 -2 (-4 to 0)  0.028*   
HADS (A) PR+CBT+PA 12±5 9±4 -3 (-5 to -1)  0.024* 2 (-4 to 2)  0.397 
 PR+CBT 10±3 9±4 -1 (-4 to 1)  0.214   
HADS (D) PR+CBT+PA 10±6 8±4 -2 (-4 to -1)  0.002* -1 (-2 to 2) 0.898 
PR+CBT 11±2 8±3 -3 (-3 to -1)  0.002*   
MRC  PR+CBT+PA 3±1 3±1 0 (-1 to 1) 0.345 0 (-1 to 1) 0.345 
PR+CBT 3±1 3±1 0 (-1 to 1) 0.345   
Abbreviations: 6MWT = Six Minute Walk Test, HG = Hand grip, QMVC = Quadriceps Muscle Voluntary Capacity, CCQ = Clinical COPD Questionnaire, T = Total, S = Symptoms, 
F = Functional, M = Mental, CAT = COPD Assessment Test, HADS = Hospital Anxiety and Depression Scale, A = Anxiety, D = Depression, m = Metres, PA = Physical activity, PR 
= Pulmonary Rehabilitation.  Values are mean±SD.  Within and between group differences are reported with 95% confidence intervals (CI). *Clinically important improvement.  
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7.4 Discussion  
7.4.1 Summary of main findings  
To the author’s knowledge this is the first study to investigate the efficacy of a PA behavioural 
modification intervention alongside PR (and CBT in those with profound anxiety and 
depression) in patients with COPD exhibiting low baseline PA and exercise capacity levels.  
Compared to the PR alone group, the PR+PA intervention, incorporating motivational 
interviewing, face-to-face twice weekly goal setting, step count monitoring and feedback, 
alongside exercise training and psychological support in those with ≥8 HADS, demonstrated 
significant and clinically important improvements in PA levels (steps/day, movement intensity 
and time spent in light PA) and PA experiences using the C-PPAC instrument.  
These findings are supported by evidence of adequate intervention completion rates, high 
patient acceptability and adherence to the components of the PA behavioural modification 
intervention, including the pedometer and step count diary to self-monitor and report daily step 
counts. Collectively these findings suggest that a PA behavioural modification intervention 
alongside PR provide insightful support to patients with low baseline levels of PA to translate 
PR-induced improvements in exercise capacity into improvements in overall PA outcomes.  
One of the most interesting findings of this chapter was demonstrated in the subgroup analysis 
of COPD patients with HADS≥8 who received CBT alongside either PR+PA or PR alone. In 
these patients, who typically reported lower baseline PA levels compared to those with 
HADS<8, significant and clinically important improvements in both steps/day and patients’ 
experiences of PA were reported following PR+PA+CBT compared to PR+CBT. Accordingly, 
it becomes apparent that in patients with profound anxiety and depression, PA behavioural 
modification strategies need to compliment CBT approaches in order to translate PR-induced 
improvements in exercise capacity into enhanced PA levels and PA experiences.    
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7.4.2 Physical activity outcomes 
 
7.4.2.1 Steps/day  
The findings of this study demonstrate significant and clinically important improvements in 
steps/day following completion of the PR+PA intervention compared to the PR alone control 
in patients with COPD exhibiting low baseline PA levels. These improvements in steps/day 
were supported by significant and clinically important improvements in all domains of the C-
PPAC instrument, indicating overall improvements in patients’ experiences of PA, and 
significant improvements in movement intensity and time spent in light PA.  
Previous studies have reported the impact of a PR+PA intervention compared to PR alone on 
steps/day in patients with COPD exhibiting low baseline PA, with limited improvements 
demonstrated (de Blok et al., 2006; Holland et al., 2017; Nolan et al., 2017). Specifically, as 
detailed in the systematic review and meta-analysis (Chapter 3), the combined change in 
steps/day from baseline to post PR of the three studies (de Blok et al., 2006; Holland et al., 
2017; Nolan et al., 2017) with patients reporting baseline steps/day ≤4000, failed to report a 
clinically important improvement in steps/day (Armstrong et al., 2019). Prior to these findings, 
previous studies have highlighted that the majority of patients with poor exercise capacity, 
measured through the 6MWT, and/or low PA levels at baseline were unlikely to improve PA 
following an intervention to promote PA (Demeyer et al., 2017; Loeckx et al., 2018a; Osadnik 
et al., 2018). A plausible reason for these findings involves the concept of “functional reserve”, 
indicating that patients with a higher tolerance to exercise and PA may have greater 
opportunities to become more physically active within their tolerance limits (i.e. high 
functional reserve). On the other hand, those with low tolerance to exercise and PA may be 
less capable of increasing PA due to an inhibitory ceiling limitation (i.e. low functional reserve) 
(Langer & Demeyer, 2016; Leidy, 1994; Osadnik et al., 2018).  
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Of the three studies investigating PR+PA in patients with COPD exhibiting low baseline PA, 
only de Blok et al. (2006) were able to demonstrate a clinically important improvement in 
steps/day following completion of PR+PA. Interesting, the PA counselling intervention 
implemented by de Blok et al. (2006) incorporated four face-to-face counselling sessions, while 
the current study implemented significantly more (16 sessions). However, these findings were 
reported across a very small sample size (n=8), making it difficult to analyse the overall 
effectiveness of this programme (de Blok et al., 2006). Furthermore, the primary outcome was 
based around pedometer step counts, which can often overestimate steps/day; whereas the 
triaxial accelerometer used to measure PA at baseline and post-PR in this study is considered 
a more accurate measure of PA (Rabinovich et al., 2013).  
The other two studies from Holland et al. (2017) and  Nolan et al. (2017) failed to report 
significant or clinically important improvements in steps/day following PR+PA compared to a 
PR alone group. In the study from Holland et al. (2017), a telephone based PA counselling 
intervention was added to home-based PR sessions. Their failure to achieve meaningful gains 
in PA was attributed to a lack of integration of health-enhancing behaviours into daily life, 
concluding that new methods of behaviour change are necessary in order to investigate tools 
to promote more effective health-enhancing behaviours (Holland et al., 2017).  
Interestingly, the study from Nolan et al. (2017) and the current study bears many similarities, 
with both incorporating the same twice-weekly, supervised, 8-week outpatient PR program in 
line with the BTS guidelines, based in the UK (Bolton et al., 2013). Furthermore, both studies 
delivered PA counselling in a similar manner, with pedometer feedback and daily step-count 
targets provided across the 8-weeks. However, there are several feasible reasons that may 
support the superior findings reported in the current study.  
Firstly, patients across this study were encouraged to reach a step target based on 10% of the 
previous week, which was both feasible and achievable in this group of patients. Alternatively, 
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Nolan et al. (2017) based their weekly step targets on 5% of the previous week, which was not 
achieved as regularly as the current studies targets. Moreover, the individualised approach used 
when delivering PA targets across this study may have stimulated the greater achievement of 
step goal targets, therefore improving the overall PA response.  
Secondly, patients in the present study had the opportunity to consult face-to-face with the 
researcher at every PR session (twice weekly), compared to every other PR session (once 
weekly) in the Nolan et al. (2017) study. This added face-to-face support, which was deemed 
acceptable by patients, provided the researcher with more opportunities to consult the patient 
on behaviour change techniques, including goal setting, action planning and guidance on self-
monitoring and management. Such behavioural components have been shown to benefit COPD 
patients’ readiness, motivation and confidence to engage in PA and were associated with 
significant improvements in PA behaviour (Bourbeau et al., 2021). As a result, the greater face-
to-face support may have empowered and motivated patients to engage in more daily PA, 
supporting the greater improvement in PA demonstrated in this study.  
Finally, inconsistencies surrounding the method of PA analysis exist between the two studies. 
Nolan et al. (2017) used the recommendations of Watz et al. (2009) requiring 5 valid days of 
PA data, including 3 weekdays and 2 weekend days from a total of 7 days. In contrast, in the 
current study, the recommendations from Demeyer et al. (2014) were followed, with 4 valid 
weekdays from a total of 7 days required. As detailed in Chapter 4, COPD patients typically 
report lower levels of PA during the weekend than during weekdays, which often influences 
the variability of data (Demeyer et al., 2014). Therefore, this may have been a key source of 
discrepancy between interventions across both studies.  
In terms of improvements in pedometer steps/day in those patients who completed the PR+PA 
intervention, improvements were significant and clinically important in line with recent data 
from an editorial letter by Polgar et al. (2021). Specifically, they demonstrated that an 
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improvement in pedometer PA following PR of 427 steps/day was deemed clinically important 
(Polgar et al., 2021). Based on the findings from Polgar et al. (2021) , it’s clear that the 
combined approach of a PA behavioural modification intervention alongside PR presented 
substantially greater improvements in pedometer steps/day than a regular PR programme.  
 
7.4.2.2 Movement intensity  
The current study is the first to assess the influence of a PR+PA intervention compared to PR 
alone on movement intensity. Two published studies have assessed movement intensity during 
a PA tele coaching intervention (Demeyer et al., 2017), and interval training exercise 
programme (Louvaris et al., 2016) in patients with COPD. Demeyer et al. (2017) reported 
significant improvements in movement intensity after a 12-week semiautomated tele coaching 
programme compared to usual care. Unfortunately, it isn’t possible to interpret these findings 
with those of the current study as movement intensity was assessed using different units across 
the separate studies (m/s vs VMU). Meanwhile, Louvaris et al. (2016) reported significant 
improvements in movement intensity after 12-weeks of high-intensity interval exercise training 
compared to usual care. The same VMU was used between Louvaris et al. (2016) and the 
current study, with  similar improvements equating to 20% and 22% respectively. Interestingly, 
baseline VMU values were much greater for COPD patients in the Louvaris et al. (2016) study, 
further demonstrating the level of deconditioning in COPD patients living in the North East of 
England.  
 
7.4.2.3 C-PPAC instrument  
The significant and clinically important improvements in steps/day and movement intensity 
detailed above are supported with significant and clinically important improvements in all 
domains of the C-PPAC instrument, indicating overall improvements in patients’ experiences 
CHAPTER 7: RANDOMISED CONTROLLED TRIAL 
W13002500 201 
of PA, following completion of the PR+PA intervention compared to PR alone. Although this 
comes as little surprise as the objective components of the C-PPAC instrument include 
steps/day and movement intensity, it presents additional knowledge on the subjective 
difficulties patients face while conducting PA and amount of PA they subjectively believe they 
complete on a weekly basis (Gimeno-Santos et al., 2015).  
To the authors knowledge, this is the first study to evaluate patients’ experiences of PA via the 
C-PPAC instrument following a PR+PA intervention compared to PR alone group. However, 
previous literature has documented the response of the C-PPAC instrument in two PA 
counselling standalone interventions and one interval exercise training intervention (Arbillaga-
Etxarri et al., 2018; Demeyer et al., 2017; Louvaris et al., 2016).  
Demeyer et al. (2017) found a significant between group difference in both the total and amount 
dimensions of the C-PPAC instrument following 12 weeks of semi-automated PA tele-
coaching delivered via a smartphone app compared to usual care. It should be noted that the 
usual care group reported a large decrease in C-PPAC scores following a 12-week period, with 
only small improvements in C-PPAC scores reported following the tele-coaching intervention, 
thereby suggesting that the tele-coaching intervention only had marginal effects on the C-
PPAC tool. Furthermore, Demeyer et al. (2017) were unable to demonstrate an improvement 
in the difficulty dimension of the C-PPAC instrument. The difficulty dimension has 
demonstrated a moderate-strong correlation with health status, chronic dyspnea and exercise 
capacity (Gimeno-Santos et al., 2015), which is not captured by the amount dimension of the 
C-PPAC. Demeyer et al. (2017) did not include any specific exercise training and as a result 
was unsuccessful in demonstrating improvements in exercise capacity, which may support the 
lack of improvement in the difficulty domain following 12-weeks of tele-coaching. In the 
current study, the significant and clinically important improvements in both exercise capacity 
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and PA were most likely the reason for improvements in the difficulty domain of the C-PPAC 
tool following the PR+PA intervention.   
Arbillaga-Etxarri et al. (2018) implemented a 12-month urban training programme that 
incorporated behavioural and community-based exercise in patients with COPD. The C-PPAC 
instrument was able to detect a significant improvement from baseline to 12 months in both 
the amount and difficulty C-PPAC scores, however improvements were not significant 
between the intervention and the usual care groups (Arbillaga-Etxarri et al., 2018). Considering 
the magnitude of change in the C-PPAC total scores between intervention and control groups 
in Arbillaga-Etxarri et al. (2018) (4.5 units) and Demeyer et al. (2017) (4.5 units) compared to 
that of the current study (7 units), it is clear that PA modification/counselling interventions 
added to PR are superior to those interventions alone in improving the total score of the C-
PPAC instrument.  
Meanwhile, Louvaris et al. (2016) investigated the impact of an interval exercise training 
intervention as part of PR, with significant and clinically important improvements in the total 
score of the C-PPAC instrument following the intervention (5.6 units). Interestingly, following 
completion of PR alone in the current study,  improvements in the total score of the C-PPAC 
instrument were minimal (1 unit). Louvaris et al. (2016) provided a different type of PR, with 
their programme consisting of 3 sessions per week for a total of 10 weeks, whilst the current 
study consisted of 2 sessions per week for 8 weeks. Secondly, Louvaris et al. (2016) prescribed 
high-intensity interval exercise, whereas the current study implemented moderate intensity 
exercise. Furthermore, COPD patients in Louvaris et al. (2016) presented greater baseline 
levels of PA and 6MWD than the current study, which has previously been documented to 
influence the effectiveness of interventions to improve PA (Armstrong et al., 2019).  
Based on the significant and clinically important improvements in PA outcomes; namely 
steps/day, movement intensity and patients experience of PA, demonstrated in the current study 
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compared to previous studies in patients exhibiting low baseline PA levels (de Blok et al., 2006; 
Holland et al., 2017; Nolan et al., 2017), several arguments towards this behavioural 
modification intervention can be made. Firstly, the implementation of greater weekly step goal 
targets (weekly increase of 10%), that were deemed acceptable and compliant by COPD 
patients in this study, may have encouraged greater improvements in overall PA compared to 
the 5% step goal target administered by (Nolan et al., 2017). Secondly, the greater emphasis 
placed on face-to-face consultations (twice weekly) throughout this PA behavioural 
modification intervention may have empowered and motivated patients to engage in more daily 
PA, supporting the greater improvement in PA outcomes demonstrated in this study. 
Specifically, the twice weekly face-to-face consultations provided more opportunities to 
contact/engage with the patient on behaviour change techniques which have been shown to 
benefit patients readiness, motivation and confidence to engage in PA and were associated with 
significant improvements in PA behaviour (Bourbeau et al., 2021). Finally, measuring 
objective PA measures (steps/day and movement intensity) at baseline and post-PR using an 
accelerometer validated for use in COPD patients increased the validity and accuracy of the 
PA measures reported across this study.  
By incorporating these novel approaches as part of a PA behavioural modification intervention 
to modify patient’s behaviour towards greater levels of PA, in conjunction with improvements 
in exercise capacity and health-related quality of life through PR, it is argued that patients with 
low baseline PA levels can in-fact improve steps/day, movement intensity and PA experiences 
by significant and clinically important margins similar to the improvements reported in patients 
with greater baseline PA levels reported in previous literature (Altenburg et al., 2015; Cruz et 
al., 2016; Varas et al., 2018).  
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7.4.3 Exercise capacity  
The findings of the current study indicate that both the PR+PA intervention and PR alone group 
reported significant and clinically important improvements in the 6MWT in patients with 
COPD following completion of PR. These findings are important as they support the BTS 
(Bolton et al., 2013) and ATS/ERS (Spruit et al., 2013) recommendations for PR, that exercise 
training as part of supervised PR elicit gains in exercise capacity. Previous literature has 
reported improvements in the 6MWT equating to 12% and 10% following PR+PA and PR 
alone respectively (Altenburg et al., 2015; Cruz et al., 2016; Holland et al., 2017; Kawagoshi 
et al., 2015). This was similar to the 19% and 14% improvements following PR+PA and PR 
alone, respectively across the current study. Interestingly, not all published RCT’s investigating 
the effects of PR+PA have assessed exercise capacity using the 6MWT, with Nolan et al. 
(2017) using the Incremental Shuttle Walk Test (ISWT) and Varas et al. (2018) using the 
Endurance Shuttle Walk Test (ESWT). Similar improvements in ISWT equating to 23% were 
reported across both groups in the Nolan et al. (2017) study, coinciding with the findings of 
the current study that improvements in exercise capacity are reported regardless of study 
allocation in UK based PR. However, Varas et al. (2018) found a significant between group 
difference in ESWT distance following completion of its 3 month programme. This was most 
likely a cause of the control group not receiving any specific supervised exercise training, with 
only informative sessions about the benefits of exercise provided. The implementation of 
externally paced field tests including the ISWT are becoming a more common measure in 
studies assessing exercise performance and exercise capacity in COPD, with the ATS/ERS 
guidelines (Spruit et al., 2013) considering paced tests more standardised than the 6MWT as 
the walking speeds are less influenced by motivating and self-selected pacing. However, the 
6MWT remains the most established and implemented field test to assess exercise capacity in 
COPD patients (Spruit et al., 2013).  
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7.4.4 Muscular strength and endurance  
In terms of muscle strength and endurance outcomes, significant improvements in both lower 
body muscle strength and endurance were reported across both groups, however upper body 
muscle strength was only significantly improved in the PR+PA intervention.  
Limited data on muscle strength and endurance outcomes are available from previous literature 
implementing PR+PA. Two RCT’s (Cruz et al., 2016; Kawagoshi et al., 2015) reported similar 
improvements in lower body muscle strength across both PR+PA and PR alone groups. In 
terms of lower body muscle endurance, only a single RCT (de Blok et al., 2006) investigated 
this outcome, with similar, clinically important improvements documented across groups (de 
Blok et al., 2006). Reporting improvements in lower body muscle strength and endurance is 
important as muscle dysfunction of the lower extremities has been identified as a specific cause 
of exercise impairment, causing many patients to avoid activities of daily living (Singer et al., 
2011). Moreover, as detailed in Chapter 6, a significant correlation between improvements in 
lower body muscle strength and levels of PA were demonstrated in COPD patients in the North 
East of England.  
This is the first study to date exploring the benefits of PR+PA on upper body muscle strength, 
with significant and clinically important improvements demonstrated. A 12 week exercise 
counselling programme by Hospes et al. (2009), that incorporated pedometers as a tool to 
feedback steps/day, reported small insignificant improvements in upper body muscle strength 
measured via handgrip strength in patients with COPD. The combined approach of PR+PA 
may be a plausible reason for the significant improvements in upper body muscle strength 
reported in the current study, because of PR induced improvements in exercise capacity and 
PA due to the behavioural modification interventions most likely involved more daily activities 
involving the upper limbs.  
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7.4.5 Health related quality of life 
Significant and clinically important improvements in health-related quality of life, documented 
by the CAT questionnaire, were found following completion of the PR+PA intervention and 
PR alone group. Interestingly, a significant and clinically important between group difference 
in CAT scores were shown. 
This is the only study to date that incorporated the CAT questionnaire as a tool to assess health 
related quality of life in COPD patients conducting an PR+PA intervention. The main reason 
for this may, in part, be due to many studies incorporating the most widely used disease-specific 
questionnaires; SGRQ and CRQ (Spruit et al., 2013). However, as detailed in Chapter 4, the 
CAT questionnaire was developed as a shorter tool which would be easier and quicker to 
complete, making it more applicable in clinical settings than the SGRQ and CRQ.  
A number of studies utilising PA counselling as a standalone intervention have included the 
CAT questionnaire to assess health related quality of life (Arbillaga-Etxarri et al., 2018; 
Demeyer et al., 2017; Mendoza et al., 2015). Significant improvements were only found in 
patients who underwent the PA counselling intervention, with a significant between group 
difference reported in two of the published RCT’s (Arbillaga-Etxarri et al., 2018; Mendoza et 
al., 2015). Findings of this nature comes as no surprise as specific exercise training was not 
provided to the control groups in either of the two published RCTs (Arbillaga-Etxarri et al., 
2018; Mendoza et al., 2015). 
In terms of the CCQ questionnaire, one published RCT implementing PR+PA and four 
published RCT’s implementing PA counselling alone used this questionnaire to assess health 
related quality of life in patients with COPD (Altenburg et al., 2015; Arbillaga-Etxarri et al., 
2018; Demeyer et al., 2016; Hospes et al., 2009; Tabak et al., 2014). In the study by Altenburg 
et al. (2015), clinically important improvements in the CCQ total domain were reported, while 
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results of the other CCQ domains were unavailable. Interestingly, the current study reported 
minimal changes across all CCQ domains. Regarding the RCT’s implementing PA counselling 
as a standalone intervention, only one study reported significant improvement in the CCQ total 
domain, with the remaining three documenting minimal effects. Therefore, further research is 
required to understand the true impact of these interventions on the various domains of the 
CCQ questionnaire.  
 
7.4.6 The importance of CBT  
Incorporation of CBT as part of standard care PR in patients who reported elevated baseline 
levels of anxiety and/or depression had yet to be investigated alongside PR or alongside PA 
behavioural modification interventions prior to this study. As detailed earlier, the novel 
approach of incorporating CBT in this group of patients was based on the theory that alleviating 
psychological difficulties in those with elevated levels of anxiety and/or depression who are 
typically less able to manage symptoms and improve levels of PA (Thew et al., 2017; Yohannes 
& Alexopoulos, 2014), may support an improved mood and better physical conditioning. Such 
support alongside behaviour change techniques and PR induced improvements in exercise 
capacity may improve the effectiveness of a PA behavioural modification intervention 
alongside PR in improving levels of PA. As demonstrated, those with elevated anxiety and/or 
depression across the current study had reduced baseline levels of PA, with a clinically 
important mean difference in steps/day between patients who completed PR with ≥8 HADS 
compared to those with <8 HADS.  
Interestingly, following completion of the combined PR+PA+CBT intervention, those patients 
with elevated anxiety and/or depression reported significant and clinically important 
improvements in steps/day, movement intensity and total and amount domains of the C-PPAC 
instrument, that matched the improvements demonstrated by the overall group. Accordingly, 
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providing patients with elevated levels of anxiety and/or depression and typically lower PA, 
with a combination of CBT, PR and PA behavioural modification strategies may yield 
improvements in PA that mimic in magnitude those in COPD patients with greater levels of 
PA at baseline. This finding was of significant importance as it may provide a solution to the 
major finding of the systematic review and meta-analysis (Chapter 3), that patients with low 
baseline levels of PA report inferior improvements in PA following PA counselling 
interventions. Interestingly, it seems that in those deconditioned COPD patients with elevated 
anxiety and/or depression and lower PA, CBT added to PR is not effective in terms of 
improving PA outcomes unless PA behavioural modification interventions are added to 
PR+CBT. This is likely because CBT, aiming to alleviate the psychological difficulties 
associated with activity related symptoms, does not provide any means of directing an increase 
in PA. The incorporation of PA behavioural modification interventions alongside CBT may 
provide this missing component, directing an increase in PA, through several behaviour change 
techniques (Bourbeau et al., 2021).  
CBT added to both PR+PA and PR alone in this subgroup of patients was associated with a 
comparable, clinically important improvement in exercise capacity, health status and 
depression scores. This finding is important as it demonstrates that the addition of CBT 
provided no negative impact towards either intervention. However, it must be acknowledged 
that anxiety scores following PR+CBT failed to reach clinical significance, which may be a 
result of the small sample size in this subgroup but should be considered when moving forward 
with future CBT alongside PR and PA behavioural modification interventions.    
As detailed above, previous literature has yet to incorporate CBT into PR and/or PA 
behavioural modification interventions, with only one ongoing RCT protocol available 
(Sohanpal et al., 2020). Within this ongoing RCT by Tandem investigators, a tailored, cognitive 
behavioural approach has been developed, issued weekly alongside PR. Their hypothesis is 
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that the inclusion of a tailored, cognitive behavioural approach will optimise the benefits of 
standard care PR. However, Sohanpal et al. (2020) have missed the opportunity to include any 
objective PA measures, meaning the current study remains the only research providing data on 
the effects of PR and CBT on PA levels in patients with COPD.  
It is important that future research studies incorporate the findings of the current study with 
that of the Tandem study investigators when their research becomes available, to 
comprehensively investigate the overall effects of CBT alongside PR and PA behavioural 
modification interventions in patients with COPD.  
 
7.4.7 Targets for recruitment, randomisation, and completion rates  
In terms of the targets for recruitment, randomisation, and completion rates of this PR+PA 
intervention, the proportion of eligible patients who were recruited into the study (45%), met 
the recruitment target set prior to initiation (30%). This percentage of recruitment was found 
to be similar to the majority of other PR+PA RCTs (Altenburg et al., 2015; Cruz et al., 2016; 
Holland et al., 2017) and was greater than the UK based PR+PA study from Nolan et al. (2017). 
In addition, the randomisation target rate of 80% was just achieved (86%) and was slightly 
lower than the rate achieved by Nolan et al. (2017). Finally, following completion of the 8-
week PR programme, 80% of patients completed the overall study, which met the pre-defined 
completion rate of 80%. In terms of the study groups, the completion rate was just missed in 
the PR+PA group (77%) but met in the PR alone group (83%), with similar rates achieved by 
Nolan et al. (2017). Meeting these targets set for recruitment, randomisation and completion 
rates highlights that the inclusion of a PA behavioural modification intervention to standard 
PR delivered across NuTH is feasible to patients with COPD living across the North East of 
England.  
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7.4.8 Patient acceptability and adherence to the PA behavioural modification intervention  
The implementation of this 8-week PR+PA intervention was well received by those patients 
who rated their satisfaction in line with several previous PA interventions in COPD and type-
2 diabetes populations (Loeckx et al., 2018a; Verwey et al., 2016). Specifically, when patients 
were asked to document their opinions on the overall intervention, aspects such as 
“enjoyment”, “coaching” and the “experience” of receiving weekly increases in PA, were all 
positively acknowledged through the patient satisfaction form. Interestingly, when asked 
whether the intervention “coached” patients to increase PA, the majority indicted that it either 
“helped a lot” or “a little bit”. These findings suggest that the aim of including feedback on PA 
through a behavioural modification intervention added to PR was effective, in that, patients 
were aware of their activity levels through PA feedback and were able to motivate themselves 
to achieve greater PA levels through the step goal targets provided. In terms of how this 
compares to other published studies, unfortunately, patient’s satisfaction regarding PR+PA 
interventions has not been provided. However, as the project-tailored satisfaction questionnaire 
was based on a previous RCT, it was possible to compare findings with a PA tele coaching 
intervention for patients with COPD (Loeckx et al., 2018a). Similar patient satisfaction scores 
were reported between the current intervention and the tele-coaching programme by Loeckx et 
al. (2018a), with the enjoyment of taking part in the intervention and the coaching aspects both 
receiving high acceptability. Interestingly, when indicating whether the weekly goals were 
reasonable, patients in the current study reported much higher acceptability than that of Loeckx 
et al. (2018a). The step goal target provided by Loeckx et al. (2018a) involved increasing 
patient median weekly step counts by 500 through a ‘yes’ or ‘no ‘option on the app, whereas 
in the current study a 10% increase in mean weekly step counts was administered during the 
weekly face-to-face consultations. It may be plausible that the lower usefulness score for daily 
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feedback reported by Loeckx et al. (2018a) may have influenced the lower acceptability scores, 
however, it was difficult to fully interpret the true meaning of these figures and thus further 
research is needed to determine how they influenced other components of the programme. The 
overall ability to appreciate patients’ acceptability perspectives regarding the current PR+PA 
intervention may be crucial in the design and implementation of future PA interventions and 
may provide a greater perspective on why previous studies have failed to consistently report 
effective improvements in PA.  
In terms of adherence to the PA behavioural modification components used in the current 
study, the step count diary and pedometer, both key components of this intervention, achieved 
high average adherence (over 90%). This is an important finding as the foundations of an 
effective PA behavioural modification intervention are based upon patients being able to 
accurately record and report their PA habits (Mantoani et al., 2016). High adherence to both 
the step count diary and pedometer can be linked to the high acceptability scores demonstrated 
by patients, with 96% of patients deeming the useability of the pedometer as “easy”. 
Furthermore, the usefulness of both the pedometer and step count diary were high, when 
reported through the project-tailored satisfaction questionnaire. This confirms that while 
patients were using the pedometer and step count diary a great deal, they were also able to 
appreciate its usefulness in regard to supporting their improvements in PA. Adherence to the 
step count diary in the current study was similar to that of a  pilot study from de Blok et al. 
(2006), who demonstrated adherence of 95% across a 10-week programme alongside PR.  
In addition, the adherence and achievability of the weekly step goal targets were reasonably 
high, with patients on average not meeting the 10% target on only 3 occasions across the 8-
week PR programme. This finding offers further evidence that the planned 10% weekly step 
goal target used during this PR+PA intervention was both feasible and achievable in this group 
of COPD patients. As detailed earlier, the 10% target set in the current study was achieved 
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more often by patients than the 5% target set by the Nolan et al. (2017) group, which may 
support the negative findings alongside UK based PR documented in that study. It is thus 
plausible to suggest that the greater achievement of step goal targets reported in the current 
study may have linked to the individualised approach of each face-to-face behavioural 
modification session, were patients influenced their own goals, providing a sense of ownership 
that may have stimulated greater self-motivation and self-efficacy. 
Finally, the positive patient acceptability and adherence to this 8-week PR+PA intervention is 
supported by all 24 patients, indicating that they would take part in at least the PA behavioural 
modification intervention in the future. Specifically, 58% stated they would use the PA 
behavioural modification intervention alongside PR and the remaining 42% stated they would 
use aspects of the behavioural modification intervention (pedometer and step count diary) as a 
standalone intervention in the future. This was similar to the tele coaching intervention from 
Loeckx et al. (2018a), with almost half indicating they were “willing to continue” with the 
intervention. Unfortunately, Loeckx et al. (2018a) did not provide additional data regarding 
patients willingness to use specific components of the intervention moving forward.  
With an overall lack of research regarding patient’s willingness to use PA interventions of this 
nature, further research is necessary in order to fully investigate patient facilitators and barriers 
towards PA behavioural modification interventions prior to the initiation of fully powered 
RCTs.   
 
7.4.9 Strengths and limitations  
The strengths of this study include novel data on the effectiveness of a PA behavioural 
modification intervention alongside a UK based PR programme to improve PA levels in 
patients with COPD who report low baseline levels of PA. Previous literature from Nolan et 
al. (2017) was the first and only RCT prior to this study to examine PA counselling alongside 
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UK based PR, with negative findings reported. In addition, novel data on the inclusion of CBT 
as a psychological behavioural modification tool in this study was the first to demonstrate its 
effectiveness alongside both PA behavioural modification interventions and PR.  
This study also strengthens the evidence base for assessing patients’ experiences of PA through 
the C-PPAC instrument, with novel data highlighting significant and clinically important 
improvements in all domains of the C-PPAC tool following the PR+PA intervention. With this 
additional evidence, the C-PPAC instrument has now shown clinically important 
improvements in patients experiences of PA across PA counselling/behavioural modification 
interventions alone and alongside PR and an interval training exercise programme (Garcia-
Aymerich et al., 2021). As a result, the C-PPAC instrument is becoming a useful tool, both for 
future rehabilitation trials of this nature and other clinical trials, for investigating patients’ 
experiences of PA.  
Regarding limitations, the inability to blind patients to the study allocation may have impacted 
on the overall quality of evidence and increased the risk of bias towards the intervention. 
Failure to blind patients was based on several reasons. Firstly, it would require a pedometer 
being issued to the PR alone group. Although the simple addition of a pedometer alongside 
generic advice on PA provided during PR doesn’t necessary provide any form of behavioural 
modification, the stimulus and incentive to self-manage and increase steps/day with the 
availability of a pedometer may impact upon the steps/day of the PR alone group. Secondly, in 
order to remain comparable with previous literature, we followed the procedure of several 
previous studies that implemented PA counselling alongside standard care PR (Altenburg et 
al., 2015; de Blok et al., 2006; Holland et al., 2017; Nolan et al., 2017), of which pedometers 
were not provided to the control group. In future studies however, they may wish to follow the 
blinding procedure of two recent studies in COPD (Arbillaga-Etxarri et al., 2018; Varas et al., 
2018). Varas et al. (2018) blinded patients by allocating a pedometer to both intervention and 
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control groups but provided no pedometer specific instructions to the control group. 
Meanwhile, Arbillaga-Etxarri et al. (2018) took a different approach by refraining the existence 
of an alternative group to patients. The latter would be difficult to incorporate into the current 
study due to the lack of resources available to run two separate PR programmes simultaneously, 
in order to refrain the existence of groups from one another.  
Due to all measures being administered in a face-to-face manner by a single researcher, bias 
related to the researcher providing the PA counselling intervention could be avoided and 
blinding of the assessor was not possible.  
Within this chapter, the intention-to-treat principle was used to analyse the primary outcome 
while the per-protocol principle was used to analyse secondary outcomes. The intention-to-
treat analysis is the recommended method in superiority trials to avoid any significant bias, 
which can often be found in per-protocol analyses (Tripepi, Chesnaye, Dekker, Zoccali, & 
Jager, 2020). Furthermore, the intention-to-treat principle can be seen as a better overall 
analysis of a treatment as it considers all individuals randomised to the protocol instead of only 
considering those who strictly adhered to the protocol (Tripepi et al., 2020).  
Although an adequate sample size calculation was used in this chapter, it was a small-scale 
study, therefore, generalisability of the results to clinical practice may be limited. Finally, the 
present PA counselling intervention alongside PR were well received by the vast majority of 
patients, however such an intervention may require significant health care resources as they are 
more time consuming compared to PA tele-coaching interventions.  
 
7.5 Conclusion  
The findings of this study suggest that for COPD patients who report predominantly low 
baseline levels of PA, an intervention including a PA behavioural modification intervention, 
PR and CBT induces significant and clinically important improvements in several PA 
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outcomes including, steps/day, movement intensity and patients’ experiences of PA. These 
findings are supported by feasible recruitment, randomisation, and completion rates in response 
to the combined intervention, high patient acceptability and adherence to the components of 
the PA behavioural modification intervention, including the pedometer and step count diary to 
self-monitor and report daily step counts. Importantly, significant, and clinically important 
improvements in both steps/day, movement intensity and PA experiences were demonstrated 
in those patients with ≥8 HADS who received CBT alongside PR+PA. These findings are of 
significance due to the typically low baseline daily activity levels reported by these patients. 
Therefore, this may provide a solution to one of the major research findings of this thesis, that 
prior to these findings, patients with low baseline levels of PA reported inferior improvements 
in PA following PA counselling interventions. Importantly this study has shown that in COPD 
patients with low baseline exercise capacity and PA levels, improvements in exercise capacity 
induced during PR may be translated into improvements in PA levels only when a tailored 
behavioural modification intervention is added to PR alongside CBT for those with profound 
anxiety and/or depression.   
Further development and delivery of this combined PA behavioural modification intervention 
alongside PR and CBT in future RCT’s may support those patients with low baseline levels of 
PA to achieve greater improvements in PA alongside PR induced improvements in exercise 
capacity, with the main end goal of lowering the risks of increased hospital admissions, 








































CHAPTER 8: GENERAL DISCUSSION 
W13002500 217 
8.1 Overview  
Overall, this thesis explored the current literature on PA counselling as a standalone 
intervention and alongside PR (Chapter 3), determined the criterion validity and test-retest 
reliability of a commercially available pedometer (Chapter 5), evaluated PA, muscle function 
and anxiety and depression in patients with COPD living in the North East of England in 
comparison to healthy individuals from the same region (Chapter 6), and investigated the 
feasibility, acceptability and efficacy of a novel intervention combining PA behavioural 
modification strategies, PR and CBT in patients with COPD living in the North East of England 
(Chapter 7).  
 
8.2 Summary of Key Findings 
The systematic review and meta-analysis in Chapter 3 explored the current literature on PA 
counselling as a standalone intervention and alongside PR on its effectiveness towards 
improving PA in patients with COPD. Overall, significant and clinically important 
improvements in steps/day were documented across PA counselling interventions alone and 
alongside PR. However, important novel evidence was presented showing that compared to 
patients with greater baseline levels of PA (≥4000 steps/day), those patients with low baseline 
levels of PA (<4000 steps/day), typically failed to achieve clinically important improvements 
in steps/day following a PA counselling intervention alongside PR. Therefore, a greater 
emphasis on those with low levels of PA were urgently needed in order to prevent the decline 
in PA and the associated risk of hospitalisation and mortality consequent to physical inactivity 
(Garcia-Aymerich et al., 2006; Garcia-Aymerich et al., 2009; Garcia-Rio et al., 2012; Vaes et 
al., 2014; Waschki et al., 2011). 
Based on these findings, it was important to investigate the baseline PA habits of COPD 
patients living in the North East of England prior to their inclusion in a PA behavioural 
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modification intervention added to PR in order to support the design and delivery of this 
combined intervention (Chapter 7). Based on this concept, Chapter 6 confirmed that patients 
with COPD living in the North East of England experienced significantly lower levels of PA 
compared to healthy age-matched individuals living in the same region. A major concern 
arising from Chapter 6 was the substantial deterioration in levels of PA reported in patients 
living in the North East of England compared to COPD patients living in other regions of the 
UK and Europe. With the combined findings of Chapters 3 and 6, it was apparent that COPD 
patients living in the North East of England would not benefit from a standard PA counselling 
intervention alongside a PR programme. Accordingly, the PA behavioural modification 
intervention implemented in Chapter 7 incorporated motivational interviewing, face-to-face 
twice weekly goal setting, step count monitoring and feedback, alongside psychological 
support in those patients with anxiety and depression (≥8 HADS).  
Chapter 7 assessed the feasibility, acceptability, and efficacy of combining PR, designed to 
improve exercise capacity, with a comprehensive PA behavioural modification intervention, 
designed to translate PR-induced improvements in exercise capacity into improved daily PA 
(and CBT in those with profound anxiety and depression) in patients with COPD exhibiting 
low baseline PA and exercise capacity. The delivery of this PA behavioural modification 
intervention demonstrated significant and clinically important improvements in PA levels 
(steps/day, movement intensity and time spent in light PA) and PA experiences using the C-
PPAC instrument compared to PR alone. These findings were supported by evidence of 
adequate intervention completion rates, high patient acceptability and adherence to the 
components of the PA behavioural modification intervention, including the pedometer and step 
count diary to self-monitor and report daily step counts. One of the most interesting findings 
of Chapter 7 was demonstrated in the subgroup analysis of COPD patients with HADS≥8 who 
received CBT alongside either PA behavioural modification interventions and PR or PR alone. 
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In these anxious and/or depressed patients, who typically reported lower baseline PA levels 
compared to those without anxiety and/or depression, significant and clinically important 
improvements in both steps/day and patients’ experiences of PA were reported following 
PR+PA+CBT compared to PR+CBT. Accordingly, it becomes apparent that in patients with 
profound anxiety and depression, PA behavioural modification strategies need to compliment 
CBT approaches in order to translate PR-induced improvements in exercise capacity into 
enhanced PA levels and PA experiences. CBT added to PR without the inclusion of a PA 
behavioural modification intervention does not convey PR-induced improvements in exercise 
capacity into enhanced levels of daily PA in anxious and or/depressed COPD patients.  
Importantly, the findings of the present thesis suggest that in COPD patients with low baseline 
exercise capacity and PA levels, improvements in exercise capacity induced during PR may be 
translated into improvements in PA levels only when a tailored behavioural modification 
intervention is added to PR alongside CBT for those with profound anxiety and/or depression. 
These may present a solution to one of the major research findings of this thesis, demonstrated 
in the systematic review and meta-analysis in Chapter 3, that patients with low baseline levels 
of PA typically reported inferior improvements in PA following PA counselling interventions. 
Furthermore, the adequate completion rates, high patient acceptability and adherence to 
components of the PA behavioural modification intervention provide vital evidence that this 
combined intervention can be rolled out without difficulty across PR outpatient and 
community-based centres in the UK.  
These findings also provide essential evidence to support the NHS long term plan, that 
proposes the need for new models of PR, including digital tools, so that patients have the 
support they need to best self-manage their condition and live as independently as possible.  
By supporting patients to use digital tools like pedometers to self-manage their condition, it 
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goes a long way to reducing the demand on healthcare utilisation and the spiralling costs 
associated with the long-term management of respiratory conditions.   
 
8.3 Future Directions and Recommendations  
With the use of wearables and mobile applications that support tele-coaching becoming more 
popular, it is important to consider how the results of this thesis may impact the use of these 
applications and how technological advances may be beneficial in future research and clinical 
practice. Benefits of using telemedicine and/or tele-coaching include the possibility of 
decreasing the burden placed on clinicians and patients, the ability to standardise interventions 
and making such interventions available to patients who live in remote locations where access 
to healthcare is limited (Demeyer et al., 2017; Institute of Medicine Committee on Evaluating 
Clinical Applications of, 1996). Interestingly, the PA tele-coaching studies from Loeckx et al. 
(2018a) and Demeyer et al. (2017) have demonstrated several similar characteristics to the 
current face-to-face PA behavioural modification intervention, including similar patient 
acceptability (Loeckx et al., 2018a) and similar improvements in PA levels (Demeyer et al., 
2017). Therefore, based on these similarities it is plausible to suggest that the PA behavioural 
modification strategies implemented in this thesis (motivational interviewing, goal setting, 
feedback, encouragement, and advice to overcome barriers) could be developed and delivered 
as a telemedicine or comprehensive tele-coaching intervention. With this in mind the following 
recommendation can be explored in future research projects. Firstly, the key component of this 
PA behavioural modification intervention was the face-to-face consultation between patient 
and researcher that aimed to empower and motivate patients to engage in more daily PA, 
supporting a continuous improvement in PA. With the development of a tele-coaching 
alternative, this face-to-face consultation needs to be replaced by other virtual means of 
consultation via telephone or video consultation (e.g., NHS attend anywhere). Secondly, PA 
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tele-coaching supported by virtual consultation may be employed to accelerate recovery of 
functional capacity following hospital discharge for an acute exacerbation of COPD and thus 
facilitate enrolment in PR within the critical 90-day post hospital discharge period (Spruit et 
al., 2013). Furthermore, an effective approach may involve a comprehensive programme, with 
face-to-face PA behavioural modification strategies used alongside PR as demonstrated in this 
thesis followed by PA tele-coaching as a maintenance intervention on completion of PR 
(Demeyer et al., 2017; Loeckx et al., 2018a; Vasilopoulou et al., 2017). This approach provides 
an opportunity for future studies to investigate whether sufficient follow-up interventions are 
required to facilitate the maintenance of enhanced PA levels following completion of a PR 
programme.  
Given the positive responses of this combined PA behavioural modification intervention 
alongside PR and CBT, future studies need to incorporate and deliver this combined 
intervention throughout standard PR programmes to support patients with COPD who report 
low baseline PA levels in order to mitigate the increased risk of hospitalisation and mortality 
associated with physical inactivity. Furthermore, with the clear benefits of CBT as a 
psychological behavioural modification tool, future research should expand the delivery of 
CBT alongside both PR and PA behavioural modification interventions particularly in cases 
where patients have elevated levels of anxiety and depression. As with PA tele-coaching, CBT 
can be delivered via virtual consultations to address the impact of depression and anxiety on 
physical inactivity.  
Finally, it is important to consider the best available tools for measuring PA in a COPD 
population. Triaxial accelerometers continue to be recommended as the most accurate and 
reliable tools and offer more detailed PA data (movement intensity and time spent in domains 
of PA) than pedometers or step counters. However, purchase costs vary considerably between 
devices which may impact the ability of research projects with a large sample size to use 
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accelerometers moving forward. Furthermore, accelerometers do not provide patients with 
real-time feedback of PA levels, making them unfeasible for self-monitoring patients’ PA. 
Alternatively, simple low-cost pedometers, step counting devices smartphones and watches are 
becoming more popular and affordable. As a result, future research should look to investigate 
the accuracy, reliability and usability of low-cost pedometers, smartphones and watches that 
provide a step counting application. By providing more clarity on these devices, new avenues 
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Appendix 3A: Characteristics of included studies (Systematic review & Meta-Analysis) 
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diary feedback- 
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sessions- 3 months) 
 
Lifestyle PA 
counselling (30 min 
x4 sessions using 
MI, GS and 
pedometer- 9 
weeks) added to PR 
(9 weeks)  
 
Received the usual 
care plus the tele 
coaching platform. 
This includes a one-
to-one interview, a 
step counter and 
smartphone 
Pedometer with 
no goal setting or 
communication 
about physical 
activity. A small 
1-1 telephone call 
to communicate 
daily steps.  
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goals and feedback 
for 6 months.  
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received access to a 
website which 







content and online 
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Received no tele-
rehabilitation. 
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of pedometer step 
counts.  
 
No pedometer or 










Data are presented as n, means or mean (range). Abbreviations: FEV1: Forced Expiratory Volume in 1 second; PA: Physical Activity; N/A: Not Applicable; PR: Pulmonary 
Rehabilitation; MI: Motivational interviewing; GS: Goal Setting; SCT: Social cognitive theory; SE: Self Efficacy; ET: Exercise training; EDU: Education.  
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Appendix 4f: Capacity and Capability Approval  
 
 
From: Caldicott@nuth.nhs.uk [mailto:Caldicott@nuth.nhs.uk]  
Sent: 10 October 2018 15:09 
To: Heslop, Karen (Nurse Consultant, Chest Clinic) 
Cc: Trust Research & Development 
Subject: Your Caldicott application has been accepted (ID: 6825) 
  
Dear Karen Heslop 
 
The Caldicott application you submitted for the following study has been accepted (ID: 6825) 
 
"A feasibility study of Physical Activity Promotion to standard care pulmonary rehabilitation and cognitive 





Head of Information Governance & Security 




















































Appendix 4h: GP Letter 
 
[  Doctor ] 
[  Address    ] 
[date] 
 
Dear [  Doctor  ] 
Re  [Patient, DOB, Address] 
The above patient currently attends Clinic under the care of  
[Consultant].   [Patient] has agreed to participate in a feasibility study observing the effects of physical activity 
promotion and cognitive behavioural therapy alongside pulmonary rehabilitation on daily physical activity. The 
purpose of the study is to identify if physical activity promotion and cognitive behavioural therapy together 
can help to improve daily physical activity while undergoing standard care pulmonary rehabilitation in patients 
with COPD. We are following patients up to 8 weeks after randomisation.  
 
 [Patient] has been screened for both COPD using spirometry and anxiety and depression using the Hospital 
Anxiety & Depression Scale.  This patient has been randomised and allocated to the [intervention or control] 
group.  The intervention group will undertake weekly physical activity promotion sessions alongside their 
standard care pulmonary rehabilitation in the Chest Clinic, RVI. This patient will receive a pedometer at the 
start of the program in order to track daily steps. At every session, this patient will undergo a feedback session 
were daily step goals will be provided and motivational support to meet these goals will be received. Three 
sessions of CBT in the Chest Clinic, RVI will be conducted throughout the 8 weeks of rehabilitation.  The control 
group will receive standard care, which includes pulmonary rehabilitation and CBT. If you require further 




Dr Karen Heslop-Marshall  
Nurse Consultant Respiratory Medicine 
Chest Clinic, RVI 




















Appendix 4i: Chapter 7 Participant Information Sheet  
 
Participant Information Sheet  
Title of Project: A feasibility study assessing the inclusion of Physical Activity Promotion 
to standard care pulmonary rehabilitation and cognitive behavioural therapy in patients 
with COPD.  
 
 
Name of researcher: Matthew Armstrong MSc, BSc 
We would like to invite you to take part in our research study. Joining the study is entirely up 
to you before you decide we would like you to understand why the research is being undertaken 
and what it would involve for you. One member of our team will go through this information 
sheet with you, to help you decide whether you would like to take part and answer any 
questions, you may have. This should take about 30 minutes. Please feel free to talk to others 
about the study if you wish. 
The first part of the Participant Information Sheet tells you the purpose of the study and what 
will happen to you if you take part. 
Then we give you more detailed information about the conduct of the study. 




What is the purpose of the study? 
In patients who suffer COPD, daily physical activity is reduced compared to healthy 
individuals. Reduced levels of physical activity are associated with increased rates of hospital 
admission and mortality. Interventions such as physical activity promotion have been found 
to improve engagement in physical activity and alongside pulmonary rehabilitation have been 
found to promote a healthy physically active lifestyle. To date no study has incorporated 
physical activity promotion alongside an intervention to adapt behaviour. Therefore, we aim 
to incorporate both physical activity promotion and cognitive behavioural therapy to the 
standard care pulmonary rehabilitation at the Royal Victoria Infirmary.  
Why have you been chosen?  
You have been chosen because you are a patient with COPD referred from the chest clinic to 
a programme of pulmonary rehabilitation at the Royal Victoria Infirmary. If you report a score 
of  8 on the HADS questionnaire you will be referred to Dr Karen Heslop for sessions of 
Cognitive Behavioural Therapy, conducted throughout your pulmonary rehabilitation 
programme. If you don’t report a score of 8 on the HADS questionnaire then you will only 
be referred to pulmonary rehabilitation. Both Pulmonary rehabilitation and Cognitive 
behavioural therapy are part of your standard care and will not be affected by your decision in 
regard to this study.   
What the study involves?  
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The added physical activity promotion intervention will include: 1) a step-counter with a 
digital display, 2) a semi-structured interview discussing motivation issues, favourite 
activities, and strategies to become more active; 3) a tailored physical activity coaching 
plan including an individualized daily activity goal (steps) revised weekly. The physical 
activity promotion intervention will take place over telephone and will only require a 5-10-
minute conversation with a member of the research team each week. During this time a 
conversation will be held to discuss the previous weeks daily step count (reported from step-
counters), leading to a new weekly step goal being set.       
Who would usually be admitted? 
In this study, the participants will be COPD patients who experience breathlessness and 
locomotor muscle discomfort during activities of daily living. If a HADS score of  8 for either 
anxiety and/or depression is reported then a referral for CBT would be arranged and patients 
would have shown interest to receive this behavioural intervention. If a HADS score of <8 for 
either anxiety and/or depression is reported then patients would be allocated to pulmonary 
rehabilitation only.  
Where the study will be conducted? 
The study will take place over telephone as part of your home-based pulmonary rehabilitation 
programme, part of the Newcastle upon Tyne Health Care Trust.  
How long will the study last; when will it start and end? 
As per the updated standard practice due to the COVID-19 pandemic, the study will involve 
one hospital visit prior to the initiation of the pulmonary rehabilitation programme and one 
hospital visit after completion of the pulmonary rehabilitation program in order to provide 
questionnaires and complete a number of small tests to assess the effects of pulmonary 
rehabilitation on your functional capacity and symptoms. The program itself will last a total 
of 8 weeks. During each home-based rehabilitation session, exercises will be provided using 
a home-exercise booklet and/or 4G tablet, with example videos and clear explanations of how 
to safely complete each exercise. The physical activity promotion intervention will take place 
over telephone once per week in conjunction with telephone calls from the respiratory 
physiotherapist team.  
Do I have to take part?  
No, it is your free choice to take part. If you decide to take part, you will be asked to sign a 
consent form. You are free at any time to withdraw from the study, and do not have to give a 
reason. If you decide to withdraw from the study, we will use the information we have gathered 
up to that point, but we will not include your personal information unless you give us 
permission to do so.  
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If you decide not to take part, you will continue to receive the same usual care treatment. 
What is physical activity promotion?   
The physical activity (PA) promotion intervention will include: 1) a step-counter with a 
digital display, 2) a telephone based semi-structured interview discussing motivation issues, 
favourite activities, and strategies to become more active; 3) a tailored physical activity 
coaching plan including an individualized daily activity goal (steps) revised weekly.   
Cognitive behavioural modification? 
Cognitive behavioural modification is made up of four elements; behaviour, 
cognition/thoughts, feelings/emotions, physical sensations. A number of techniques will be 
used to aid symptoms of anxiety and depression including; education on anxiety and depression 
and COPD, distraction techniques, breathing control and relaxation and rating 
achievement/pleasure of physical activities.   
 
What are the possible disadvantages and risks to taking part?  
It is likely to feel breathless or experience muscle discomfort during the PR programme, 
nevertheless it is expected to recover very quickly after each session. Exercise is good for you. 
 
What are the advantages to taking part? 
You will have the chance to experience the positive effects of pulmonary rehabilitation and 
your results will contribute to inform clinical service in the future so that an optimal form of 
exercise training is prescribed to patients in the future.   
Will my personal information be kept confidential?  
During the study, we will collect information from you about your health and well-being. Your 
personal information such as your name and date of birth will be kept confidential and only 
available to the research team. The information given will only be used in a way that cannot be 
traced back to you, and any personal information will be stored securely. With your permission, 
we will write to your GP to let him/her know that you are taking part in the study. No one 
outside the research team will know if you decide not to take part. 
What if there is a problem or I need more information?  
If you wish to complain, or have any concerns about the study, please ask to speak to the 
physicians who oversee the study and will do his/her best to answer your questions. If you are 
still unhappy, you can complain formally using the normal NHS complaints channels. 
What will happen with the results of the study?  
The results will be discussed at scientific medical meetings and will be published in medical 
journals so that others can learn from our findings. You can receive a copy of the results by 
contacting Dr. Karen Heslop-Marshall. 
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Newcastle upon Tyne Healthcare trust is the sponsor for this study based in England. We will 
be using information from you and/or your medical records in order to undertake this study 
and will act as the data controller for this study. This means that we are responsible for 
looking after your information and using it properly. Newcastle upon Tune Healthcare trust 
will keep identifiable information about you for three years after the study has finished.  
Your rights to access change or move your information are limited, as we need to manage 
your information in specific ways in order for the research to be reliable and accurate. If you 
withdraw from the study, we will keep the information about you that we already have 
obtained. To safeguard your rights, we will use the minimum personally identifiable 
information possible.   
You can find out more about how we use your information by contacting the Respiratory 
Nurse Consultant in charge of this study, who’s contact details can be found below;  
 
Dr. Karen Heslop-Marshall, Chest Clinic, RVI Hospital. 
Telephone: 0191 282 29095  
Email: karen.heslop@nuth.nhs.uk 
 





















Appendix 4j: Chapter 7 Informed Consent Form  
 
CONSENT FORM 
Title of Project: A feasibility study assessing the inclusion of Physical Activity Promotion 
to standard care pulmonary rehabilitation in patients with COPD. 
Name of Researcher: Matthew Armstrong  
Please read the following statements, placing an initial in each box to confirm that you have 
read and agreed the terms required. Once complete please provide your name, date of 
completion and a signature on the lines provided.  On completion of this consent form, the 
original copy will be kept alongside the study documents and a copy will be made for your 
personal use.  
1. /I confirm that I have read the information sheet dated.................... (version............) for the 
above study. I have had the opportunity to consider the information, ask questions and have 
had these answered satisfactorily. 
 
2. /I understand that my participation is voluntary and that I am free to withdraw at any time 
without giving any reason, without my medical care or legal rights being affected. 
/ 
3. I understand that the information collected about me will be used to support 
other research in the future and may be shared anonymously with other researchers. 
 
4. / I agree to my General Practitioner being informed of my participation in the 
study. / I agree to my General Practitioner being involved in the study, including any necessary 
exchange of information about me between my GP and the research team. 
 
5. / I understand that the information held and maintained by  
________________________________ [(enter name of organisation(s) that will be  
 providing you with data, including any NHS/HSC organisations)] may be used to help contact  
 me or provide information about my health status. 
/ 
6. I agree to take part in the above study. 
 
            
Name of Participant  Date    Signature 
            
Name of research  Date    Signature 
 
 cccxxv 





Appendix 4l: Chapter 6 & 7 Participant Information Sheet  
 
Normative daily physical activity levels in healthy individuals 
living in the UK 
 











1. What is the purpose of the study?  
Physical activity can provide immediate and long-term health benefits for 
everyone. The World Health Organisation recommends that adults should aim to 
achieve 150  
minutes of moderate or 75 minutes of vigorous activity per week. Reaching these 
guidelines can lead to improvements in many aspects of health including fitness, 
psychological well-being and reduce the risk of developing chronic conditions 
such as type 2 diabetes and cancer.  
In patients with chronic lung disease, low levels of physical activity are common 
due to impaired muscle function and symptoms such as breathlessness and 
fatigue. This can adversely affect physical functioning, which can impact 
psychological wellbeing and quality of life. Given the multiple health benefits of 
improved physical activity, it is important to study levels of activity in this patient 
population. However, comparison of physical activity levels between patients with 
chronic lung disease and healthy individuals are lacking. 
Therefore, this study aims to compare levels of physical activity and muscle 
function in healthy individuals with patients who have chronic lung disease. 
Alongside the assessment of daily physical activity and muscle function, the study 
will investigate the accuracy and reliability of a low cost, high street pedometer.  
2. Who can take part?  
You have been chosen because you are a healthy individual aged between 18-
80 years of age with low to moderate levels of everyday physical activity. Before 
you can be enrolled onto this research study you must be able to meet the study 
inclusion criteria which will be outlined by a member of the research team during 
enrolment/screening over telephone.  
3. Do I have to take part?  
No, there is no obligation to take part. If you decide to take part, you will be asked 
to sign a consent form. You are free at any time to withdraw from the study, and 
do not have to give a reason. If you decide to withdraw from the study, we will 
use the information we have gathered up to that point, but we will not include your 
personal information unless you give us permission to do so.  
4. What would taking part involve?  
You have been invited to take part in a research study. Before you decide 
whether to participate, it is important for you to understand why the 
research is being carried out and what it will involve. 
Please take time to read the information carefully, discuss it with others 
and ask any questions you may have. 
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If interested in the study, a member of the research team will ask you to provide 
informed consent. If you chose to take part, you will need to attend Northumbria 
University on two separate occasions. Each visit should last no longer than 60 
minutes.  
During visit 1, you will be asked to complete a short physical activity questionnaire 
and an assessment of your lung function will be conducted. A member of the 
research team will then check that you meet the study inclusion/exclusion criteria. 
Following this, you will perform an 8-minute walking protocol on a treadmill, which 
will involve walking for 2 minutes with no incline at 4 different speeds (2.5, 3, 3.5 
and 4 km/h). Whilst walking you will be required to attach a pedometer to your 
waist and wrist, as well as an activity tracker around your waist. Throughout the 
walking protocol, a video camera will record the number of steps that you take, 
so that this number can be compared to the pedometer and activity tracker.  
At the end of visit 1, you will be given the activity tracker to take home with you 
to measure your daily physical activity. This should be worn around your waist for 
7 days during waking hours.  
Following 7 days of wearing the activity tracker, you will be asked to return to the 
university. During visit 2, the walking protocol performed in visit 1 will be repeated 
again followed by measures of muscle function. These will include: 
• A 30-second sit-to-stand test which will involve you standing and sitting 
from a chair as many times as you can in 30 seconds.  
• A hand grip strength test which will involve you squeezing a device with 
your hand as hard as you can.  
• A leg strength test where you will be sat on a chair with your ankle attached 
to a cuff and will be asked to push your leg out as hard as you can.  
5. Are there any expense of payments involved?  
Unfortunately, there are no payments involved for taking part in this research 
study and we are unable to reimburse you for any travel expenses incurred.  
6. What are the possible benefits, disadvantages, risks or discomfort of 
taking part?  
The findings of this study will help to understand how physical activity levels in 
chronic lung disease patients compare to those seen in healthy individuals in the 
UK. As well as this, we will gauge a better understanding of the accuracy and 
reliability of a pedometer for reporting daily steps.  
You may feel a slight level of fatigue in your legs following the muscle function 
tests and treadmill walking exercise, however none of the speeds in our walking 
protocol are greater than every day walking speeds. No risk or discomfort will be 
felt while wearing either the pedometer or accelerometer.  
7. How will my information be kept confidential? How will my data be 
stored?  
All data collected in this study will be fully anonymised using numerical coding to 
maintain confidentiality. Only the researcher will have access to any identifiable 
information which will be kept separate from any data that can identify you. All 
data will be stored on a password protected computer in accordance with 
university guidelines and the Data Protection Act (2018). At no point will your 
personal information or data be revealed unless forced to do so by the courts.  




If you do decide to take part, you are still free to withdraw at any time with no 
reason required. Inform the researcher as soon as possible (contact details 
provided below) and they will facilitate your withdrawal and discuss how you 
would like your data to be treated. We would like to use all your data collected up 
to this point to help with analysis, however if you would prefer your data not be 
used you may request it to be removed from the study. If you do complete the 
study, it may not be possible to withdraw your individual data after a month as 
the results may have already been published. However, as all data are 
anonymous, your individual data will not be identifiable in any way. 
9. What will happen to the results of the study?  
The results will be used in the formation of a PhD thesis that will be examined as 
part of a postgraduate degree. Occasionally, some results might be reported in a 
scientific journal or presented at a research conference, however the data will 
always remain anonymous unless specific consent is obtained beforehand. 
Findings may also be shared with other organisations/institutions that have been 
involved with the study. A summary of the study’s findings can be provided to you 
if you request them from the research team. 
10. Who is funding the study?  
This study has not received any funding.  
11. What happens if I have a complaint?  
If you are unhappy about the way you have been approached or treated before, 
during or after your participation, the researcher should be contacted. However, 
if you feel this is not appropriate you should contact the Chair of ethics for Sport, 
Exercise and Rehabilitation: Dr Nick Neave, 
Email: nick.neave@northumbria.ac.uk 
12. Who has reviewed this study?  
This study has received full ethical approval from the organisation Northumbria 
University, Department of Sport, Exercise and Rehabilitation postgraduate ethics 
committee. If you require confirmation of this please contact the chair of ethics committee 
using the details below, please state the full title of this project and the chief investigator. 
Dr Nick Neave 



















For further information please contact:  
Emily Hume or Matthew Armstrong (Study Co-ordinators):  
Email: emily.c.hume@northumbria.ac.uk  or  matthew.armstrong@northumbria.ac.uk 
Professor Ioannis Vogiatzis (Chief Investigator) 
Email: Ioannis.vogiatzis@northumbria.ac.uk  










Normative daily physical activity levels in elderly healthy individuals 
living in the North east of England.  
 
INFORMED CONSENT FORM  
1. I confirm that I have read and understood the participation information sheet 
provided for the above study. I have had the opportunity to consider and discuss the 
information, ask questions and have had these answered satisfactory. 
 
2. I understand that my participation is voluntary, and I am free to withdraw from the 
study at any time, without having to give any reason and without prejudice 
 
3. I understand that any personal information collected during this study will be 
anonymised and may be used to support other future research 
 
4. I agree to my General Practitioner (GP) being informed of any results that are 
indicative of requiring treatment 
 
5. I understand that my participation in this research study involves exposure to 
radiation in addition to what I may receive as part of my standard care 
 
6. I understand that if I would like to receive feedback on the overall results of the 
study I must contact the researcher at: matthew.armstrong@northumbria.ac.uk 
 
7. I agree to take part in the above study 
 
Statement by the researcher 
I can confirm that the participant was given the information sheet and the opportunity 
to ask any questions or queries related to this study. All the questions asked by the 
participant have been answered correctly and to the best of my ability the participant 
understands what they are required to do. I confirm that the individual has not been 
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Participant ID:                  
 
Completion Date:       /     / 
                                                                       DAY                   MONTH                               YEAR 
How much did you enjoy taking part in this activity program?  
• I liked it a lot  
 






• I did not like it  
 












Did the intervention coach you in increasing your physical activity outside of pulmonary 
rehabilitation?  
• Yes, it helped me a lot 
 
• Yes, a little bit  
 
• Not noticeable  
 
• No, not at all  
 












How did you experience the weekly increases proposed during the intervention? 
• Much too low 
 
• A little bit too low 
 
• Reasonable  
 
















How was it for you to work with the pedometer provided?  
• Very easy  
 
• Easy  
 
• Not easy, but I managed  
 
• Difficult  
 
















1) The step counter 
 
0 1 2 3 4 5 6 7 8 9 10 
 
2) The step count diary provided  
0 1 2 3 4 5 6 7 8 9 10 
 
3) Daily step goals displayed on your step count diary each week 





4) Activity feedback during each of the pulmonary rehabilitation sessions  
0 1 2 3 4 5 6 7 8 9 10  
 
5) If your HADS levels were >8, your sessions of CBT 
0 1 2 3 4 5 6 7 8 9 10 
 
 








but not every 
day  
Once or twice 
per week  
Never  
 
Look at your step 
counter during the day  
 
     
 
Look and use your 
daily step diary  
 
     
 
 
Which part of the intervention would you be willing to use further in the 
future/recommend to future patients in your position?  
 
• Nothing  
 
• The step counter 
 
• The step counter and daily step diary  
 
• CBT (HADS >8 patients)  
 
• Pulmonary rehabilitation alone  
 
• All of the above interventions together  
 
 



































Thank you for your time throughout this research study and I hope the benefits you 




















Appendix 4o: C-PPAC Instrument 
 
Clinical Visit Of Proactive Physical Activity In COPD (C-PPAC) 
   
INSTRUCTIONS TO PATIENTS: 
Patients with chronic lung disease like you often report that they have problems during 
physical activity. By physical activity, we mean all activities that require movement of your 
body. Examples are household activities, walking, going to work, or getting dressed. 
However, please consider all activities you do, and not only these examples. We would 
like to know how you experienced your physical activity IN THE PAST 7 DAYS.  
Please select the box next to the response that best applies to you IN THE PAST 7 DAYS.  






In the past 7 days, how much walking did you do outside?   
  None at all  0 
  A little bit (about 10 minutes every day)  1 
  Some (about 30 minutes every day)    2 
  A lot (about 1 hour every day)   3 
  A great deal (more than 1 hour every day)  3 
In the past 7 days, how many chores did you do outside the house? 
Some examples are gardening, taking the rubbish out, or doing 
small errands.  
  
  None at all  0 
  A few  1 
  Some  2 
  A lot  3 
  A large amount  4 
In the past 7 days, how much difficulty did you have getting 
dressed? 
  
 None at all 4  
  A little bit 3  
  Some 2  
  A lot 1  
  A great deal 0  




  None at all 4  
  A little bit 3  
  Some 2  
  A lot 1  
  A great deal 0  
 
 
In the past 7 days, how often did you avoid doing activities because 
of your lung problems? 
  
  Not at all 4  
  Rarely 3  
  Sometimes 2  
  Frequently 1  
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In the past 7 days, how breathless were you in general during your 
activities? 
  
  Not at all 4  
  A little bit 3  
  Moderately 2  
  Very 1  
  Extremely 0  
In the past 7 days, how often did you lack physical strength to do 
things because of your lung problems? 
  
  Not at all 4  
  Rarely 3  
  Sometimes 2  
  Frequently 1  
  All the time 0  
In the past 7 days, how tired were you in general during your 
activities? 
  
  Not at all 4  
  A little bit 3  
  Moderately 2  
  Very 1  
  Extremely 0  
In the past 7 days, how often did you have to take breaks during 
your physical activities? 
  
  Not at all 4  
  Rarely 3  
  Sometimes 2  
  Frequently 1  






In the past 7 days, how breathless were you when walking on level 
ground indoors and outdoors? 
  
  Not at all 4  
  A little bit 3  
  Moderately 2  
  Very 1  
  Extremely 0  
In the past 7 days, how much time did you need to recover from your 
physical activities? 
  
  None at all 4  
  A little bit 3  
  Some 2  
  A lot 1  
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  A great deal 0  
In the past 7 days, did you need to consider your lung problems 
when you planned your activities because of your lung problems? 
Examples are a trip out, an appointment or expecting visitors. 
  
  No 4  
  A little bit 3  
  Sometimes 2  
  A lot 1  
  A great deal 0  
   






























  0 <1000 <1500  0 
  1 1000-2000 1500-2500  1 
  2 2000-4000 2500-4500  2 
  3 4000-6000 4500-6500  3 
  4 >6000 >6500  4 
Weekly VMU score  
 
Measured by Actigraph Measured by Dynaport   
  0 <100 <60  0 
  1 100-200 60-130  1 
  2 200-300 130-210  2 
  3 300-500 210-370  3 
  4 >500 >370  4 
 Amount scores (sum above):   
 Difficulty scores (sum above):   
 Total scores (sum above):  
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Appendix 7b: Step Diary  
 
 
 
